{"_id": "NCT06074562", "title": "A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain", "text": "Summary: The main purpose of this study is to determine the safety and efficacy of LY3556050 versus placebo in participants with diabetic peripheral neuropathic pain (DPNP). The study will lasts approximately 24 weeks, across 3 study periods.\n\nInclusion criteria: inclusion criteria: \n\n Have a history and current diagnosis of Type 1 Diabetes (T1D) or Type 2 Diabetes (T2D) diagnosed for at least 6 months prior to screening.\n Have a stable glycemic control on stable diabetes treatment regimen for at least 90 days prior to day 1 with a hemoglobin A1c (HbA1c) \u226410 for T1D and HbA1c \u226411 for participants with T2D at time of screening.\n Have a history of daily peripheral neuropathic pain for at least 12 weeks based on participant report or medical history.\n Have a visual analog scale (VAS) pain value \u226540 and \\<95 during screening.\n Have presence of diabetic peripheral neuropathy of symmetrical nature and in lower extremities for \u22656 months and diagnosed by a score of Part B \u22653 on Michigan Neuropathy Screening Instrument\n Are willing to maintain a consistent regimen of any ongoing nonpharmacologic pain-relieving therapies (for example, physical therapy) and will not start any new nonpharmacologic pain-relieving therapies during study participation.\n Are willing to discontinue all medications taken for chronic pain conditions, except allowed concomitant pain medication permitted per protocol, for the duration of the study\n\n   Have a body mass index \u226445 kilogram/square meter (kg/m\u00b2) (inclusive).\n   Are men, or women able to abide by reproductive and contraceptive requirements.\n\nExclusion criteria: exclusion criteria: \n\nHistory of other potentially causative and/or confounding sources of pain that may impair self-assessment of pain due to DPNP.\nHave had a procedure within the past 6 months intended to produce permanent sensory loss in the target area of interest (for example, ablation techniques.\nHave had cancer within 2 years of baseline, except for cutaneous basal cell or squamous cell carcinoma resolved by excision.\nAre, in the judgment of the investigator, actively suicidal and therefore deemed to be at significant risk for suicide.\nHave in the judgement of the investigator, an acute, serious, or unstable medical condition or a history or presence of any other medical illness that would preclude study participation.\nHave a positive HIV test result at screening.\nHave a surgery planned during the study for any reason.\nHave a substance use disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders (5th edition; DSM-5; American Psychiatric Association)", "metadata": {"brief_title": "A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain", "phase": ["PHASE2"], "drugs_list": ["LY3556050", "Placebo"], "diseases_list": ["Diabetic Peripheral Neuropathy"], "enrollment": 410, "inclusion_criteria": "inclusion criteria: \n\n Have a history and current diagnosis of Type 1 Diabetes (T1D) or Type 2 Diabetes (T2D) diagnosed for at least 6 months prior to screening.\n Have a stable glycemic control on stable diabetes treatment regimen for at least 90 days prior to day 1 with a hemoglobin A1c (HbA1c) \u226410 for T1D and HbA1c \u226411 for participants with T2D at time of screening.\n Have a history of daily peripheral neuropathic pain for at least 12 weeks based on participant report or medical history.\n Have a visual analog scale (VAS) pain value \u226540 and \\<95 during screening.\n Have presence of diabetic peripheral neuropathy of symmetrical nature and in lower extremities for \u22656 months and diagnosed by a score of Part B \u22653 on Michigan Neuropathy Screening Instrument\n Are willing to maintain a consistent regimen of any ongoing nonpharmacologic pain-relieving therapies (for example, physical therapy) and will not start any new nonpharmacologic pain-relieving therapies during study participation.\n Are willing to discontinue all medications taken for chronic pain conditions, except allowed concomitant pain medication permitted per protocol, for the duration of the study\n\n   Have a body mass index \u226445 kilogram/square meter (kg/m\u00b2) (inclusive).\n   Are men, or women able to abide by reproductive and contraceptive requirements.", "exclusion_criteria": "exclusion criteria: \n\nHistory of other potentially causative and/or confounding sources of pain that may impair self-assessment of pain due to DPNP.\nHave had a procedure within the past 6 months intended to produce permanent sensory loss in the target area of interest (for example, ablation techniques.\nHave had cancer within 2 years of baseline, except for cutaneous basal cell or squamous cell carcinoma resolved by excision.\nAre, in the judgment of the investigator, actively suicidal and therefore deemed to be at significant risk for suicide.\nHave in the judgement of the investigator, an acute, serious, or unstable medical condition or a history or presence of any other medical illness that would preclude study participation.\nHave a positive HIV test result at screening.\nHave a surgery planned during the study for any reason.\nHave a substance use disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders (5th edition; DSM-5; American Psychiatric Association)", "brief_summary": "The main purpose of this study is to determine the safety and efficacy of LY3556050 versus placebo in participants with diabetic peripheral neuropathic pain (DPNP). The study will lasts approximately 24 weeks, across 3 study periods.", "keywords": []}}
{"_id": "NCT06864026", "title": "A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)", "text": "Summary: The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe PsA and obesity or overweight with at least 1 weight-related comorbidity.\n\nThe study will last up to 12 months.\n\nInclusion criteria: inclusion criteria: \n\n Have a diagnosis of active psoriatic arthritis (PsA) as defined by a rheumatologist or other healthcare professional (HCP) experienced in treating PsA.\n Body Mass Index (BMI) of 30 kilograms per meter squared (kg/m\u00b2) or greater (obesity) or 27 kg/m2 to \\<30 kg/m\u00b2 (overweight) in the presence of at least 1 weight-related comorbid condition (hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease).\n Who have been treated with ixekizumab for approximately 3 months (\u00b11 month) prior to decision to add tirzepatide.\n Must be able to initiate tirzepatide (Day 0) within 30 days of treatment decision (baseline or screening).\n\nExclusion criteria: exclusion criteria: \n\nHave currently received ixekizumab for more than 4 months or less than 2 months.\nHad any exposure to tirzepatide or other glucagon-like peptide-1 (GLP-1) receptor agonist (for example, dulaglutide, liraglutide, or semaglutide).\nAre currently enrolled in any other clinical study.\nHave a known hypersensitivity to any component of tirzepatide.\nHave a personal or family history of medullary thyroid cancer.\nHave multiple endocrine neoplasia type 2.\nHave type 1 diabetes mellitus.\nHave a history of chronic or acute pancreatitis at any time before screening.\nHave a history of proliferative diabetic retinopathy, diabetic maculopathy, or nonproliferative diabetic retinopathy that requires acute treatment.\nHave a history of ketoacidosis or hyperosmolar state/coma.\nHave a history of severe hypoglycemia unawareness within the 6 months before screening.\nHave a history of severe gastrointestinal complications, including gastroparesis, gastroesophageal reflux disease, dyspepsia, chronic nausea/vomiting.", "metadata": {"brief_title": "A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)", "phase": ["PHASE4"], "drugs_list": ["Tirzepatide"], "diseases_list": ["Psoriatic Arthritis", "Overweight or Obesity"], "enrollment": 200, "inclusion_criteria": "inclusion criteria: \n\n Have a diagnosis of active psoriatic arthritis (PsA) as defined by a rheumatologist or other healthcare professional (HCP) experienced in treating PsA.\n Body Mass Index (BMI) of 30 kilograms per meter squared (kg/m\u00b2) or greater (obesity) or 27 kg/m2 to \\<30 kg/m\u00b2 (overweight) in the presence of at least 1 weight-related comorbid condition (hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease).\n Who have been treated with ixekizumab for approximately 3 months (\u00b11 month) prior to decision to add tirzepatide.\n Must be able to initiate tirzepatide (Day 0) within 30 days of treatment decision (baseline or screening).", "exclusion_criteria": "exclusion criteria: \n\nHave currently received ixekizumab for more than 4 months or less than 2 months.\nHad any exposure to tirzepatide or other glucagon-like peptide-1 (GLP-1) receptor agonist (for example, dulaglutide, liraglutide, or semaglutide).\nAre currently enrolled in any other clinical study.\nHave a known hypersensitivity to any component of tirzepatide.\nHave a personal or family history of medullary thyroid cancer.\nHave multiple endocrine neoplasia type 2.\nHave type 1 diabetes mellitus.\nHave a history of chronic or acute pancreatitis at any time before screening.\nHave a history of proliferative diabetic retinopathy, diabetic maculopathy, or nonproliferative diabetic retinopathy that requires acute treatment.\nHave a history of ketoacidosis or hyperosmolar state/coma.\nHave a history of severe hypoglycemia unawareness within the 6 months before screening.\nHave a history of severe gastrointestinal complications, including gastroparesis, gastroesophageal reflux disease, dyspepsia, chronic nausea/vomiting.", "brief_summary": "The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe PsA and obesity or overweight with at least 1 weight-related comorbidity.\n\nThe study will last up to 12 months.", "keywords": []}}
{"_id": "NCT05026866", "title": "A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)", "text": "Summary: The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD). Approximately 800 additional participants will be enrolled in a 12-month addendum to assess safety of a different titration regimen.\n\nInclusion criteria: inclusion criteria: \n\n A Telephone Interview for Cognitive Status - modified (TICS-M) score reflective of intact cognitive functioning.\n Has a phosphorylated tau (P-tau) result consistent with the presence of amyloid and early-tau pathology.\n Has a reliable study partner and backup study partner familiar with overall function and behavior, such as day-to-day activities and cognitive abilities.\n Have adequate literacy, vision, and hearing for neuropsychological testing at screening.\n Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies\n Female participants include those who are infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy, or tubal ligation), congenital anomaly such as Mullerian agenesis; or post menopausal (women 55 or older not on hormone therapy and had at least 12 months of spontaneous amenorrhea; or with a diagnosis of menopause prior to starting hormone replacement therapy.\n\nExclusion criteria: exclusion criteria: \n\nMild cognitive impairment or dementia, or significant other neurodegenerative disease that can affect cognition.\nCurrent serious or unstable illnesses including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, neurologic, psychiatric, immunologic, or hematologic disease that could interfere with the analysis of the study or a life expectancy of approximately \u22645 years.\nHistory of cancer with high risk of recurrence and preventing completion of the trial.\nHistory of clinically significant multiple or severe drug allergies, or severe posttreatment hypersensitivity reactions (including but not limited to erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, and/or exfoliative dermatitis).\nHave any clinically important abnormality at screening on magnetic resonance imaging (MRI) or clinical laboratory test results that could be detrimental to the participant or study integrity.\nHave any contraindications for MRI, including claustrophobia or the presence of contraindicated metal (ferromagnetic) implants/cardiac pacemaker.\nHave a centrally read MRI demonstrating presence of amyloid-related imaging abnormalities (ARIA-E), \\>4 cerebral microhemorrhages, more than 1 area of superficial siderosis, any macrohemorrhage or severe white matter disease at screening.\nHave had prior treatment with a passive anti-amyloid immunotherapy \\<5 half-lives prior to randomization.\nHave received active immunization against amyloid beta (A\u03b2) in any other study.\nHave received active immunization against A\u03b2 in any other study.\nCurrent or previous use of prescription medications used as treatment for mild cognitive impairment (MCI) or AD.\n\nAddendum 7 Exclusion Criteria for Clinicaltrials.gov:\n\nSame as the main study except contraindications for florbetapir F 18 PET are exclusionary.", "metadata": {"brief_title": "A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)", "phase": ["PHASE3"], "drugs_list": ["Donanemab", "Placebo"], "diseases_list": ["Alzheimer Disease"], "enrollment": 2196, "inclusion_criteria": "inclusion criteria: \n\n A Telephone Interview for Cognitive Status - modified (TICS-M) score reflective of intact cognitive functioning.\n Has a phosphorylated tau (P-tau) result consistent with the presence of amyloid and early-tau pathology.\n Has a reliable study partner and backup study partner familiar with overall function and behavior, such as day-to-day activities and cognitive abilities.\n Have adequate literacy, vision, and hearing for neuropsychological testing at screening.\n Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies\n Female participants include those who are infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy, or tubal ligation), congenital anomaly such as Mullerian agenesis; or post menopausal (women 55 or older not on hormone therapy and had at least 12 months of spontaneous amenorrhea; or with a diagnosis of menopause prior to starting hormone replacement therapy.", "exclusion_criteria": "exclusion criteria: \n\nMild cognitive impairment or dementia, or significant other neurodegenerative disease that can affect cognition.\nCurrent serious or unstable illnesses including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, neurologic, psychiatric, immunologic, or hematologic disease that could interfere with the analysis of the study or a life expectancy of approximately \u22645 years.\nHistory of cancer with high risk of recurrence and preventing completion of the trial.\nHistory of clinically significant multiple or severe drug allergies, or severe posttreatment hypersensitivity reactions (including but not limited to erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, and/or exfoliative dermatitis).\nHave any clinically important abnormality at screening on magnetic resonance imaging (MRI) or clinical laboratory test results that could be detrimental to the participant or study integrity.\nHave any contraindications for MRI, including claustrophobia or the presence of contraindicated metal (ferromagnetic) implants/cardiac pacemaker.\nHave a centrally read MRI demonstrating presence of amyloid-related imaging abnormalities (ARIA-E), \\>4 cerebral microhemorrhages, more than 1 area of superficial siderosis, any macrohemorrhage or severe white matter disease at screening.\nHave had prior treatment with a passive anti-amyloid immunotherapy \\<5 half-lives prior to randomization.\nHave received active immunization against amyloid beta (A\u03b2) in any other study.\nHave received active immunization against A\u03b2 in any other study.\nCurrent or previous use of prescription medications used as treatment for mild cognitive impairment (MCI) or AD.\n\nAddendum 7 Exclusion Criteria for Clinicaltrials.gov:\n\nSame as the main study except contraindications for florbetapir F 18 PET are exclusionary.", "brief_summary": "The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD). Approximately 800 additional participants will be enrolled in a 12-month addendum to assess safety of a different titration regimen.", "keywords": []}}
{"_id": "NCT04616326", "title": "A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine", "text": "Summary: The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participants 12 to 17 years of age. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.\n\nInclusion criteria: inclusion criteria: \n\n Have a diagnosis of chronic migraine as defined by the IHS ICHD-3 guidelines (1.3 according to ICHD-3 \\[2018\\]), that is, a headache occurring on 15 or more days per month for at least the last 3 months, which has the features of migraine headache on at least 8 days per month.\n\nExclusion criteria: exclusion criteria: \n\nParticipants who are taking, or are expected to take, therapeutic antibodies during the course of the study (adalimumab, infliximab, trastuzumab, bevacizumab, etc.). Prior use of therapeutic antibodies is allowed if that use was more than 12 months prior to baseline, except for antibodies to CGRP or its receptor, which are not allowed at any time prior to study entry.\nKnown hypersensitivity monoclonal antibodies or other therapeutic proteins, or to galcanezumab or its excipients.\nCurrent use or prior exposure to galcanezumab, another CGRP antibody, or CGRP receptor antibody, including those who have previously completed or withdrawn from this study or any other study investigating a CGRP antibody. Participant must also not have prior oral CGRP antagonist use within 30 days prior to baseline.\nHistory of IHS ICHD-3 diagnosis of new daily persistent headache, cluster headache or migraine subtypes including hemiplegic (sporadic or familial) migraine and migraine with brainstem aura (previously basilar-type migraine).\nHistory of significant head or neck injury within 6 months prior to screening; or traumatic head injury at any time that is associated with significant change in the quality or frequency of their headaches, including new onset of migraine following traumatic head injury.\nParticipants with a known history of intracranial tumors or developmental malformations including Chiari malformations.", "metadata": {"brief_title": "A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine", "phase": ["PHASE3"], "drugs_list": ["Galcanezumab", "Placebo"], "diseases_list": ["Chronic Migraine"], "enrollment": 300, "inclusion_criteria": "inclusion criteria: \n\n Have a diagnosis of chronic migraine as defined by the IHS ICHD-3 guidelines (1.3 according to ICHD-3 \\[2018\\]), that is, a headache occurring on 15 or more days per month for at least the last 3 months, which has the features of migraine headache on at least 8 days per month.", "exclusion_criteria": "exclusion criteria: \n\nParticipants who are taking, or are expected to take, therapeutic antibodies during the course of the study (adalimumab, infliximab, trastuzumab, bevacizumab, etc.). Prior use of therapeutic antibodies is allowed if that use was more than 12 months prior to baseline, except for antibodies to CGRP or its receptor, which are not allowed at any time prior to study entry.\nKnown hypersensitivity monoclonal antibodies or other therapeutic proteins, or to galcanezumab or its excipients.\nCurrent use or prior exposure to galcanezumab, another CGRP antibody, or CGRP receptor antibody, including those who have previously completed or withdrawn from this study or any other study investigating a CGRP antibody. Participant must also not have prior oral CGRP antagonist use within 30 days prior to baseline.\nHistory of IHS ICHD-3 diagnosis of new daily persistent headache, cluster headache or migraine subtypes including hemiplegic (sporadic or familial) migraine and migraine with brainstem aura (previously basilar-type migraine).\nHistory of significant head or neck injury within 6 months prior to screening; or traumatic head injury at any time that is associated with significant change in the quality or frequency of their headaches, including new onset of migraine following traumatic head injury.\nParticipants with a known history of intracranial tumors or developmental malformations including Chiari malformations.", "brief_summary": "The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participants 12 to 17 years of age. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.", "keywords": ["pediatric", "children", "prevention", "prophylaxis", "headache", "pediatric migraine"]}}
{"_id": "NCT03773965", "title": "A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis", "text": "Summary: The reason for this study is to see if the study drug baricitinib is safe and effective in the treatment of JIA in participants ages 1 to 17. This study is for participants that have been enrolled in studies I4V-MC-JAHV (NCT03773978) or I4V-MC-JAHU.\n\nInclusion criteria: inclusion criteria: \n\n Participants must have completed a previous study of baricitinib for the treatment of JIA.\n\nExclusion criteria: exclusion criteria: \n\nParticipants must not have had a permanent discontinuation of baricitinib in the prior study.\nParticipants must have not developed an allergy to baricitinib.", "metadata": {"brief_title": "A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis", "phase": ["PHASE3"], "drugs_list": ["Baricitinib"], "diseases_list": ["Juvenile Idiopathic Arthritis"], "enrollment": 190, "inclusion_criteria": "inclusion criteria: \n\n Participants must have completed a previous study of baricitinib for the treatment of JIA.", "exclusion_criteria": "exclusion criteria: \n\nParticipants must not have had a permanent discontinuation of baricitinib in the prior study.\nParticipants must have not developed an allergy to baricitinib.", "brief_summary": "The reason for this study is to see if the study drug baricitinib is safe and effective in the treatment of JIA in participants ages 1 to 17. This study is for participants that have been enrolled in studies I4V-MC-JAHV (NCT03773978) or I4V-MC-JAHU.", "keywords": ["Polyarticular JIA", "Oligoarthritis", "Juvenile psoriatic arthritis (JPsA)", "Enthesitis-related juvenile idiopathic arthritis (ERA)", "Systemic JIA with and without systemic features"]}}
{"_id": "NCT06229366", "title": "[Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer", "text": "Summary: ACCEL is a multicenter, open label phase Ia/Ib/II study of \\[Ac-225\\]-PSMA-62 in participants with prostate-specific membrane antigen (PSMA)-positive prostate cancer.\n\nInclusion criteria: inclusion criteria: \n\n1. Histological, pathological, and/or cytological confirmation of adenocarcinoma of the prostate\n2. ECOG performance status 0 to 1\n3. Criteria specific for patients with mCRPC:\n\n   1. Previously received an androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy (unless ineligible or refused taxane). Received a maximum of 3 prior systemic therapy regimens in the mCRPC setting\n   2. Progressive mCRPC at the time of consent based on at least 1 of the following criteria being met in the context of castrate levels of testosterone:\n\n       PSA progression defined as rising PSA values at a minimum of 1-week intervals, with the last result being at least 1.0 ng/mL\n       Soft-tissue progression defined as an increase \u226520% in the sum of the diameter (SOD) (short axis for nodal lesions and long axis for non-nodal lesions) of all target lesions based on the smallest SOD since treatment started or the appearance of one or more new lesions\n       Progression of bone disease defined as the appearance of two or more new lesions by bone scan\n   3. At least one PSMA-PET positive lesion for prostate cancer\n   4. Castrate circulating testosterone levels (\\<1.74 nmol/L or \\<50 ng/dL)\n4. Criteria specific for patients with OmHSPC:\n\n   1. PSA recurrence after radical prostatectomy (RP) or definitive radiation therapy (RT), with or without adjuvant/salvage local therapy (radiation or surgery), with or without (neo)adjuvant ADT\n\n       PSA \u2265 0.2ng/mL for patients with prior RP +/- RT, or\n       PSA of \u2265 2 ng/mL above nadir for patients with only prior RT\n   2. 1- 5 PSMA-PET positive lesions identified outside the prostate bed or remaining gland.\n\nExclusion criteria: exclusion criteria: \n\n1. Patient has received any other investigational therapeutic agents within 4 weeks or 5 half-lives (whichever is shorter) of starting the study treatment\n2. Evidence of ongoing and untreated urinary tract obstruction\n3. Existing Grade 1 dry mouth (xerostomia) or symptomatic Grade 1 dry eye (xerophthalmia) for any reason\n4. Patient has any concurrent severe and/or uncontrolled medical conditions that could increase the patient's risk for toxicity while on the study or that could confound discrimination between disease- and study treatment-related toxicities\n5. Criteria specific for patients with mCRPC:\n\n   1. Patient has received any PSMA-directed radioligand therapy (e.g., Lu-177-PSMA, Lu-177-PNT2002, Ac-225-J591)\n   2. Patient has received any therapeutic systemic radionuclides (e.g., radium-223, rhenium-186, strontium-89), or non-PSMA-directed therapeutic radioligands (e.g., Lu-177-Dotatate) within 5 half-lives of starting the study treatment\n6. Criteria specific for patients with OmHSPC:\n\n   1. Patient has received any systemic anti-cancer therapy for prostate cancer with the exception of (neo)adjuvant ADT for management of localized disease\n   2. Presence of any liver metastases\n   3. Known presence of central nervous system metastases", "metadata": {"brief_title": "[Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer", "phase": ["PHASE1"], "drugs_list": ["[Ac-225]-PSMA-62 (mCRPC)", "[Ac-225]-PSMA-62 (OmHSPC)"], "diseases_list": ["Prostate Cancer", "Metastatic Castration-resistant Prostate Cancer", "Oligometastatic Prostate Carcinoma", "Hormone Sensitive Prostate Cancer"], "enrollment": 142, "inclusion_criteria": "inclusion criteria: \n\n1. Histological, pathological, and/or cytological confirmation of adenocarcinoma of the prostate\n2. ECOG performance status 0 to 1\n3. Criteria specific for patients with mCRPC:\n\n   1. Previously received an androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy (unless ineligible or refused taxane). Received a maximum of 3 prior systemic therapy regimens in the mCRPC setting\n   2. Progressive mCRPC at the time of consent based on at least 1 of the following criteria being met in the context of castrate levels of testosterone:\n\n       PSA progression defined as rising PSA values at a minimum of 1-week intervals, with the last result being at least 1.0 ng/mL\n       Soft-tissue progression defined as an increase \u226520% in the sum of the diameter (SOD) (short axis for nodal lesions and long axis for non-nodal lesions) of all target lesions based on the smallest SOD since treatment started or the appearance of one or more new lesions\n       Progression of bone disease defined as the appearance of two or more new lesions by bone scan\n   3. At least one PSMA-PET positive lesion for prostate cancer\n   4. Castrate circulating testosterone levels (\\<1.74 nmol/L or \\<50 ng/dL)\n4. Criteria specific for patients with OmHSPC:\n\n   1. PSA recurrence after radical prostatectomy (RP) or definitive radiation therapy (RT), with or without adjuvant/salvage local therapy (radiation or surgery), with or without (neo)adjuvant ADT\n\n       PSA \u2265 0.2ng/mL for patients with prior RP +/- RT, or\n       PSA of \u2265 2 ng/mL above nadir for patients with only prior RT\n   2. 1- 5 PSMA-PET positive lesions identified outside the prostate bed or remaining gland.", "exclusion_criteria": "exclusion criteria: \n\n1. Patient has received any other investigational therapeutic agents within 4 weeks or 5 half-lives (whichever is shorter) of starting the study treatment\n2. Evidence of ongoing and untreated urinary tract obstruction\n3. Existing Grade 1 dry mouth (xerostomia) or symptomatic Grade 1 dry eye (xerophthalmia) for any reason\n4. Patient has any concurrent severe and/or uncontrolled medical conditions that could increase the patient's risk for toxicity while on the study or that could confound discrimination between disease- and study treatment-related toxicities\n5. Criteria specific for patients with mCRPC:\n\n   1. Patient has received any PSMA-directed radioligand therapy (e.g., Lu-177-PSMA, Lu-177-PNT2002, Ac-225-J591)\n   2. Patient has received any therapeutic systemic radionuclides (e.g., radium-223, rhenium-186, strontium-89), or non-PSMA-directed therapeutic radioligands (e.g., Lu-177-Dotatate) within 5 half-lives of starting the study treatment\n6. Criteria specific for patients with OmHSPC:\n\n   1. Patient has received any systemic anti-cancer therapy for prostate cancer with the exception of (neo)adjuvant ADT for management of localized disease\n   2. Presence of any liver metastases\n   3. Known presence of central nervous system metastases", "brief_summary": "ACCEL is a multicenter, open label phase Ia/Ib/II study of \\[Ac-225\\]-PSMA-62 in participants with prostate-specific membrane antigen (PSMA)-positive prostate cancer.", "keywords": ["mCRPC", "OmHSPC", "Prostatic Neoplasms", "Genital Neoplasms, Male", "Castration Resistant Prostate Cancer", "Hormone Sensitive Prostate Cancer", "Oligometastatic Prostate Cancer", "[225Ac]-PSMA-62", "Ac-225-PSMA-62", "Actinium", "Radioligand Therapy", "Radiopharmaceuticals", "Urogenital Neoplasm"]}}
{"_id": "NCT05074420", "title": "A Study of Baricitinib (LY3009104) in Children With COVID-19", "text": "Summary: The purpose for this study is to determine if the study drug baricitinib is effective and safe in hospitalized pediatric participants with Coronavirus disease 2019 (COVID -19) and to confirm the dose.\n\nInclusion criteria: inclusion criteria: \n\n Hospitalized with coronavirus (SARS-CoV-2) infection.\n Male or female participants from 1 to \\<18 years of age.\n Requires supplemental oxygen and have chest imaging findings to confirm respiratory disease due to COVID-19 within 72 hours of study entry and enrollment.\n Supplemental oxygen including but not limited to: nasal cannula, mask, high flow devices, CPAP/BiPAP, invasive mechanical ventilation as well as ECMO.\n\nExclusion criteria: exclusion criteria: \n\nAre receiving biologic treatments (such as Tumor Necrosis Factor \\[TNF\\] inhibitors, interleukin inhibitors, T-cell or B-cell targeted therapies, interferon, or Janus kinase (JAK) inhibitors); or are receiving other immunosuppressants such that, in the opinion of the investigator, participating in the study would put the participant at an unacceptable risk of immunosuppression.\n\nNote: A washout period is required prior to screening.\n\nAre receiving strong inhibitors of Organic Anion Transporter 3 (OAT3) (such as probenecid) that cannot be discontinued at study entry.\nHave diagnosis of current active tuberculosis (TB) or, if known, latent TB treated for less than 4 weeks with appropriate anti-tuberculosis therapy per local guidelines (by history only, no screening tests required).\nSuspected serious, active bacterial, fungal, viral, or other infection (besides COVID-19) that in the opinion of the investigator could constitute a risk when taking investigational product.\nHave received any live vaccine within 4 weeks before screening, or intend to receive a live vaccine during the study. Note: Use of non-live (inactivated) vaccinations are allowed for all participants.\nRequire invasive mechanical ventilation, including extracorporeal membrane oxygenation (ECMO) at study entry.\nCurrent diagnosis of active malignancy that, in the opinion of the investigator, could constitute a risk when taking investigational product.\nHave a history of venous thromboembolism (VTE) (deep vein thrombosis \\[DVT\\] and/or pulmonary embolism \\[PE\\]) or considered high risk of VTE (DVT/PE).\nAnticipated discharge from the hospital, or transfer to another hospital (or another unit), which is not a study site within 72 hours after study entry.\nHave neutropenia (absolute neutrophil count \\<1000 cells/microliters).\nHave lymphopenia (absolute lymphocyte count \\<200 cells/microliters).\nHave alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>5 times AAULN.\nEstimated glomerular filtration rate (eGFR) (Modification of Diet in Renal Disease \\[MDRD\\]) \\<40 milliliter/minute/1.73 meters squared.\nHave a known hypersensitivity to baricitinib or any of its excipients.\nAre currently enrolled in any other clinical study involving an investigation product or any other type of medical research judged not to be scientifically or medically compatible with this study. Note: The participant should not be enrolled (started) in another clinical trial for the treatment of COVID-19 or SARS CoV-2 through Day 28.\nAre pregnant, or intend to become pregnant or breastfeed during the study.\nAre, in the opinion of the investigator or sponsor, at risk of immunosuppression or otherwise unsuitable for inclusion in the study.\nAre using or will use extracorporeal blood purification (EBP) device to remove proinflammatory cytokines from the blood such as a cytokine absorption or filtering device, for example, CytoSorb\u00ae.\nAre, in the opinion of the investigator, unlikely to survive for at least 48 hours after screening.", "metadata": {"brief_title": "A Study of Baricitinib (LY3009104) in Children With COVID-19", "phase": ["PHASE3"], "drugs_list": ["Baricitinib"], "diseases_list": ["Covid19", "Corona Virus Infection"], "enrollment": 24, "inclusion_criteria": "inclusion criteria: \n\n Hospitalized with coronavirus (SARS-CoV-2) infection.\n Male or female participants from 1 to \\<18 years of age.\n Requires supplemental oxygen and have chest imaging findings to confirm respiratory disease due to COVID-19 within 72 hours of study entry and enrollment.\n Supplemental oxygen including but not limited to: nasal cannula, mask, high flow devices, CPAP/BiPAP, invasive mechanical ventilation as well as ECMO.", "exclusion_criteria": "exclusion criteria: \n\nAre receiving biologic treatments (such as Tumor Necrosis Factor \\[TNF\\] inhibitors, interleukin inhibitors, T-cell or B-cell targeted therapies, interferon, or Janus kinase (JAK) inhibitors); or are receiving other immunosuppressants such that, in the opinion of the investigator, participating in the study would put the participant at an unacceptable risk of immunosuppression.\n\nNote: A washout period is required prior to screening.\n\nAre receiving strong inhibitors of Organic Anion Transporter 3 (OAT3) (such as probenecid) that cannot be discontinued at study entry.\nHave diagnosis of current active tuberculosis (TB) or, if known, latent TB treated for less than 4 weeks with appropriate anti-tuberculosis therapy per local guidelines (by history only, no screening tests required).\nSuspected serious, active bacterial, fungal, viral, or other infection (besides COVID-19) that in the opinion of the investigator could constitute a risk when taking investigational product.\nHave received any live vaccine within 4 weeks before screening, or intend to receive a live vaccine during the study. Note: Use of non-live (inactivated) vaccinations are allowed for all participants.\nRequire invasive mechanical ventilation, including extracorporeal membrane oxygenation (ECMO) at study entry.\nCurrent diagnosis of active malignancy that, in the opinion of the investigator, could constitute a risk when taking investigational product.\nHave a history of venous thromboembolism (VTE) (deep vein thrombosis \\[DVT\\] and/or pulmonary embolism \\[PE\\]) or considered high risk of VTE (DVT/PE).\nAnticipated discharge from the hospital, or transfer to another hospital (or another unit), which is not a study site within 72 hours after study entry.\nHave neutropenia (absolute neutrophil count \\<1000 cells/microliters).\nHave lymphopenia (absolute lymphocyte count \\<200 cells/microliters).\nHave alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>5 times AAULN.\nEstimated glomerular filtration rate (eGFR) (Modification of Diet in Renal Disease \\[MDRD\\]) \\<40 milliliter/minute/1.73 meters squared.\nHave a known hypersensitivity to baricitinib or any of its excipients.\nAre currently enrolled in any other clinical study involving an investigation product or any other type of medical research judged not to be scientifically or medically compatible with this study. Note: The participant should not be enrolled (started) in another clinical trial for the treatment of COVID-19 or SARS CoV-2 through Day 28.\nAre pregnant, or intend to become pregnant or breastfeed during the study.\nAre, in the opinion of the investigator or sponsor, at risk of immunosuppression or otherwise unsuitable for inclusion in the study.\nAre using or will use extracorporeal blood purification (EBP) device to remove proinflammatory cytokines from the blood such as a cytokine absorption or filtering device, for example, CytoSorb\u00ae.\nAre, in the opinion of the investigator, unlikely to survive for at least 48 hours after screening.", "brief_summary": "The purpose for this study is to determine if the study drug baricitinib is effective and safe in hospitalized pediatric participants with Coronavirus disease 2019 (COVID -19) and to confirm the dose.", "keywords": ["coronavirus"]}}
{"_id": "NCT04396574", "title": "A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine", "text": "Summary: The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will last about 12 months and may include up to 7 visits.\n\nInclusion criteria: inclusion criteria: \n\n Participants must have completed study H8H-MC-LAHX (NCT03988088) or study H8H-MC-LAHV (NCT number to be determined)\n Participants must weigh at least 15 kilograms (kg)\n\nExclusion criteria: exclusion criteria: \n\nParticipants must not be pregnant or nursing\nParticipants must not have any acute, serious, or unstable medical condition\nParticipants must not be actively suicidal or at significant risk for suicide, in the opinion of the investigator", "metadata": {"brief_title": "A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine", "phase": ["PHASE3"], "drugs_list": ["Lasmiditan"], "diseases_list": ["Migraine"], "enrollment": 1000, "inclusion_criteria": "inclusion criteria: \n\n Participants must have completed study H8H-MC-LAHX (NCT03988088) or study H8H-MC-LAHV (NCT number to be determined)\n Participants must weigh at least 15 kilograms (kg)", "exclusion_criteria": "exclusion criteria: \n\nParticipants must not be pregnant or nursing\nParticipants must not have any acute, serious, or unstable medical condition\nParticipants must not be actively suicidal or at significant risk for suicide, in the opinion of the investigator", "brief_summary": "The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will last about 12 months and may include up to 7 visits.", "keywords": ["acute", "long-term", "open label", "safety"]}}
{"_id": "NCT05999994", "title": "A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer", "text": "Summary: The main purpose of the master is to help the research sites and sponsor carry out several clinical trials more efficiently by providing a common research protocol. Individual clinical trials under this master protocol define drug/disease-specific research goals and activities to test them. New studies will be added as new drugs emerge against different cancers. Participation in the trial will depend on how long the benefit lasts.\n\nInclusion criteria: inclusion criteria: \n\n \n\nExclusion criteria: exclusion criteria: \n\n ", "metadata": {"brief_title": "A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer", "phase": ["PHASE2"], "drugs_list": ["Ramucirumab", "Cyclophosphamide", "Vinorelbine", "Gemcitabine", "Docetaxel", "Abemaciclib", "Irinotecan", "Temozolomide"], "diseases_list": ["Neoplasms", "Child", "Adolescent"], "enrollment": 105, "inclusion_criteria": "inclusion criteria: \n\n ", "exclusion_criteria": "exclusion criteria: \n\n ", "brief_summary": "The main purpose of the master is to help the research sites and sponsor carry out several clinical trials more efficiently by providing a common research protocol. Individual clinical trials under this master protocol define drug/disease-specific research goals and activities to test them. New studies will be added as new drugs emerge against different cancers. Participation in the trial will depend on how long the benefit lasts.", "keywords": []}}
{"_id": "NCT06859294", "title": "A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis", "text": "Summary: The main purpose of this study is to evaluate the effects of LY3541860 in adult participants with moderately to severely active Rheumatoid Arthritis with inadequate response to a least one biologic disease-modifying antirheumatic drug (bDMARD)or targeted synthetic disease-modifying antirheumatic drug (tsDMARD).\n\nStudy participation is approximately 50 weeks, including a 6-week screening period, 24-week treatment period, and a 20-week safety follow up period.\n\nInclusion criteria: inclusion criteria: \n\n Have a diagnosis of adult-onset Rheumatoid Arthritis (RA) for at least 3 months prior to screening, as defined by the 2010 ACR/EULAR classification criteria.\n Have moderately to severely active RA, at screening (Visit 1) and baseline (Visit 2), defined by the presence of\n\n   \u22656 swollen joints based on 66 joint count (and \u22654 swollen joints on 28 joint count), and\n   \u22656 tender joints based on 68 joint count (and \u22654 tender joints on 28 joint count).\n Have active synovitis in \u22651 joint, in hands or wrists, of the investigator choosing at screening, having an MRI synovitis RAMRIS score of \u22652 as determined from the central reading of the images.\n\nExclusion criteria: exclusion criteria: \n\nHave a diagnosis or history of malignant disease within 5 years prior to baseline, with the exceptions of\n\n  basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years, or\n  cervical carcinoma in situ, with no evidence of recurrence within the 5 years prior to baseline.\nHave estimated glomerular filtration rate (eGFR) of \\<45 milliliter per minute (mL/minute) from serum creatinine using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation.\nHave a current or recent active infection.\nHave presence of 1 or more significant concurrent medical conditions per investigator judgment, including but not limited to\n\n  poorly controlled diabetes or hypertension\n  chronic kidney disease Stage 3a or b, 4, or 5\n  symptomatic heart failure according to New York Heart Association Class 2, 3, or 4\n  myocardial infarction, unstable angina pectoris, stroke, or transient ischemic attack within the past 12 months before baseline\n  severe chronic pulmonary disease, for example, requiring oxygen therapy major chronic inflammatory disease or connective tissue disease other than RA, including but not limited to\n  systemic lupus erythematosus\n  psoriatic arthritis\n  axial spondyloarthritis, including ankylosing spondylitis and non-radiographic axial spondyloarthritis\n  reactive arthritis\n  gout\n  scleroderma\n  polymyositis\n  dermatomyositis\n  active fibromyalgia, or\n  multiple sclerosis\nHave received any prior B-cell targeted therapy (for example, anti-CD19 antibodies or anti-CD20 antibodies, such as rituximab).\nReceived corticosteroids, opioids, conventional disease-modifying antirheumatic drug (cDMARD), with changes in dose or have received Janus kinase (JAK) inhibitors within 28 days prior to the screening MRI or plan on receiving these drugs during the study.", "metadata": {"brief_title": "A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis", "phase": ["PHASE2"], "drugs_list": ["LY3541860"], "diseases_list": ["Rheumatoid Arthritis"], "enrollment": 40, "inclusion_criteria": "inclusion criteria: \n\n Have a diagnosis of adult-onset Rheumatoid Arthritis (RA) for at least 3 months prior to screening, as defined by the 2010 ACR/EULAR classification criteria.\n Have moderately to severely active RA, at screening (Visit 1) and baseline (Visit 2), defined by the presence of\n\n   \u22656 swollen joints based on 66 joint count (and \u22654 swollen joints on 28 joint count), and\n   \u22656 tender joints based on 68 joint count (and \u22654 tender joints on 28 joint count).\n Have active synovitis in \u22651 joint, in hands or wrists, of the investigator choosing at screening, having an MRI synovitis RAMRIS score of \u22652 as determined from the central reading of the images.", "exclusion_criteria": "exclusion criteria: \n\nHave a diagnosis or history of malignant disease within 5 years prior to baseline, with the exceptions of\n\n  basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years, or\n  cervical carcinoma in situ, with no evidence of recurrence within the 5 years prior to baseline.\nHave estimated glomerular filtration rate (eGFR) of \\<45 milliliter per minute (mL/minute) from serum creatinine using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation.\nHave a current or recent active infection.\nHave presence of 1 or more significant concurrent medical conditions per investigator judgment, including but not limited to\n\n  poorly controlled diabetes or hypertension\n  chronic kidney disease Stage 3a or b, 4, or 5\n  symptomatic heart failure according to New York Heart Association Class 2, 3, or 4\n  myocardial infarction, unstable angina pectoris, stroke, or transient ischemic attack within the past 12 months before baseline\n  severe chronic pulmonary disease, for example, requiring oxygen therapy major chronic inflammatory disease or connective tissue disease other than RA, including but not limited to\n  systemic lupus erythematosus\n  psoriatic arthritis\n  axial spondyloarthritis, including ankylosing spondylitis and non-radiographic axial spondyloarthritis\n  reactive arthritis\n  gout\n  scleroderma\n  polymyositis\n  dermatomyositis\n  active fibromyalgia, or\n  multiple sclerosis\nHave received any prior B-cell targeted therapy (for example, anti-CD19 antibodies or anti-CD20 antibodies, such as rituximab).\nReceived corticosteroids, opioids, conventional disease-modifying antirheumatic drug (cDMARD), with changes in dose or have received Janus kinase (JAK) inhibitors within 28 days prior to the screening MRI or plan on receiving these drugs during the study.", "brief_summary": "The main purpose of this study is to evaluate the effects of LY3541860 in adult participants with moderately to severely active Rheumatoid Arthritis with inadequate response to a least one biologic disease-modifying antirheumatic drug (bDMARD)or targeted synthetic disease-modifying antirheumatic drug (tsDMARD).\n\nStudy participation is approximately 50 weeks, including a 6-week screening period, 24-week treatment period, and a 20-week safety follow up period.", "keywords": []}}
{"_id": "NCT06046729", "title": "A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa", "text": "Summary: This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis suppurativa (HS) for further clinical development. The study will last approximately 62 weeks and may include up to 31 visits.\n\nInclusion criteria: inclusion criteria: \n\n Have a diagnosis of HS for at least 12 months.\n Have HS lesions in at least 2 distinct anatomical regions. At least 1 of the lesions must be at least Hurley Stage II or III.\n Have an (abscess plus inflammatory nodule) count of at least 5.\n Agree to use topical antiseptics daily.\n Had an inadequate response or intolerance to a 28-day course of oral antibiotics.\n\nExclusion criteria: exclusion criteria: \n\nHave more than 20 draining fistulae.\nHave had surgical treatment for HS in the last 4 weeks before randomization.\nHave an active skin disease or condition, that could interfere with the assessment of HS.\nHave a current or recent acute, active infection.\nAre immunocompromised.\nHave a history of chronic alcohol abuse, IV drug abuse, or other illicit drug abuse within 1 year before screening.", "metadata": {"brief_title": "A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa", "phase": ["PHASE2"], "drugs_list": ["Eltrekibart", "Placebo"], "diseases_list": ["Hidradenitis Suppurativa"], "enrollment": 350, "inclusion_criteria": "inclusion criteria: \n\n Have a diagnosis of HS for at least 12 months.\n Have HS lesions in at least 2 distinct anatomical regions. At least 1 of the lesions must be at least Hurley Stage II or III.\n Have an (abscess plus inflammatory nodule) count of at least 5.\n Agree to use topical antiseptics daily.\n Had an inadequate response or intolerance to a 28-day course of oral antibiotics.", "exclusion_criteria": "exclusion criteria: \n\nHave more than 20 draining fistulae.\nHave had surgical treatment for HS in the last 4 weeks before randomization.\nHave an active skin disease or condition, that could interfere with the assessment of HS.\nHave a current or recent acute, active infection.\nAre immunocompromised.\nHave a history of chronic alcohol abuse, IV drug abuse, or other illicit drug abuse within 1 year before screening.", "brief_summary": "This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis suppurativa (HS) for further clinical development. The study will last approximately 62 weeks and may include up to 31 visits.", "keywords": []}}
{"_id": "NCT06338995", "title": "A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)", "text": "Summary: The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with chronic rhinosinusitis and nasal polyps treated with intranasal corticosteroids. The study will last about 18 months.\n\nInclusion criteria: inclusion criteria: \n\n Physician-diagnosed chronic rhinosinusitis (CRS) with bilateral nasal polyps (NP).\n Prior treatment with systemic corticosteroids (SCS) within the last 2 years (or a medical contraindication or intolerance to SCS), prior surgery for NP, or both.\n Endoscopic bilateral NPS score of at least 5 out of 8, with a minimum score of 2 in each nasal cavity performed at screening and baseline.\n Ongoing symptoms for at least 8 weeks prior to study entry (screening), including:\n\n  1. Nasal congestion with moderate or severe symptom severity (score 2 or 3) at screening and a weekly average severity score of at least 1 (range 0 to 3) at randomization, and\n  2. At least one other symptom, such as partial loss of smell (hyposmia), total loss of smell (anosmia), or anterior or posterior rhinorrhea.\n Have concomitant asthma must be stable in the 3 months prior to screening using permitted regular asthma treatment.\n\nExclusion criteria: exclusion criteria: \n\nHave received a dose of lebrikizumab.\nHave received treatment with any rescue medication and/or have the need for surgery for NP during screening and/or run-in period.\nAllergen immunotherapy (subcutaneous immunotherapy \\[SCIT\\]/sublingual immunotherapy \\[SLIT\\]) initiated within 6 months prior to screening, that is not on a stable dose (3 months prior to screening) or may require a dose change during study.\nPrior or current biologic treatment for CRSwNP and/or asthma including but not limited to omalizumab, dupilumab, mepolizumab, reslizumab, and benralizumab.\nHave received treatment with any biologic or systemic immunosuppressants for inflammatory disease or autoimmune disease prior to the baseline visit:\n\n  1. B cell-depleting biologics, including rituximab, within 6 months.\n  2. other biologics within 5 half-lives (if known) or 8 weeks, whichever is longer.\n  3. Systemic immunosuppressants within 4 weeks prior to baseline.\nHave had any sinus intranasal surgery (including nasal polypectomy) within 6 months prior to screening\nHave had prior sino-nasal surgery or sinus surgery changing lateral wall structure of the nose making it difficult to assess endoscopic NPS\nHave a presence of any of the following conditions that may impact the assessment of endpoints at screening or baseline:\n\n  1. Nasal septal deviation occluding at least one nostril.\n  2. Antrochoanal polyps.\n  3. Acute sinusitis, acute nasal infection, or acute upper respiratory infection.\n  4. Ongoing rhinitis medicamentosa.\n  5. Presence of another diagnosis associated with NP (ie, eosinophilic granulomatosis with polyangiitis, granulomatosis with polyangiitis, Young's syndrome, primary ciliary dyskinesia, cystic fibrosis).\n  6. A nasal cavity tumor (malignant or benign).\n  7. Evidence of fungal rhinosinusitis.\nHave anosmia from COVID or any reason other than CRSwNP.\nParticipants with forced expiratory volume in 1 second (FEV1) 50% or less (of predicted normal) at screening.\nFemale participant who is pregnant, breastfeeding, or is planning to become pregnant, or to breastfeed during the study.", "metadata": {"brief_title": "A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)", "phase": ["PHASE3"], "drugs_list": ["LY3650150", "Placebo", "Standard therapy for INCS"], "diseases_list": ["Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)"], "enrollment": 510, "inclusion_criteria": "inclusion criteria: \n\n Physician-diagnosed chronic rhinosinusitis (CRS) with bilateral nasal polyps (NP).\n Prior treatment with systemic corticosteroids (SCS) within the last 2 years (or a medical contraindication or intolerance to SCS), prior surgery for NP, or both.\n Endoscopic bilateral NPS score of at least 5 out of 8, with a minimum score of 2 in each nasal cavity performed at screening and baseline.\n Ongoing symptoms for at least 8 weeks prior to study entry (screening), including:\n\n  1. Nasal congestion with moderate or severe symptom severity (score 2 or 3) at screening and a weekly average severity score of at least 1 (range 0 to 3) at randomization, and\n  2. At least one other symptom, such as partial loss of smell (hyposmia), total loss of smell (anosmia), or anterior or posterior rhinorrhea.\n Have concomitant asthma must be stable in the 3 months prior to screening using permitted regular asthma treatment.", "exclusion_criteria": "exclusion criteria: \n\nHave received a dose of lebrikizumab.\nHave received treatment with any rescue medication and/or have the need for surgery for NP during screening and/or run-in period.\nAllergen immunotherapy (subcutaneous immunotherapy \\[SCIT\\]/sublingual immunotherapy \\[SLIT\\]) initiated within 6 months prior to screening, that is not on a stable dose (3 months prior to screening) or may require a dose change during study.\nPrior or current biologic treatment for CRSwNP and/or asthma including but not limited to omalizumab, dupilumab, mepolizumab, reslizumab, and benralizumab.\nHave received treatment with any biologic or systemic immunosuppressants for inflammatory disease or autoimmune disease prior to the baseline visit:\n\n  1. B cell-depleting biologics, including rituximab, within 6 months.\n  2. other biologics within 5 half-lives (if known) or 8 weeks, whichever is longer.\n  3. Systemic immunosuppressants within 4 weeks prior to baseline.\nHave had any sinus intranasal surgery (including nasal polypectomy) within 6 months prior to screening\nHave had prior sino-nasal surgery or sinus surgery changing lateral wall structure of the nose making it difficult to assess endoscopic NPS\nHave a presence of any of the following conditions that may impact the assessment of endpoints at screening or baseline:\n\n  1. Nasal septal deviation occluding at least one nostril.\n  2. Antrochoanal polyps.\n  3. Acute sinusitis, acute nasal infection, or acute upper respiratory infection.\n  4. Ongoing rhinitis medicamentosa.\n  5. Presence of another diagnosis associated with NP (ie, eosinophilic granulomatosis with polyangiitis, granulomatosis with polyangiitis, Young's syndrome, primary ciliary dyskinesia, cystic fibrosis).\n  6. A nasal cavity tumor (malignant or benign).\n  7. Evidence of fungal rhinosinusitis.\nHave anosmia from COVID or any reason other than CRSwNP.\nParticipants with forced expiratory volume in 1 second (FEV1) 50% or less (of predicted normal) at screening.\nFemale participant who is pregnant, breastfeeding, or is planning to become pregnant, or to breastfeed during the study.", "brief_summary": "The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with chronic rhinosinusitis and nasal polyps treated with intranasal corticosteroids. The study will last about 18 months.", "keywords": []}}
{"_id": "NCT06119581", "title": "A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer", "text": "Summary: The purpose of this study is to assess if adding LY3537982 in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including follow-up, could last up to 3 years, depending on how you and your lung cancer are doing.\n\nInclusion criteria: inclusion criteria: \n\n Histologically or cytologically confirmed NSCLC with Stage IIIB-IIIC or Stage IV disease, not suitable for curative intent radical surgery or radiation therapy.\n Part B and Safety Lead-In Part B: the histology of the tumor must be predominantly non-squamous (in line with pemetrexed label).\n Must have disease with evidence of KRAS G12C mutation.\n Must have known programmed death-ligand 1 (PD-L1) expression\n\n   Part A: Greater than or equal to (\u2265)50 percent (%).\n   Part B: 0% to 100%.\n Must have measurable disease per RECIST v1.1.\n Must have an ECOG performance status of 0 or 1.\n Estimated life expectancy \u226512 weeks.\n Ability to swallow capsules.\n Must have adequate laboratory parameters.\n Contraceptive use should be consistent with local regulations for those participating in clinical studies.\n Women of childbearing potential must\n\n   Have a negative pregnancy test.\n   Not be breastfeeding during treatment\n\nExclusion criteria: exclusion criteria: \n\nHave a documented additional validated targetable oncogenic driver mutation or alteration in genes such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), BRAF (V600E), human epidermal growth factor receptor 2 (HER2), MET (exon 14), ROS1, rearranged during transfection (RET), or neurotrophic tyrosine receptor kinase (NTRK)1/2/3.\nHave had any of the following prior to randomization:\n\n  -- Prior systemic therapy (chemotherapy, immunotherapy, targeted therapy, or biological therapy) for advanced or metastatic NSCLC.\n\n  --- 1 cycle of standard-of-care treatment prior to study enrollment will be allowed for cases where immediate treatment is clinically indicated:\nHave known active central nervous system metastases and/or carcinomatous meningitis.\n\nExclusion Criteria for Participants receiving Pemetrexed and Platinum (Part B and Safety Lead-In Part B)\n\nHave predominantly squamous cell histology for NSCLC\nIs unable to interrupt aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs)\nIs unable or unwilling to take folic acid or vitamin B12 supplementation.", "metadata": {"brief_title": "A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer", "phase": ["PHASE3"], "drugs_list": ["LY3537982", "Pembrolizumab", "Placebo", "Cisplatin", "Carboplatin", "Pemetrexed"], "diseases_list": ["Carcinoma, Non-Small-Cell Lung", "Neoplasm Metastasis"], "enrollment": 1016, "inclusion_criteria": "inclusion criteria: \n\n Histologically or cytologically confirmed NSCLC with Stage IIIB-IIIC or Stage IV disease, not suitable for curative intent radical surgery or radiation therapy.\n Part B and Safety Lead-In Part B: the histology of the tumor must be predominantly non-squamous (in line with pemetrexed label).\n Must have disease with evidence of KRAS G12C mutation.\n Must have known programmed death-ligand 1 (PD-L1) expression\n\n   Part A: Greater than or equal to (\u2265)50 percent (%).\n   Part B: 0% to 100%.\n Must have measurable disease per RECIST v1.1.\n Must have an ECOG performance status of 0 or 1.\n Estimated life expectancy \u226512 weeks.\n Ability to swallow capsules.\n Must have adequate laboratory parameters.\n Contraceptive use should be consistent with local regulations for those participating in clinical studies.\n Women of childbearing potential must\n\n   Have a negative pregnancy test.\n   Not be breastfeeding during treatment", "exclusion_criteria": "exclusion criteria: \n\nHave a documented additional validated targetable oncogenic driver mutation or alteration in genes such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), BRAF (V600E), human epidermal growth factor receptor 2 (HER2), MET (exon 14), ROS1, rearranged during transfection (RET), or neurotrophic tyrosine receptor kinase (NTRK)1/2/3.\nHave had any of the following prior to randomization:\n\n  -- Prior systemic therapy (chemotherapy, immunotherapy, targeted therapy, or biological therapy) for advanced or metastatic NSCLC.\n\n  --- 1 cycle of standard-of-care treatment prior to study enrollment will be allowed for cases where immediate treatment is clinically indicated:\nHave known active central nervous system metastases and/or carcinomatous meningitis.\n\nExclusion Criteria for Participants receiving Pemetrexed and Platinum (Part B and Safety Lead-In Part B)\n\nHave predominantly squamous cell histology for NSCLC\nIs unable to interrupt aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs)\nIs unable or unwilling to take folic acid or vitamin B12 supplementation.", "brief_summary": "The purpose of this study is to assess if adding LY3537982 in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including follow-up, could last up to 3 years, depending on how you and your lung cancer are doing.", "keywords": []}}
{"_id": "NCT05508789", "title": "A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)", "text": "Summary: The reason for this study is to assess the safety and efficacy of donanemab in participants with early Alzheimer's disease. The study duration including screening and follow-up is up to 93 weeks.\n\nInclusion criteria: inclusion criteria: \n\n Gradual and progressive change in memory function reported by the participant or informant for \u22656 months\n A MMSE score of 20 to 28 (inclusive) at Day 601 or 1.\n Meet flortaucipir F18 scan (central read) criteria\n Meet florbetapir F18 scan (central read) criteria\n Have a study partner who will provide written informed consent to participate, is in frequent contact with the participant (defined as at least 10 hours per week), and will accompany the participant to the study or be available by telephone at designated times.\n A second study partner may serve as backup. The study partner(s) is/are required to accompany the participant for signing consent. The study partner must be present on all days the cognitive and functional scales are administered.\n If a participant has a second study partner, it is preferred that 1 study partner be primarily responsible for the CDR and the ADCS-ADL assessments.\n Days requiring the following assessments and scales must have a study partner available by telephone if not accompanying participant for the following assessments\n\n   AEs and concomitant medications\n   CDR, and\n   ADCS-ADL\n Stable concomitant symptomatic AD medications and other medications that may impact cognition for at least approximately 30 days prior to randomization.\n\nExclusion criteria: exclusion criteria: \n\nHas significant neurological disease affect the central nervous system other than AD, that may affect cognition or ability to complete the study, including but not limited to, other dementias, serious infection of the brain, Parkinson's disease, multiple concussions, or epilepsy or recurrent seizures (except febrile childhood seizures).\nHas current serious or unstable illnesses including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, neurologic (other than AD), psychiatric, immunologic, or hematologic disease and other conditions that, in the investigator's opinion, could interfere with the analyses in this study; or has a life expectancy of \\<24 months.\nHistory of cancer within the last 5 years, except of non-metastatic basal and/or squamous cell carcinoma of the skin, in situ cervical cancer, nonprogressive prostate cancer, or other cancers with low risk of recurrence or spread.\nContraindication to MRI or PET scans", "metadata": {"brief_title": "A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)", "phase": ["PHASE3"], "drugs_list": ["Donanemab", "Placebo"], "diseases_list": ["Alzheimer Disease", "Dementia", "Brain Diseases", "Central Nervous System Diseases", "Nervous System Diseases", "Tauopathies", "Neurodegenerative Diseases", "Neurocognitive Disorders", "Mental Disorders"], "enrollment": 1500, "inclusion_criteria": "inclusion criteria: \n\n Gradual and progressive change in memory function reported by the participant or informant for \u22656 months\n A MMSE score of 20 to 28 (inclusive) at Day 601 or 1.\n Meet flortaucipir F18 scan (central read) criteria\n Meet florbetapir F18 scan (central read) criteria\n Have a study partner who will provide written informed consent to participate, is in frequent contact with the participant (defined as at least 10 hours per week), and will accompany the participant to the study or be available by telephone at designated times.\n A second study partner may serve as backup. The study partner(s) is/are required to accompany the participant for signing consent. The study partner must be present on all days the cognitive and functional scales are administered.\n If a participant has a second study partner, it is preferred that 1 study partner be primarily responsible for the CDR and the ADCS-ADL assessments.\n Days requiring the following assessments and scales must have a study partner available by telephone if not accompanying participant for the following assessments\n\n   AEs and concomitant medications\n   CDR, and\n   ADCS-ADL\n Stable concomitant symptomatic AD medications and other medications that may impact cognition for at least approximately 30 days prior to randomization.", "exclusion_criteria": "exclusion criteria: \n\nHas significant neurological disease affect the central nervous system other than AD, that may affect cognition or ability to complete the study, including but not limited to, other dementias, serious infection of the brain, Parkinson's disease, multiple concussions, or epilepsy or recurrent seizures (except febrile childhood seizures).\nHas current serious or unstable illnesses including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, neurologic (other than AD), psychiatric, immunologic, or hematologic disease and other conditions that, in the investigator's opinion, could interfere with the analyses in this study; or has a life expectancy of \\<24 months.\nHistory of cancer within the last 5 years, except of non-metastatic basal and/or squamous cell carcinoma of the skin, in situ cervical cancer, nonprogressive prostate cancer, or other cancers with low risk of recurrence or spread.\nContraindication to MRI or PET scans", "brief_summary": "The reason for this study is to assess the safety and efficacy of donanemab in participants with early Alzheimer's disease. The study duration including screening and follow-up is up to 93 weeks.", "keywords": ["Alzheimer's", "Dementia", "Cognitive Impairment", "Amyloid Plaque"]}}
{"_id": "NCT06362265", "title": "A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus", "text": "Summary: The main purpose of this study is to evaluate how much of LY3209590 gets into the blood stream after a single dose and how long it takes the body to remove it in pediatric participants with Type 2 Diabetes Mellitus (T2DM). The study will last for approximately 100 days.\n\nInclusion criteria: inclusion criteria: \n\n Participants with Type 2 Diabetes Mellitus (T2DM) for at least 3 months\n Have Glycated hemoglobin (HbA1c) level of 6.5 percent (%) to 9.5% at screening\n Have a body mass index equal to or less than 45.0 kilograms per square meter (kg/m\u00b2)\n Participants are insulin na\u00efve or have been without insulin treatment for at least 3 months prior to screening\n\nExclusion criteria: exclusion criteria: \n\nHave had a severe hypoglycemia in the past 6 months\nHave a history of renal impairment\nHave had a blood transfusion or severe blood loss within last 90 days\nHave had a significant weight gain or loss of approximately 6% or more within 3 months prior to screening.\nHave a history of an active or untreated malignancy\nAre receiving or received systemic glucocorticoid therapy\nAre currently enrolled in another clinical study trial involving medical research or have participated within the last 30 days in a clinical study involving an investigational product", "metadata": {"brief_title": "A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus", "phase": ["PHASE1"], "drugs_list": ["LY3209590"], "diseases_list": ["Type 2 Diabetes Mellitus"], "enrollment": 22, "inclusion_criteria": "inclusion criteria: \n\n Participants with Type 2 Diabetes Mellitus (T2DM) for at least 3 months\n Have Glycated hemoglobin (HbA1c) level of 6.5 percent (%) to 9.5% at screening\n Have a body mass index equal to or less than 45.0 kilograms per square meter (kg/m\u00b2)\n Participants are insulin na\u00efve or have been without insulin treatment for at least 3 months prior to screening", "exclusion_criteria": "exclusion criteria: \n\nHave had a severe hypoglycemia in the past 6 months\nHave a history of renal impairment\nHave had a blood transfusion or severe blood loss within last 90 days\nHave had a significant weight gain or loss of approximately 6% or more within 3 months prior to screening.\nHave a history of an active or untreated malignancy\nAre receiving or received systemic glucocorticoid therapy\nAre currently enrolled in another clinical study trial involving medical research or have participated within the last 30 days in a clinical study involving an investigational product", "brief_summary": "The main purpose of this study is to evaluate how much of LY3209590 gets into the blood stream after a single dose and how long it takes the body to remove it in pediatric participants with Type 2 Diabetes Mellitus (T2DM). The study will last for approximately 100 days.", "keywords": ["Insulin"]}}
{"_id": "NCT06709820", "title": "A Study of LY4060874 in Healthy Participants", "text": "Summary: The purpose of this study is to evaluate safety and tolerability of LY4060874 in healthy participants.\n\nStudy participation may last up to 22 weeks and up to approximately 16 study visits.\n\nInclusion criteria: inclusion criteria: \n\n Are overtly healthy as determined by medical evaluation, including medical history and physical examination.\n Have a body mass index in the range of 20 to 29.9 kilogram per meter squared (kg/m\u00b2), inclusive, at screening.\n To qualify as Chinese for this study, all 4 of the participant's biological grandparents must be of exclusive Chinese descent and born in China.\n To qualify as a participant of first-generation Japanese origin, the participant, the participant's biological parents, and all the participants' biological grandparents must be of exclusive Japanese descent and born in Japan.\n\nExclusion criteria: exclusion criteria: \n\nHave a history of or have been diagnosed with Type 1 or Type 2 diabetes mellitus.\nHave hemoglobin A1c (HbA1c) \\> 6.4% or 46 millimoles/mole (mmol/mol) at screening.\nHave taken approved, including over the counter (OTC) or prescribed, medication or investigational medication for weight loss, including GLP-1 receptor agonists, within the previous 3 months of study screening.\nHave had surgical treatment for obesity.\nAre actively participating in a weight loss program or intend to initiate an intensive diet and/or exercise program during the study.", "metadata": {"brief_title": "A Study of LY4060874 in Healthy Participants", "phase": ["PHASE1"], "drugs_list": ["LY4060874", "LY4060874", "Placebo", "Placebo"], "diseases_list": ["Healthy Participants"], "enrollment": 132, "inclusion_criteria": "inclusion criteria: \n\n Are overtly healthy as determined by medical evaluation, including medical history and physical examination.\n Have a body mass index in the range of 20 to 29.9 kilogram per meter squared (kg/m\u00b2), inclusive, at screening.\n To qualify as Chinese for this study, all 4 of the participant's biological grandparents must be of exclusive Chinese descent and born in China.\n To qualify as a participant of first-generation Japanese origin, the participant, the participant's biological parents, and all the participants' biological grandparents must be of exclusive Japanese descent and born in Japan.", "exclusion_criteria": "exclusion criteria: \n\nHave a history of or have been diagnosed with Type 1 or Type 2 diabetes mellitus.\nHave hemoglobin A1c (HbA1c) \\> 6.4% or 46 millimoles/mole (mmol/mol) at screening.\nHave taken approved, including over the counter (OTC) or prescribed, medication or investigational medication for weight loss, including GLP-1 receptor agonists, within the previous 3 months of study screening.\nHave had surgical treatment for obesity.\nAre actively participating in a weight loss program or intend to initiate an intensive diet and/or exercise program during the study.", "brief_summary": "The purpose of this study is to evaluate safety and tolerability of LY4060874 in healthy participants.\n\nStudy participation may last up to 22 weeks and up to approximately 16 study visits.", "keywords": []}}
{"_id": "NCT05848258", "title": "An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis", "text": "Summary: The main purpose of this study is to evaluate the efficacy and safety of LY3871801 in adult participants with active moderately-to-severe rheumatoid arthritis (RA).\n\nInclusion criteria: inclusion criteria: \n\n Have a diagnosis of adult-onset RA for at least 3 months prior to screening as defined by the 2010 ACR/European League Against Rheumatism (EULAR) classification criteria.\n Have moderately-to-severely active RA at screening and baseline, defined by the presence of\n\n   \u22656 swollen joints based on 66 joint count, and\n   \u22656 tender joints based on 68 joint count.\n Have had a history of failure (an inadequate response, intolerance, or loss of response) to at least 1 conventional synthetic disease modifying anti rheumatic drug (csDMARD) and either 1 biologic (bDMARD), or targeted synthetic (tsDMARD) treatment.\n\nExclusion criteria: exclusion criteria: \n\nHave Class IV RA according to ACR revised criteria\nHave presence of 1 or more significant concurrent medical conditions per investigator judgment, including but not limited to\n\n  poorly controlled diabetes or hypertension\n  chronic kidney disease stage IIIa or IIIb, IV, or V\n  symptomatic heart failure according to New York Heart Association class II, III, or IV\n  myocardial infarction,unstable angina pectoris, stroke, or transient ischemic attack within the past 12 months before randomization\n  severe chronic pulmonary disease, for example, requiring oxygen therapy\n  major chronic inflammatory disease or connective tissue disease other than RA, including but not limited to\n\n    systemic lupus erythematosus\n    psoriatic arthritis\n    axial spondyloarthritis,including ankylosing spondylitis and non-radiographic axial spondyloarthritis\n    reactive arthritis\n    gout\n    scleroderma\n    polymyositis\n    dermatomyositis\n    active fibromyalgia, or\n    multiple sclerosis", "metadata": {"brief_title": "An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis", "phase": ["PHASE2"], "drugs_list": ["LY3871801", "Placebo"], "diseases_list": ["Rheumatoid Arthritis"], "enrollment": 380, "inclusion_criteria": "inclusion criteria: \n\n Have a diagnosis of adult-onset RA for at least 3 months prior to screening as defined by the 2010 ACR/European League Against Rheumatism (EULAR) classification criteria.\n Have moderately-to-severely active RA at screening and baseline, defined by the presence of\n\n   \u22656 swollen joints based on 66 joint count, and\n   \u22656 tender joints based on 68 joint count.\n Have had a history of failure (an inadequate response, intolerance, or loss of response) to at least 1 conventional synthetic disease modifying anti rheumatic drug (csDMARD) and either 1 biologic (bDMARD), or targeted synthetic (tsDMARD) treatment.", "exclusion_criteria": "exclusion criteria: \n\nHave Class IV RA according to ACR revised criteria\nHave presence of 1 or more significant concurrent medical conditions per investigator judgment, including but not limited to\n\n  poorly controlled diabetes or hypertension\n  chronic kidney disease stage IIIa or IIIb, IV, or V\n  symptomatic heart failure according to New York Heart Association class II, III, or IV\n  myocardial infarction,unstable angina pectoris, stroke, or transient ischemic attack within the past 12 months before randomization\n  severe chronic pulmonary disease, for example, requiring oxygen therapy\n  major chronic inflammatory disease or connective tissue disease other than RA, including but not limited to\n\n    systemic lupus erythematosus\n    psoriatic arthritis\n    axial spondyloarthritis,including ankylosing spondylitis and non-radiographic axial spondyloarthritis\n    reactive arthritis\n    gout\n    scleroderma\n    polymyositis\n    dermatomyositis\n    active fibromyalgia, or\n    multiple sclerosis", "brief_summary": "The main purpose of this study is to evaluate the efficacy and safety of LY3871801 in adult participants with active moderately-to-severe rheumatoid arthritis (RA).", "keywords": []}}
{"_id": "NCT06672939", "title": "A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities", "text": "Summary: The main purpose of this study, performed under Master Protocol J4M-MC-PWMP, is to evaluate the efficacy, safety, and pharmacokinetics of orforglipron once daily oral versus Placebo in adolescent participants with obesity, or overweight with related comorbidities. Participation in the study will last about 18 months.\n\nInclusion criteria: inclusion criteria: \n\nJ4M-MC-PWMP\n\n Have a history of at least 1 unsuccessful effort to lose sufficient body weight after participation in a structured lifestyle modification program (diet and exercise counseling for at least 3 months) prior to screening.\n Obesity as defined by BMI equal to or above the 95th percentile for age and sex (on age- and gender-specific growth chart \\[CDC-NCHS, 2022\\]); OR\n Overweight as defined by BMI equal to or above the 85th percentile but less than the 95th percentile for age and sex, on age- and sex-specific growth chart (CDC-NCHS, 2022), and at least 1 weight-related comorbidity,\n\n   hypertension\n   type 2 diabetes (T2D)\n   prediabetes\n   dyslipidemia\n   obstructive sleep apnea\n   metabolic dysfunction-associated steatohepatitis (MASH) or metabolic dysfunction-associated steatotic liver disease (MASLD)\n\nExclusion criteria: exclusion criteria: \n\nJ4M-MC-PW01\n\nPrepubertal (Tanner stage 1)\nHave a self-reported, or by parent or legal guardian where applicable, decrease in body weight greater than 5 kilograms (kg) (11 pounds) within 90 days before screening\n\nJ4M-MC-PWMP\n\nHave undergone or plan to undergo weight reduction procedure during the study, such as, but not limited to:\n\n  gastric bypass\n  sleeve gastrectomy\n  restrictive bariatric surgery, such as Lap-Band\u00ae gastric banding, or\n  any other procedure intended to result in weight reduction.\nHave a diagnosis that is a secondary cause of obesity or have a history of abrupt onset of obesity suggesting a secondary cause, such as hypothalamic, monogenetic, syndromic, or endocrine causes.\nHave type 1 diabetes or history of ketoacidosis, or hyperosmolar state.\nHave HbA1c \\>9.0% (75 mmol/mol) as measured by central laboratory at screening.\nHave a family or personal history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia Syndrome Type 2.", "metadata": {"brief_title": "A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities", "phase": ["PHASE3"], "drugs_list": ["Orforglipron", "Placebo"], "diseases_list": ["Obesity", "Overweight"], "enrollment": 125, "inclusion_criteria": "inclusion criteria: \n\nJ4M-MC-PWMP\n\n Have a history of at least 1 unsuccessful effort to lose sufficient body weight after participation in a structured lifestyle modification program (diet and exercise counseling for at least 3 months) prior to screening.\n Obesity as defined by BMI equal to or above the 95th percentile for age and sex (on age- and gender-specific growth chart \\[CDC-NCHS, 2022\\]); OR\n Overweight as defined by BMI equal to or above the 85th percentile but less than the 95th percentile for age and sex, on age- and sex-specific growth chart (CDC-NCHS, 2022), and at least 1 weight-related comorbidity,\n\n   hypertension\n   type 2 diabetes (T2D)\n   prediabetes\n   dyslipidemia\n   obstructive sleep apnea\n   metabolic dysfunction-associated steatohepatitis (MASH) or metabolic dysfunction-associated steatotic liver disease (MASLD)", "exclusion_criteria": "exclusion criteria: \n\nJ4M-MC-PW01\n\nPrepubertal (Tanner stage 1)\nHave a self-reported, or by parent or legal guardian where applicable, decrease in body weight greater than 5 kilograms (kg) (11 pounds) within 90 days before screening\n\nJ4M-MC-PWMP\n\nHave undergone or plan to undergo weight reduction procedure during the study, such as, but not limited to:\n\n  gastric bypass\n  sleeve gastrectomy\n  restrictive bariatric surgery, such as Lap-Band\u00ae gastric banding, or\n  any other procedure intended to result in weight reduction.\nHave a diagnosis that is a secondary cause of obesity or have a history of abrupt onset of obesity suggesting a secondary cause, such as hypothalamic, monogenetic, syndromic, or endocrine causes.\nHave type 1 diabetes or history of ketoacidosis, or hyperosmolar state.\nHave HbA1c \\>9.0% (75 mmol/mol) as measured by central laboratory at screening.\nHave a family or personal history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia Syndrome Type 2.", "brief_summary": "The main purpose of this study, performed under Master Protocol J4M-MC-PWMP, is to evaluate the efficacy, safety, and pharmacokinetics of orforglipron once daily oral versus Placebo in adolescent participants with obesity, or overweight with related comorbidities. Participation in the study will last about 18 months.", "keywords": []}}
{"_id": "NCT05614739", "title": "FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3", "text": "Summary: The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-435 by itself or when it is combined with other standard medicines that treat cancer. LOXO-435 may be used to treat cancer of the cells that line the urinary system and other solid tumor cancers that have a change in a particular gene (known as the FGFR3 gene). Participation could last up to 30 months (2.5 years) and possibly longer if the disease does not get worse.\n\nInclusion criteria: inclusion criteria: \n\n Have solid tumor cancer with an FGFR3 pathway alteration on molecular testing in tumor or blood sample that is deemed as actionable\n\n   Cohort A1: Presence of an alteration in FGFR3 or its ligands\n   Cohort A2, B2, B3, and B5: Histological diagnosis of urothelial cancer (UC) that is locally advanced or metastatic with a qualifying FGFR3 genetic alteration\n   Cohorts B1 and B4: Histological diagnosis of urothelial cancer that is locally advanced or metastatic\n   Cohort C1: Must have histological diagnosis of a non-urothelial solid tumor malignancy that is locally advanced or metastatic with a qualifying FGFR3 genetic alteration\n Measurability of disease:\n\n   Cohort A1 and B3: Measurable or non-measurable disease as defined by Response Evaluation Criteria in Solid Tumors v 1.1 (RECIST v1.1)\n   Cohorts A2, B1, B2, B4, B5, and C1: Measurable disease required as defined by RECIST v1.1\n Have adequate tumor tissue sample available. Participants with inadequate tissue sample availability may still be considered for enrollment upon review\n Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 for Cohorts A1, A2, B3, and B5\n\n   Less than or equal to 2 for Cohorts B1, B2, B4, and C1\n Prior Systemic Therapy Criteria:\n\n   Cohort A1/C1: Participant has received all standard therapies for which the participant was deemed to be an appropriate candidate by the treating Investigator; OR the participant is refusing the remaining most appropriate standard of care treatment; OR there is no standard therapy available for the disease. There is no restriction on number of prior therapies.\n   Cohort A2, B2, B3 participants must have received at least one prior regimen, and cohorts B1 and B4 participants at least 2 prior regimens, in the locally advanced or metastatic setting\n   There is no restriction on number of prior therapies\n Cohort B5: Participants have not received prior systemic therapy for locally advanced or metastatic UC\n FGFR inhibitor specific requirements:\n\n   Cohort A1/A2/B3: Prior FGFR inhibitor treatment is permitted but not required\n   Cohort B1/B4: Participants must have been previously treated with erdafitinib\n   Cohort B2, B5, and C1: Participants must be FGFR inhibitor na\u00efve\n\nExclusion criteria: exclusion criteria: \n\nParticipants with primary central nervous system (CNS) malignancy\nUntreated or uncontrolled CNS metastases\nCurrent evidence of corneal keratopathy or retinal disorder. Individuals with asymptomatic ophthalmic conditions may be eligible\nAny serious unresolved toxicities from prior therapy\nSignificant cardiovascular disease\nProlongation of the QT interval corrected for heart rate using Fridericia's formula (QTcF)\nActive uncontrolled systemic infection or other clinically significant medical conditions\nParticipants who are pregnant, lactating, or plan to breastfeed during the study or within 6 months of the last dose of study treatment. Participants who have stopped breastfeeding may be enrolled", "metadata": {"brief_title": "FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3", "phase": ["PHASE1"], "drugs_list": ["LOXO-435", "Pembrolizumab", "enfortumab vedotin"], "diseases_list": ["Urinary Bladder Neoplasms", "Neoplasm Metastasis", "Ureteral Neoplasms"], "enrollment": 535, "inclusion_criteria": "inclusion criteria: \n\n Have solid tumor cancer with an FGFR3 pathway alteration on molecular testing in tumor or blood sample that is deemed as actionable\n\n   Cohort A1: Presence of an alteration in FGFR3 or its ligands\n   Cohort A2, B2, B3, and B5: Histological diagnosis of urothelial cancer (UC) that is locally advanced or metastatic with a qualifying FGFR3 genetic alteration\n   Cohorts B1 and B4: Histological diagnosis of urothelial cancer that is locally advanced or metastatic\n   Cohort C1: Must have histological diagnosis of a non-urothelial solid tumor malignancy that is locally advanced or metastatic with a qualifying FGFR3 genetic alteration\n Measurability of disease:\n\n   Cohort A1 and B3: Measurable or non-measurable disease as defined by Response Evaluation Criteria in Solid Tumors v 1.1 (RECIST v1.1)\n   Cohorts A2, B1, B2, B4, B5, and C1: Measurable disease required as defined by RECIST v1.1\n Have adequate tumor tissue sample available. Participants with inadequate tissue sample availability may still be considered for enrollment upon review\n Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 for Cohorts A1, A2, B3, and B5\n\n   Less than or equal to 2 for Cohorts B1, B2, B4, and C1\n Prior Systemic Therapy Criteria:\n\n   Cohort A1/C1: Participant has received all standard therapies for which the participant was deemed to be an appropriate candidate by the treating Investigator; OR the participant is refusing the remaining most appropriate standard of care treatment; OR there is no standard therapy available for the disease. There is no restriction on number of prior therapies.\n   Cohort A2, B2, B3 participants must have received at least one prior regimen, and cohorts B1 and B4 participants at least 2 prior regimens, in the locally advanced or metastatic setting\n   There is no restriction on number of prior therapies\n Cohort B5: Participants have not received prior systemic therapy for locally advanced or metastatic UC\n FGFR inhibitor specific requirements:\n\n   Cohort A1/A2/B3: Prior FGFR inhibitor treatment is permitted but not required\n   Cohort B1/B4: Participants must have been previously treated with erdafitinib\n   Cohort B2, B5, and C1: Participants must be FGFR inhibitor na\u00efve", "exclusion_criteria": "exclusion criteria: \n\nParticipants with primary central nervous system (CNS) malignancy\nUntreated or uncontrolled CNS metastases\nCurrent evidence of corneal keratopathy or retinal disorder. Individuals with asymptomatic ophthalmic conditions may be eligible\nAny serious unresolved toxicities from prior therapy\nSignificant cardiovascular disease\nProlongation of the QT interval corrected for heart rate using Fridericia's formula (QTcF)\nActive uncontrolled systemic infection or other clinically significant medical conditions\nParticipants who are pregnant, lactating, or plan to breastfeed during the study or within 6 months of the last dose of study treatment. Participants who have stopped breastfeeding may be enrolled", "brief_summary": "The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-435 by itself or when it is combined with other standard medicines that treat cancer. LOXO-435 may be used to treat cancer of the cells that line the urinary system and other solid tumor cancers that have a change in a particular gene (known as the FGFR3 gene). Participation could last up to 30 months (2.5 years) and possibly longer if the disease does not get worse.", "keywords": ["Bladder Cancer", "Bladder Urothelial Carcinoma", "Urinary Bladder Cancer", "Urinary Tract Cancer", "Renal Pelvis Cancer", "Ureter Cancer"]}}
{"_id": "NCT06859268", "title": "A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity", "text": "Summary: This is a study of retatrutide in participants with obesity. The main purpose is to learn more about how retatrutide maintains body weight loss. The study will have two treatment phases: an 80 week lead-in phase in which all participants will take retatrutide dose 1 and a 36 week randomized, double-blinded phase in which participants will either take retatrutide dose 1, retatrutide dose 2, or switch to placebo. Participation in the study will last around 125 weeks.\n\nInclusion criteria: inclusion criteria: \n\n Have obesity and a history of at least one self-reported unsuccessful dietary effort to reduce body weight\n\nExclusion criteria: exclusion criteria: \n\nHave a self-reported change in body weight \\>5 kilograms (kg) (11 pounds) within 90 days before screening\nHave a prior or planned surgical treatment for obesity\nHave a prior or planned endoscopic procedure and/or device-based therapy for obesity\nHave Type 1 Diabetes, Type 2 Diabetes, or any other type of diabetes\nHave a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)\nHave had within the past 90 days before screening:\n\n  acute myocardial infarction\n  cerebrovascular accident (stroke)\n  hospitalization for unstable angina, or\n  hospitalization due to congestive heart failure\nHave New York Heart Association Functional Classification Class IV congestive heart failure\nHave a history of chronic or acute pancreatitis\nHave taken weight loss drugs, including over-the-counter medications, within 90 days prior to screening", "metadata": {"brief_title": "A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity", "phase": ["PHASE3"], "drugs_list": ["Retatrutide", "Placebo"], "diseases_list": ["Obesity"], "enrollment": 586, "inclusion_criteria": "inclusion criteria: \n\n Have obesity and a history of at least one self-reported unsuccessful dietary effort to reduce body weight", "exclusion_criteria": "exclusion criteria: \n\nHave a self-reported change in body weight \\>5 kilograms (kg) (11 pounds) within 90 days before screening\nHave a prior or planned surgical treatment for obesity\nHave a prior or planned endoscopic procedure and/or device-based therapy for obesity\nHave Type 1 Diabetes, Type 2 Diabetes, or any other type of diabetes\nHave a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)\nHave had within the past 90 days before screening:\n\n  acute myocardial infarction\n  cerebrovascular accident (stroke)\n  hospitalization for unstable angina, or\n  hospitalization due to congestive heart failure\nHave New York Heart Association Functional Classification Class IV congestive heart failure\nHave a history of chronic or acute pancreatitis\nHave taken weight loss drugs, including over-the-counter medications, within 90 days prior to screening", "brief_summary": "This is a study of retatrutide in participants with obesity. The main purpose is to learn more about how retatrutide maintains body weight loss. The study will have two treatment phases: an 80 week lead-in phase in which all participants will take retatrutide dose 1 and a 36 week randomized, double-blinded phase in which participants will either take retatrutide dose 1, retatrutide dose 2, or switch to placebo. Participation in the study will last around 125 weeks.", "keywords": []}}
{"_id": "NCT05536804", "title": "A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes", "text": "Summary: We are doing this study to learn more about how tirzepatide may help fight chronic kidney disease in people with obesity with or without type 2 diabetes (T2D).\n\nThe study will last about 56 weeks and include up to 12 visits.\n\nInclusion criteria: inclusion criteria: \n\nAll participants with or without diabetes:\n\n Have a Body Mass Index (BMI) \u226527 kilogram/square meter (kg/m\u00b2) at screening\n Diagnosed with chronic kidney disease (CKD)\n Has an estimated glomerular filtration rate (eGFR) \u226525 to \u226460 ml/min/1.73 m\u00b2 or eGFR \u226525 to \u226475 ml/min/1.73 m\u00b2 if urine albumin-to-creatinine ratio (UACR) \\>30 milligram/gram (mg/g)\n Have been receiving an angiotensin-converting enzyme (ACE) or angiotensin II receptor blockers (ARB) that is considered the maximal appropriate dose by the investigator for treatment of chronic kidney disease or hypertension (unless the participant has low blood pressure or hypotension)\n\nParticipants without diabetes:\n\n Have Hemoglobin A1c (HbA1c) \\<6.5% at screening\n\nParticipants with Type 2 diabetes:\n\n Have been diagnosed at least 180 days prior to screening\n Have HbA1c \u22649.5% at screening\n\nExclusion criteria: exclusion criteria: \n\nAll participants:\n\nHave a self-reported change in body weight \\>5 kilogram (kg) within 90 days prior to screening.\nHave a prior or planned surgical treatment for obesity\nHave or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 180 days\nHave eGFR \\<25 mL/min/1.73m\u00b2 calculated by using creatinine-based chronic kidney disease epidemiology collaboration (CKD-EPI) equations, as determined by central laboratory at screening.\nHave a history of unstable or rapidly progressing renal disease according to investigator judgment\nHave a known clinically significant gastric emptying abnormality (for example, severe diabetic gastroparesis or gastric outlet obstruction) or chronically take drugs that directly affect GI motility)\nHave had a history of chronic or acute pancreatitis\n\nParticipants with T2D:\n\nHave history of proliferative diabetic retinopathy or diabetic macular edema or non-proliferative diabetic retinopathy that requires acute treatment.\nHave been diagnosed with type 1 diabetes (T1D) or have history of ketoacidosis or hyperosmolar state/coma", "metadata": {"brief_title": "A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes", "phase": ["PHASE2"], "drugs_list": ["Tirzepatide", "Placebo"], "diseases_list": ["Overweight", "Obesity", "Chronic Kidney Disease", "Type 2 Diabetes", "T2D"], "enrollment": 140, "inclusion_criteria": "inclusion criteria: \n\nAll participants with or without diabetes:\n\n Have a Body Mass Index (BMI) \u226527 kilogram/square meter (kg/m\u00b2) at screening\n Diagnosed with chronic kidney disease (CKD)\n Has an estimated glomerular filtration rate (eGFR) \u226525 to \u226460 ml/min/1.73 m\u00b2 or eGFR \u226525 to \u226475 ml/min/1.73 m\u00b2 if urine albumin-to-creatinine ratio (UACR) \\>30 milligram/gram (mg/g)\n Have been receiving an angiotensin-converting enzyme (ACE) or angiotensin II receptor blockers (ARB) that is considered the maximal appropriate dose by the investigator for treatment of chronic kidney disease or hypertension (unless the participant has low blood pressure or hypotension)\n\nParticipants without diabetes:\n\n Have Hemoglobin A1c (HbA1c) \\<6.5% at screening\n\nParticipants with Type 2 diabetes:\n\n Have been diagnosed at least 180 days prior to screening\n Have HbA1c \u22649.5% at screening", "exclusion_criteria": "exclusion criteria: \n\nAll participants:\n\nHave a self-reported change in body weight \\>5 kilogram (kg) within 90 days prior to screening.\nHave a prior or planned surgical treatment for obesity\nHave or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 180 days\nHave eGFR \\<25 mL/min/1.73m\u00b2 calculated by using creatinine-based chronic kidney disease epidemiology collaboration (CKD-EPI) equations, as determined by central laboratory at screening.\nHave a history of unstable or rapidly progressing renal disease according to investigator judgment\nHave a known clinically significant gastric emptying abnormality (for example, severe diabetic gastroparesis or gastric outlet obstruction) or chronically take drugs that directly affect GI motility)\nHave had a history of chronic or acute pancreatitis\n\nParticipants with T2D:\n\nHave history of proliferative diabetic retinopathy or diabetic macular edema or non-proliferative diabetic retinopathy that requires acute treatment.\nHave been diagnosed with type 1 diabetes (T1D) or have history of ketoacidosis or hyperosmolar state/coma", "brief_summary": "We are doing this study to learn more about how tirzepatide may help fight chronic kidney disease in people with obesity with or without type 2 diabetes (T2D).\n\nThe study will last about 56 weeks and include up to 12 visits.", "keywords": []}}
{"_id": "NCT06075667", "title": "A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities", "text": "Summary: The main purpose of this study is to evaluate the safety and efficacy of tirzepatide in adolescents that have obesity or overweight with at least one weight-related comorbidity. The study will last approximately 90 weeks and may include up to 25 visits.\n\nInclusion criteria: inclusion criteria: \n\n Have obesity, as defined by BMI equal to or above the 95th percentile for age and sex, on age- and sex-specific growth chart, OR\n Have overweight, as defined by BMI equal to or above the 85th percentile but less than the 95th percentile for age and sex, on age- and sex-specific growth chart, with at least 1 weight-related comorbidity.\n\n   dyslipidemia\n   pre-hypertension\n   hypertension\n   nonalcoholic fatty liver disease\n   obstructive sleep apnea\n   prediabetes\n   documented preexisting condition of Type 2 Diabetes\n\nParticipants with Type 2 Diabetes Mellitus (T2DM)\n\n Have been treated with either diet and exercise alone or stable treatment with metformin for at least 90 days prior to screening and have a HbA1c\\<9.0%\n\nExclusion criteria: exclusion criteria: \n\nHave a self-reported, or by parent or legal guardian where applicable, decrease in body weight more than 5 kilogram (kg) (11 lbs.) within 90 days before screening irrespective of medical records.\nHave Type 1 Diabetes\nHave taken within 90 days before screening or intend to start prescribed or over-the-counter medications, or alternative remedies including herbal or nutritional supplements, intended to promote body weight reduction.\nAre prepubertal (Tanner stage 1).\nHave a family or personal history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia (MEN) Syndrome Type 2\nHave a history of chronic or acute pancreatitis.\nHave undergone or plan to undergo weight reduction procedure during the study, such as, but not limited to\n\n  gastric bypass\n  sleeve gastrectomy\n  restrictive bariatric surgery, such as Lap-Band gastric banding, or\n  any other procedure intended to result in weight reduction.", "metadata": {"brief_title": "A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities", "phase": ["PHASE3"], "drugs_list": ["Tirzepatide", "Placebo"], "diseases_list": ["Obesity", "Overweight"], "enrollment": 150, "inclusion_criteria": "inclusion criteria: \n\n Have obesity, as defined by BMI equal to or above the 95th percentile for age and sex, on age- and sex-specific growth chart, OR\n Have overweight, as defined by BMI equal to or above the 85th percentile but less than the 95th percentile for age and sex, on age- and sex-specific growth chart, with at least 1 weight-related comorbidity.\n\n   dyslipidemia\n   pre-hypertension\n   hypertension\n   nonalcoholic fatty liver disease\n   obstructive sleep apnea\n   prediabetes\n   documented preexisting condition of Type 2 Diabetes\n\nParticipants with Type 2 Diabetes Mellitus (T2DM)\n\n Have been treated with either diet and exercise alone or stable treatment with metformin for at least 90 days prior to screening and have a HbA1c\\<9.0%", "exclusion_criteria": "exclusion criteria: \n\nHave a self-reported, or by parent or legal guardian where applicable, decrease in body weight more than 5 kilogram (kg) (11 lbs.) within 90 days before screening irrespective of medical records.\nHave Type 1 Diabetes\nHave taken within 90 days before screening or intend to start prescribed or over-the-counter medications, or alternative remedies including herbal or nutritional supplements, intended to promote body weight reduction.\nAre prepubertal (Tanner stage 1).\nHave a family or personal history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia (MEN) Syndrome Type 2\nHave a history of chronic or acute pancreatitis.\nHave undergone or plan to undergo weight reduction procedure during the study, such as, but not limited to\n\n  gastric bypass\n  sleeve gastrectomy\n  restrictive bariatric surgery, such as Lap-Band gastric banding, or\n  any other procedure intended to result in weight reduction.", "brief_summary": "The main purpose of this study is to evaluate the safety and efficacy of tirzepatide in adolescents that have obesity or overweight with at least one weight-related comorbidity. The study will last approximately 90 weeks and may include up to 25 visits.", "keywords": []}}
{"_id": "NCT06148272", "title": "A Study of LY3971297 in Healthy Participants", "text": "Summary: The purpose of this study is to measure side effects of LY3971297 injection administered under the skin in healthy participants and obese participants with high blood pressure (BP). Blood tests will be performed to check how much LY3971297 gets into the bloodstream and how long it takes the body to eliminate it. This is a 7-part study. The study duration will be approximately 60 days for Parts A and F, and approximately 90 days for Parts B, C, D, E, and G.\n\nInclusion criteria: inclusion criteria: \n\n For Parts A, B, C, E, and F: Overtly healthy males or females as determined by medical history and physical examination\n For Parts A, B, C, E, and F: Have a screening body mass index (BMI) in the range of 18.5 to 35 kilogram per square meter (kg/m\u00b2), inclusive, with no significant weight gain or loss in the past 3 months prior to screening\n For Part C, to qualify as Chinese for the purpose of this study, all the participants' biological grandparents must be of exclusive Chinese descent and born in China\n For Part D, participants must have a stable dose of medications within the past 3 months prior to screening\n For Part D, obesity BMI in the range of 30 to 40 kg/m\u00b2, inclusive, with a waist circumference of at least 102 centimeter (cm) for men and at least 89 cm for women for participants of US sites only. For participants of Singaporean, South Asian, Japanese, and/or Chinese Origin at sites outside the US, the BMI range is 27 to 40 kg/m2 and the waist circumference is at least 90 cm for men and at least 80 cm for women\n For Part E, to qualify as a participant of the first-generation Japanese origin, the participant, the participant's biological parents, and all of the participants' biological grandparents must be of exclusive Japanese descent and born in Japan\n Male participants must agree to adhere to contraception restrictions and female participants must be women not of childbearing potential\n For Part G, have a screening BMI in the range of 18.5 to 40 kg/m\u00b2, inclusive, with no significant weight gain or loss in the past 3 months prior to screening\n For Part G, participants have a decreased estimated glomerular filtration rate (eGFR)\n For Parts D and G, participants are allowed to have stable background treatment for hypertension, type 2 diabetes mellitus (on oral drug therapy and/or long-acting insulin), dyslipidemia (on statin therapy) and/or hypothyroidism as determined by the investigator\n For Part G, Participants should be on a stable dose of angiotensin converting enzyme inhibitor or angiotensin II receptor blocker\n\nExclusion criteria: exclusion criteria: \n\nHave a history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders\nHave known or ongoing psychiatric disorders that, in the opinion of the investigator, increases the risks associated with study participation\nHave blood pressure and/or pulse rate constituting a risk as determined by the investigator\nHave a systolic blood pressure (BP) of less than 100 millimeters of mercury (mmHg)\nDiagnosed with orthostatic hypotension defined as a decrease in systolic blood pressure of equal to or greater than 20 mmHg or a decrease in diastolic blood pressure of equal to or greater than 10 mmHg when compared with BP from the supine position\nFor US sites: have donated blood of more than 500 mL within the previous 3 months of screening or intend to donate blood during the course of the study\nFor Singapore sites: Have donated blood of more than 450 mL or more in the past 3 months or provided any blood donation within the past 1 month before screening\nConsume more than 10 cigarettes per day (or the equivalent) or are unable or unwilling to abstain from nicotine\nHave alcohol intake that exceeds recommended alcohol consumption limits per local regulation or are unwilling to stop alcohol consumption 24 hours prior to dosing until discharge\nFor Part D, has concurrent use or anticipated use of phosphodiesterase 5 inhibitor such as vardenafil, tadalafil, and sildenafil, soluble guanylyl cyclase activators (such as riociguat and vericiguat)\nFor Parts D and G, has concurrent or anticipated use of long-acting nitrates or nitric oxide (NO) donors\nFor Part D, has current use of more than 3 mechanism of actions for treatment of hypertension\nFor Part G, has previous or current diagnosis of primary glomerulopathy, vasculitic renal disease, prior dialysis or unstable rapidly progressing renal disease, autosomal dominant or autosomal recessive polycystic kidney disease, lupus nephritis, or anti-neutrophil cytoplasm antibody-associated vasculitis", "metadata": {"brief_title": "A Study of LY3971297 in Healthy Participants", "phase": ["PHASE1"], "drugs_list": ["LY3971297", "Placebo", "LY3971297 IV"], "diseases_list": ["Healthy", "Obesity", "Hypertension"], "enrollment": 225, "inclusion_criteria": "inclusion criteria: \n\n For Parts A, B, C, E, and F: Overtly healthy males or females as determined by medical history and physical examination\n For Parts A, B, C, E, and F: Have a screening body mass index (BMI) in the range of 18.5 to 35 kilogram per square meter (kg/m\u00b2), inclusive, with no significant weight gain or loss in the past 3 months prior to screening\n For Part C, to qualify as Chinese for the purpose of this study, all the participants' biological grandparents must be of exclusive Chinese descent and born in China\n For Part D, participants must have a stable dose of medications within the past 3 months prior to screening\n For Part D, obesity BMI in the range of 30 to 40 kg/m\u00b2, inclusive, with a waist circumference of at least 102 centimeter (cm) for men and at least 89 cm for women for participants of US sites only. For participants of Singaporean, South Asian, Japanese, and/or Chinese Origin at sites outside the US, the BMI range is 27 to 40 kg/m2 and the waist circumference is at least 90 cm for men and at least 80 cm for women\n For Part E, to qualify as a participant of the first-generation Japanese origin, the participant, the participant's biological parents, and all of the participants' biological grandparents must be of exclusive Japanese descent and born in Japan\n Male participants must agree to adhere to contraception restrictions and female participants must be women not of childbearing potential\n For Part G, have a screening BMI in the range of 18.5 to 40 kg/m\u00b2, inclusive, with no significant weight gain or loss in the past 3 months prior to screening\n For Part G, participants have a decreased estimated glomerular filtration rate (eGFR)\n For Parts D and G, participants are allowed to have stable background treatment for hypertension, type 2 diabetes mellitus (on oral drug therapy and/or long-acting insulin), dyslipidemia (on statin therapy) and/or hypothyroidism as determined by the investigator\n For Part G, Participants should be on a stable dose of angiotensin converting enzyme inhibitor or angiotensin II receptor blocker", "exclusion_criteria": "exclusion criteria: \n\nHave a history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders\nHave known or ongoing psychiatric disorders that, in the opinion of the investigator, increases the risks associated with study participation\nHave blood pressure and/or pulse rate constituting a risk as determined by the investigator\nHave a systolic blood pressure (BP) of less than 100 millimeters of mercury (mmHg)\nDiagnosed with orthostatic hypotension defined as a decrease in systolic blood pressure of equal to or greater than 20 mmHg or a decrease in diastolic blood pressure of equal to or greater than 10 mmHg when compared with BP from the supine position\nFor US sites: have donated blood of more than 500 mL within the previous 3 months of screening or intend to donate blood during the course of the study\nFor Singapore sites: Have donated blood of more than 450 mL or more in the past 3 months or provided any blood donation within the past 1 month before screening\nConsume more than 10 cigarettes per day (or the equivalent) or are unable or unwilling to abstain from nicotine\nHave alcohol intake that exceeds recommended alcohol consumption limits per local regulation or are unwilling to stop alcohol consumption 24 hours prior to dosing until discharge\nFor Part D, has concurrent use or anticipated use of phosphodiesterase 5 inhibitor such as vardenafil, tadalafil, and sildenafil, soluble guanylyl cyclase activators (such as riociguat and vericiguat)\nFor Parts D and G, has concurrent or anticipated use of long-acting nitrates or nitric oxide (NO) donors\nFor Part D, has current use of more than 3 mechanism of actions for treatment of hypertension\nFor Part G, has previous or current diagnosis of primary glomerulopathy, vasculitic renal disease, prior dialysis or unstable rapidly progressing renal disease, autosomal dominant or autosomal recessive polycystic kidney disease, lupus nephritis, or anti-neutrophil cytoplasm antibody-associated vasculitis", "brief_summary": "The purpose of this study is to measure side effects of LY3971297 injection administered under the skin in healthy participants and obese participants with high blood pressure (BP). Blood tests will be performed to check how much LY3971297 gets into the bloodstream and how long it takes the body to eliminate it. This is a 7-part study. The study duration will be approximately 60 days for Parts A and F, and approximately 90 days for Parts B, C, D, E, and G.", "keywords": []}}
{"_id": "NCT05986292", "title": "A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain", "text": "Summary: The purpose of the chronic pain master protocol is to compare independent pain interventions and establish an overarching structure for the disease-state addenda (DSA) and intervention-specific appendices (ISAs). The ISAs may start independently of other ISAs as interventions become available for clinical testing.\n\nInclusion criteria: inclusion criteria: \n\n have a visual analog scale (VAS) pain value \\>40 and \\<95 at screening and prerandomization screening.\n have a history of daily pain for at least 12 weeks based on participant report or medical history\n have a value of \u226430 on the pain catastrophizing scale\n have a body mass index \\<40 kilogram/square meter (kg/m\u00b2) (inclusive)\n are willing to maintain a consistent regimen of any ongoing nonpharmacologic pain-relieving therapies (for example, physical therapy) and will not start any new nonpharmacologic pain-relieving therapies during study participation.\n are willing to discontinue all medications taken for chronic pain conditions, except rescue medication for the duration of the study\n\nExclusion criteria: exclusion criteria: \n\nhave second- or third-degree atrioventricular (AV) heart block or AV dissociation or history of ventricular tachycardia\nhave had a procedure within the past 6 months intended to produce permanent sensory loss in the target area of interest (for example, ablation techniques)\nhave surgery planned during the study for any reason, related or not to the disease state under evaluation.\nhave, in the judgment of the investigator, an acute, serious, or unstable medical condition or a history or presence of any other medical illness that would preclude study participation.\nhave had cancer within 2 years of baseline, except for cutaneous basal cell or squamous cell carcinoma resolved by excision.\nhave fibromyalgia\nhave substance use disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders (5th edition; DSM-5; American Psychiatric Association)\nhave any clinically important abnormality at screening, as determined by investigator, in physical or neurological examination, vital signs, electrocardiogram (ECG), or clinical laboratory test results that could be detrimental to the participant or could compromise the study.\nhave a positive human immunodeficiency virus (HIV) test result at screening\nhave a history of alcohol, illicit drug, analgesic or narcotic use disorder within 2 years prior to screening.", "metadata": {"brief_title": "A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain", "phase": ["PHASE2"], "drugs_list": ["LY3016859 ISA", "LY3556050 ISA", "LY3526318 ISA", "LY3857210 ISA", "Placebo Oral", "Placebo"], "diseases_list": ["Osteoarthritis, Knee", "Diabetic Neuropathic Pain", "Chronic Low-back Pain"], "enrollment": 10000, "inclusion_criteria": "inclusion criteria: \n\n have a visual analog scale (VAS) pain value \\>40 and \\<95 at screening and prerandomization screening.\n have a history of daily pain for at least 12 weeks based on participant report or medical history\n have a value of \u226430 on the pain catastrophizing scale\n have a body mass index \\<40 kilogram/square meter (kg/m\u00b2) (inclusive)\n are willing to maintain a consistent regimen of any ongoing nonpharmacologic pain-relieving therapies (for example, physical therapy) and will not start any new nonpharmacologic pain-relieving therapies during study participation.\n are willing to discontinue all medications taken for chronic pain conditions, except rescue medication for the duration of the study", "exclusion_criteria": "exclusion criteria: \n\nhave second- or third-degree atrioventricular (AV) heart block or AV dissociation or history of ventricular tachycardia\nhave had a procedure within the past 6 months intended to produce permanent sensory loss in the target area of interest (for example, ablation techniques)\nhave surgery planned during the study for any reason, related or not to the disease state under evaluation.\nhave, in the judgment of the investigator, an acute, serious, or unstable medical condition or a history or presence of any other medical illness that would preclude study participation.\nhave had cancer within 2 years of baseline, except for cutaneous basal cell or squamous cell carcinoma resolved by excision.\nhave fibromyalgia\nhave substance use disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders (5th edition; DSM-5; American Psychiatric Association)\nhave any clinically important abnormality at screening, as determined by investigator, in physical or neurological examination, vital signs, electrocardiogram (ECG), or clinical laboratory test results that could be detrimental to the participant or could compromise the study.\nhave a positive human immunodeficiency virus (HIV) test result at screening\nhave a history of alcohol, illicit drug, analgesic or narcotic use disorder within 2 years prior to screening.", "brief_summary": "The purpose of the chronic pain master protocol is to compare independent pain interventions and establish an overarching structure for the disease-state addenda (DSA) and intervention-specific appendices (ISAs). The ISAs may start independently of other ISAs as interventions become available for clinical testing.", "keywords": []}}
{"_id": "NCT04956640", "title": "Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)", "text": "Summary: The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care, except for specific groups who have not had cancer treatment. The study will last up to approximately 4 years.\n\nInclusion criteria: inclusion criteria: \n\n Patients have measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).\n Patients must have disease with evidence of KRAS G12C mutation in tumor tissue or circulating tumor deoxyribonucleic acid (DNA).\n Participants must have a histological or a cytologically proven diagnosis of locally advanced, unresectable, and/or metastatic cancer and meet cohort-specific criteria.\n Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.\n Have adequate organ function.\n Have discontinued all previous treatments for cancer with resolution of any significant ongoing adverse events (AEs), (except in certain scenarios).\n Must be able to swallow capsule/tablet.\n Agree and adhere to contraceptive use, if applicable.\n For some parts of the study, (i.e., one of the two arms with LY3537982 in combination with pembrolizumab and the arm of LY3537982 in combination with pembrolizumab, pemetrexed, and platinum therapy) histologically or cytologically confirmed Stage IIIB-IIIC or Stage IV NSCLC that is previously untreated in the advanced/metastatic setting and not suitable for curative intent radical surgery or radiation therapy. Previously untreated patients who received adjuvant and neoadjuvant therapy are eligible if the last dose of the systemic treatment was completed at least 6 months prior to enrollment. For untreated patients in the arm with LY3537982 in combination with pembrolizumab noted above, a single cycle of pembrolizumab may be initiated within 21 days prior to enrollment. For untreated patients in the arm of LY3537982 in combination with pembrolizumab, pemetrexed, and platinum therapy, a single cycle of any or all of the drugs other than LY3537982 may be initiated within 21 days prior to enrollment. Start of study treatment may be delayed to allow sufficient time for recovery from treatment-related toxicity.\n For one part of the study, participants must have received at least one prior oxaliplatin- or irinotecan-containing regimen for advanced or metastatic CRC.\n\nExclusion criteria: exclusion criteria: \n\nDisease suitable for local therapy administered with curative intent.\nHave an active, ongoing, or untreated infection.\nHave a serious pre-existing medical condition(s) that, in the judgment of the investigator, would preclude participation in this study.\nHave a serious cardiac condition.\nHave a second active primary malignancy or have been diagnosed and/or treated for an additional malignancy within 3 years prior to enrollment.\nFor some parts of the study only: have untreated active central nervous system (CNS) metastases and/or leptomeningeal disease. Patients with treated CNS metastases are eligible for this study if their disease is asymptomatic, radiographically stable for at least 30 days, and they do not require treatment with steroids in the two-week period prior to study treatment. Patients with active CNS metastases are eligible for one part of the study.\nHave received prior treatment with any KRAS G12C small molecule inhibitor, except in certain scenarios where such prior therapy is allowed as per protocol.\nThe following patients will be excluded from some parts of the study:\n\n  Experienced certain serious side effects with prior immunotherapy.\n  Have an active autoimmune disease that has required systemic anti-autoimmune treatment in the past 2 years.\n  Have received a live vaccine within 30 days prior to the first dose of study drug.\nPregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the trial through 35 days after the last dose of study medication.\nKnown allergic reaction against any of the components of the study treatments.", "metadata": {"brief_title": "Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)", "phase": ["PHASE1", "PHASE2"], "drugs_list": ["LY3537982", "Pembrolizumab", "Cetuximab", "Pemetrexed", "Cisplatin", "Carboplatin"], "diseases_list": ["Carcinoma, Non-Small-Cell Lung", "Colorectal Neoplasms", "Endometrial Neoplasms", "Ovarian Neoplasms", "Pancreatic Neoplasms", "Biliary Tract Neoplasms"], "enrollment": 540, "inclusion_criteria": "inclusion criteria: \n\n Patients have measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).\n Patients must have disease with evidence of KRAS G12C mutation in tumor tissue or circulating tumor deoxyribonucleic acid (DNA).\n Participants must have a histological or a cytologically proven diagnosis of locally advanced, unresectable, and/or metastatic cancer and meet cohort-specific criteria.\n Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.\n Have adequate organ function.\n Have discontinued all previous treatments for cancer with resolution of any significant ongoing adverse events (AEs), (except in certain scenarios).\n Must be able to swallow capsule/tablet.\n Agree and adhere to contraceptive use, if applicable.\n For some parts of the study, (i.e., one of the two arms with LY3537982 in combination with pembrolizumab and the arm of LY3537982 in combination with pembrolizumab, pemetrexed, and platinum therapy) histologically or cytologically confirmed Stage IIIB-IIIC or Stage IV NSCLC that is previously untreated in the advanced/metastatic setting and not suitable for curative intent radical surgery or radiation therapy. Previously untreated patients who received adjuvant and neoadjuvant therapy are eligible if the last dose of the systemic treatment was completed at least 6 months prior to enrollment. For untreated patients in the arm with LY3537982 in combination with pembrolizumab noted above, a single cycle of pembrolizumab may be initiated within 21 days prior to enrollment. For untreated patients in the arm of LY3537982 in combination with pembrolizumab, pemetrexed, and platinum therapy, a single cycle of any or all of the drugs other than LY3537982 may be initiated within 21 days prior to enrollment. Start of study treatment may be delayed to allow sufficient time for recovery from treatment-related toxicity.\n For one part of the study, participants must have received at least one prior oxaliplatin- or irinotecan-containing regimen for advanced or metastatic CRC.", "exclusion_criteria": "exclusion criteria: \n\nDisease suitable for local therapy administered with curative intent.\nHave an active, ongoing, or untreated infection.\nHave a serious pre-existing medical condition(s) that, in the judgment of the investigator, would preclude participation in this study.\nHave a serious cardiac condition.\nHave a second active primary malignancy or have been diagnosed and/or treated for an additional malignancy within 3 years prior to enrollment.\nFor some parts of the study only: have untreated active central nervous system (CNS) metastases and/or leptomeningeal disease. Patients with treated CNS metastases are eligible for this study if their disease is asymptomatic, radiographically stable for at least 30 days, and they do not require treatment with steroids in the two-week period prior to study treatment. Patients with active CNS metastases are eligible for one part of the study.\nHave received prior treatment with any KRAS G12C small molecule inhibitor, except in certain scenarios where such prior therapy is allowed as per protocol.\nThe following patients will be excluded from some parts of the study:\n\n  Experienced certain serious side effects with prior immunotherapy.\n  Have an active autoimmune disease that has required systemic anti-autoimmune treatment in the past 2 years.\n  Have received a live vaccine within 30 days prior to the first dose of study drug.\nPregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the trial through 35 days after the last dose of study medication.\nKnown allergic reaction against any of the components of the study treatments.", "brief_summary": "The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care, except for specific groups who have not had cancer treatment. The study will last up to approximately 4 years.", "keywords": ["Frontline", "1L", "First Line"]}}
{"_id": "NCT06553872", "title": "Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL", "text": "Summary: This is a phase 2, open-label, randomized, multicenter clinical trial in patients with relapsed/refractory mantle cell lymphoma (R/R MCL) who meet the criteria for standard-of-care FDA label for CD19 CAR T-cell therapy with brexucabtagene autoleucel (brexu-cel).\n\nInclusion criteria: inclusion criteria: \n\n Patients with a histologically confirmed diagnosis of mantle cell lymphoma (MCL) will be eligible.\n Adult males or females who are 18 years of age or older at time of signing informed consent.\n Must have ability to comprehend and the willingness to sign written informed consent for study participation.\n Eligible to receive CAR T-cell therapy (Brexucabtagene autoleucel) for MCL by the standard of care label, which states: \"TECARTUS or Brexucabtagene autoleucel is a CD19-directed genetically modified autologous T-cell immunotherapy indicated for the treatment of: Adult patients with relapsed or refractory mantle cell lymphoma (MCL)\"\n ECOG performance status 0 to 2.\n Patients are required to have the following washout periods prior to leukapheresis. In addition, prior treatment-related AEs must have recovered to Grade \u2264 1 with the exception of alopecia and Grade 2 peripheral neuropathy.\n\n   Targeted agents (i.e. BTK inhibitors), investigational agents, therapeutic monoclonal antibodies or cytotoxic chemotherapy: 5 half-lives or 2 weeks, whichever is shorter\n   Antibody-drug conjugates (ADC): 10 weeks\n   Radiation therapy: Broad field radiation (\u2265 30% of the bone marrow or whole brain radiotherapy): 14 days. Palliative limited field radiation: 7 days. Note: In the case of known central nervous system (CNS) involvement by systemic lymphoma: Patients with previous treatment for CNS involvement who are neurologically stable and without evidence of disease may be eligible if a compelling clinical rationale is provided by the Investigator and with documented Sponsor approval.\n   Bendamustine or other purine analogues: 3 months.\n   Corticosteroids: 5 days\n The effects of Pirtobrutinib on the developing human fetus are unknown. For this reason and because other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation as outlined in criteria below:\n\n   Men must agree to take appropriate precautions to avoid fathering children (with at least 99% certainty) from screening through safety follow up and must refrain from donating sperm during this period. Permitted methods that are at least 99% effective in preventing pregnancy should be communicated to the participants in their understanding confirmed.\n   Willingness of women of reproductive potential and their partners to observe highly effective birth control methods for the duration of treatment and for 1 month following the last dose of study treatment (see Section 4.3 and Section 4.4 for further details)\n   Women of childbearing potential must have a negative serum pregnancy test at screening and before the first dose of pirtobrutinib and must agree to take appropriate precautions to avoid pregnancy (with at least 99% certainty) from screening through safety follow up. Permitted methods that are at least 99% effective in preventing pregnancy should be communicated to the participants and their understanding confirmed.\n   Women of non-childbearing potential (i.e. surgically sterile with a hysterectomy and/or bilateral oophorectomy OR \\>= 12 months of amenorrhea) are eligible.\n Patients must meet the following laboratory parameters at screening:\n\n   Hematology (criteria the same regardless of bone marrow involvement; must be independent of transfusions and G-CSF support within 7 days of assessment)\n\n     Platelets \\>= 50 x 10\\^9/L\n     Hemoglobin \\>= 8g/dL\n     Absolute Neutrophil Count \\>=1.0 x 10\\^9/L\n   Hepatic\n\n     ALT \\< 2.5 x ULN for age, \\<5 x ULN in the presence of liver metastases\n     AST \\< 2.5 x ULN for age, \\<5 x ULN in the presence of liver metastases\n     Total bilirubin \\< 1.5 x ULN or \\<3 x ULN in the presence of documented Gilbert's syndrome unconjugated hyperbilirubinemia)\n   Renal Creatinine clearance \\>= 30 mL/minute based on Cockcroft-Gault formula.\n   Cardiopulmonary Cardiac LVEF \\>=40% confirmed by ECHO/multigated analysis\n   Adequate pulmonary function \\<= Grade 2 dyspnea and \\<= Grade 2 hypoxia per CTCAE v5.0.\n   Adequate coagulation, defined as activated partial thromboplastin time (aPTT) or partial thromboplastin time (PTT) and prothrombin (PT) or (international normalized ratio (INR) not greater than 1.5 x ULN.\n\nExclusion criteria: exclusion criteria: \n\nPatients who have previously received treatment with pirtobrutinib for \\>2 months prior to study enrollment are ineligible. Patients who are relapsed or refractory and then received less than 2 months of pirtobrutinib as \"holding therapy\" while awaiting CAR T-cell therapy evaluation, and who did not demonstrate disease progression while on pirtobrutinib holding therapy, are eligible.\nPatients who have previously discontinued pirtobrutinib due to disease progression, intolerance, or toxicity.\nPatients who are currently receiving or who have received any investigational study agent \u22644 weeks prior to screening visit are ineligible.\nPrior treatment with chimeric antigen receptor (CAR) T-cell therapy.\nParticipants with clinically significant or uncontrolled cardiac disease, including unstable angina or acute coronary syndrome within the past 2 months prior to randomization, history of myocardial infarction within 3 months prior to randomization, documented LVEF by any method of \u2264 40% in the 12 months prior to randomization, or \u2265 Grade 3 NYHA functional classification system of heart failure.\nUncontrolled or symptomatic arrhythmias, including prolongation of the QT interval corrected for heart rate (QTcF) \\> 470 msec. QTcF is calculated using Fridericia's Formula (QTcF): QTcF = QT/(RR0.33). Correction of suspected drug induced QTcF prolongation can be attempted at the investigator's discretion and only if clinically safe to do so with either discontinuation of the offending drug or switch to another drug not known to be associated with QTcF prolongation. Correction for underlying bundle branch block (BBB) allowed. Note: Patients with pacemakers are eligible if they have no history of fainting or clinically relevant arrhythmias while using the pacemaker\nEvidence of active uncontrolled/untreated infection (viral, bacterial, fungal, opportunistic) of any origin.\nParticipants with active immunologic or inflammatory/autoimmune disease affecting the CNS, and unrelated to their disease under study or previous treatment.\nPatients with active CNS involvement of Mantle Cell Lymphoma. A history of CNS Mantle Cell Lymphoma is allowed, as long as it has cleared, and the patient is able to comply with study procedures. Patients with previous treatment for CNS involvement who are neurologically stable and without evidence of disease may be eligible with documented Sponsor approval.\nKnown positive Human immunodeficiency virus (HIV) status. For patients with unknown HIV status, HIV testing will be performed at Screening and result must be negative for enrollment.\nHepatitis B virus (HBV): Patients with positive hepatitis B surface antigen (HBsAg) are excluded. Patients with positive hepatitis B core antibody (anti-HBc) and negative HBsAg require a negative hepatitis B polymerase chain reaction (PCR) evaluation before randomization. Patients who are HBV DNA PCR positive will be excluded. Patients who are HBV DNA PCR negative with positive anti-HBc require prophylaxis against Hepatitis B reactivation (see Section 6.4 \"General Guidance for Hepatic Monitoring\").\nHepatitis C virus (HCV): positive hepatitis C antibody. If positive hepatitis C antibody result, patient will need to have a negative result for hepatitis C ribonucleic acid (RNA) before randomization. Patients who are hepatitis C RNA positive will be excluded.\nKnown active cytomegalovirus (CMV) infection. Unknown or negative status are eligible.\nParticipants who require the concurrent use of chronic systemic steroids or immunosuppressant medications. Steroids should not be given within 5 days prior to leukapheresis. Concomitant bridging steroids (section 6.6) are allowed after leukapheresis.\nKnown hypersensitivity or severe reaction to pirtobrutinib, similar compounds, or excipients.\nParticipants who have not recovered from adverse events (AEs) due to prior anticancer therapy (i.e., have residual toxicities \\> Grade 1), with the exception of stable Grade 2 peripheral neuropathy and/or any grade alopecia.\nPregnant or nursing (breast-feeding) women are excluded from this study because there is an unknown but potential risk to using pirtobrutinib in pregnant or nursing women. Patients are excluded if they are pregnant or plan to become pregnant during the study or within 1 year of the last dose of study treatment. Patients are also excluded if they are lactating or plan to breastfeed during the study or within 1 week of the last dose of study treatment. Please see Section 4.3 and Section 4.4 for General Guidance for Women of Child Bearing Potential and/or Use of Contraceptive Methods.\nAny condition that would, in the investigator's judgement, interfere with full participation in the study, including administration of pirtobrutinib and attending required study visits (if outpatient); pose a significant risk to the participant; or interfere with interpretation of study data.\nInability of the participant to swallow and retain oral medication. Or, if there is clinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal (GI) absorption of the study drug.\nPatients who experienced a major bleeding event or grade \u2265 3 arrhythmia on prior treatment with a BTK inhibitor. NOTE: Major bleeding is defined as bleeding having one or more of the following features: potentially life-threatening bleeding with signs or symptoms of hemodynamic compromise; bleeding associated with a decrease in the hemoglobin level of at least 2g per deciliter; or bleeding in a critical area or organ (e.g., retroperitoneal, intraarticular, pericardial, epidural, or intracranial bleeding or intramuscular bleeding with compartment syndrome)\nMajor surgery within 4 weeks prior to enrollment.\nHistory of a previously diagnosed hereditary bleeding disorder.\nPatients requiring therapeutic anticoagulation with warfarin or another vitamin K antagonist.\nActive second malignancy unless in remission and with life expectancy \\> 2 years.\nVaccination with live vaccine within 28 days prior to randomization.\nHistory of stroke or intracranial hemorrhage within 6 months of enrollment.\nHistory of allogeneic or autologous stem cell transplant within 60 days of enrollment, presence of either of the following regardless of prior stem cell transplant timing: active graft vs. host disease; cytopenias from incomplete blood cell count recovery post-transplant.\nActive uncontrolled autoimmune cytopenia, including autoimmune hemolytic anemia or idiopathic thrombocytopenic purpura for which new therapy was introduced or existing therapy was escalated within the 4 weeks prior to study enrollment to maintain adequate blood counts.", "metadata": {"brief_title": "Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL", "phase": ["PHASE2"], "drugs_list": ["Pirtobrutinib", "Brexucabtagene Autoleucel"], "diseases_list": ["Mantle Cell Lymphoma"], "enrollment": 60, "inclusion_criteria": "inclusion criteria: \n\n Patients with a histologically confirmed diagnosis of mantle cell lymphoma (MCL) will be eligible.\n Adult males or females who are 18 years of age or older at time of signing informed consent.\n Must have ability to comprehend and the willingness to sign written informed consent for study participation.\n Eligible to receive CAR T-cell therapy (Brexucabtagene autoleucel) for MCL by the standard of care label, which states: \"TECARTUS or Brexucabtagene autoleucel is a CD19-directed genetically modified autologous T-cell immunotherapy indicated for the treatment of: Adult patients with relapsed or refractory mantle cell lymphoma (MCL)\"\n ECOG performance status 0 to 2.\n Patients are required to have the following washout periods prior to leukapheresis. In addition, prior treatment-related AEs must have recovered to Grade \u2264 1 with the exception of alopecia and Grade 2 peripheral neuropathy.\n\n   Targeted agents (i.e. BTK inhibitors), investigational agents, therapeutic monoclonal antibodies or cytotoxic chemotherapy: 5 half-lives or 2 weeks, whichever is shorter\n   Antibody-drug conjugates (ADC): 10 weeks\n   Radiation therapy: Broad field radiation (\u2265 30% of the bone marrow or whole brain radiotherapy): 14 days. Palliative limited field radiation: 7 days. Note: In the case of known central nervous system (CNS) involvement by systemic lymphoma: Patients with previous treatment for CNS involvement who are neurologically stable and without evidence of disease may be eligible if a compelling clinical rationale is provided by the Investigator and with documented Sponsor approval.\n   Bendamustine or other purine analogues: 3 months.\n   Corticosteroids: 5 days\n The effects of Pirtobrutinib on the developing human fetus are unknown. For this reason and because other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation as outlined in criteria below:\n\n   Men must agree to take appropriate precautions to avoid fathering children (with at least 99% certainty) from screening through safety follow up and must refrain from donating sperm during this period. Permitted methods that are at least 99% effective in preventing pregnancy should be communicated to the participants in their understanding confirmed.\n   Willingness of women of reproductive potential and their partners to observe highly effective birth control methods for the duration of treatment and for 1 month following the last dose of study treatment (see Section 4.3 and Section 4.4 for further details)\n   Women of childbearing potential must have a negative serum pregnancy test at screening and before the first dose of pirtobrutinib and must agree to take appropriate precautions to avoid pregnancy (with at least 99% certainty) from screening through safety follow up. Permitted methods that are at least 99% effective in preventing pregnancy should be communicated to the participants and their understanding confirmed.\n   Women of non-childbearing potential (i.e. surgically sterile with a hysterectomy and/or bilateral oophorectomy OR \\>= 12 months of amenorrhea) are eligible.\n Patients must meet the following laboratory parameters at screening:\n\n   Hematology (criteria the same regardless of bone marrow involvement; must be independent of transfusions and G-CSF support within 7 days of assessment)\n\n     Platelets \\>= 50 x 10\\^9/L\n     Hemoglobin \\>= 8g/dL\n     Absolute Neutrophil Count \\>=1.0 x 10\\^9/L\n   Hepatic\n\n     ALT \\< 2.5 x ULN for age, \\<5 x ULN in the presence of liver metastases\n     AST \\< 2.5 x ULN for age, \\<5 x ULN in the presence of liver metastases\n     Total bilirubin \\< 1.5 x ULN or \\<3 x ULN in the presence of documented Gilbert's syndrome unconjugated hyperbilirubinemia)\n   Renal Creatinine clearance \\>= 30 mL/minute based on Cockcroft-Gault formula.\n   Cardiopulmonary Cardiac LVEF \\>=40% confirmed by ECHO/multigated analysis\n   Adequate pulmonary function \\<= Grade 2 dyspnea and \\<= Grade 2 hypoxia per CTCAE v5.0.\n   Adequate coagulation, defined as activated partial thromboplastin time (aPTT) or partial thromboplastin time (PTT) and prothrombin (PT) or (international normalized ratio (INR) not greater than 1.5 x ULN.", "exclusion_criteria": "exclusion criteria: \n\nPatients who have previously received treatment with pirtobrutinib for \\>2 months prior to study enrollment are ineligible. Patients who are relapsed or refractory and then received less than 2 months of pirtobrutinib as \"holding therapy\" while awaiting CAR T-cell therapy evaluation, and who did not demonstrate disease progression while on pirtobrutinib holding therapy, are eligible.\nPatients who have previously discontinued pirtobrutinib due to disease progression, intolerance, or toxicity.\nPatients who are currently receiving or who have received any investigational study agent \u22644 weeks prior to screening visit are ineligible.\nPrior treatment with chimeric antigen receptor (CAR) T-cell therapy.\nParticipants with clinically significant or uncontrolled cardiac disease, including unstable angina or acute coronary syndrome within the past 2 months prior to randomization, history of myocardial infarction within 3 months prior to randomization, documented LVEF by any method of \u2264 40% in the 12 months prior to randomization, or \u2265 Grade 3 NYHA functional classification system of heart failure.\nUncontrolled or symptomatic arrhythmias, including prolongation of the QT interval corrected for heart rate (QTcF) \\> 470 msec. QTcF is calculated using Fridericia's Formula (QTcF): QTcF = QT/(RR0.33). Correction of suspected drug induced QTcF prolongation can be attempted at the investigator's discretion and only if clinically safe to do so with either discontinuation of the offending drug or switch to another drug not known to be associated with QTcF prolongation. Correction for underlying bundle branch block (BBB) allowed. Note: Patients with pacemakers are eligible if they have no history of fainting or clinically relevant arrhythmias while using the pacemaker\nEvidence of active uncontrolled/untreated infection (viral, bacterial, fungal, opportunistic) of any origin.\nParticipants with active immunologic or inflammatory/autoimmune disease affecting the CNS, and unrelated to their disease under study or previous treatment.\nPatients with active CNS involvement of Mantle Cell Lymphoma. A history of CNS Mantle Cell Lymphoma is allowed, as long as it has cleared, and the patient is able to comply with study procedures. Patients with previous treatment for CNS involvement who are neurologically stable and without evidence of disease may be eligible with documented Sponsor approval.\nKnown positive Human immunodeficiency virus (HIV) status. For patients with unknown HIV status, HIV testing will be performed at Screening and result must be negative for enrollment.\nHepatitis B virus (HBV): Patients with positive hepatitis B surface antigen (HBsAg) are excluded. Patients with positive hepatitis B core antibody (anti-HBc) and negative HBsAg require a negative hepatitis B polymerase chain reaction (PCR) evaluation before randomization. Patients who are HBV DNA PCR positive will be excluded. Patients who are HBV DNA PCR negative with positive anti-HBc require prophylaxis against Hepatitis B reactivation (see Section 6.4 \"General Guidance for Hepatic Monitoring\").\nHepatitis C virus (HCV): positive hepatitis C antibody. If positive hepatitis C antibody result, patient will need to have a negative result for hepatitis C ribonucleic acid (RNA) before randomization. Patients who are hepatitis C RNA positive will be excluded.\nKnown active cytomegalovirus (CMV) infection. Unknown or negative status are eligible.\nParticipants who require the concurrent use of chronic systemic steroids or immunosuppressant medications. Steroids should not be given within 5 days prior to leukapheresis. Concomitant bridging steroids (section 6.6) are allowed after leukapheresis.\nKnown hypersensitivity or severe reaction to pirtobrutinib, similar compounds, or excipients.\nParticipants who have not recovered from adverse events (AEs) due to prior anticancer therapy (i.e., have residual toxicities \\> Grade 1), with the exception of stable Grade 2 peripheral neuropathy and/or any grade alopecia.\nPregnant or nursing (breast-feeding) women are excluded from this study because there is an unknown but potential risk to using pirtobrutinib in pregnant or nursing women. Patients are excluded if they are pregnant or plan to become pregnant during the study or within 1 year of the last dose of study treatment. Patients are also excluded if they are lactating or plan to breastfeed during the study or within 1 week of the last dose of study treatment. Please see Section 4.3 and Section 4.4 for General Guidance for Women of Child Bearing Potential and/or Use of Contraceptive Methods.\nAny condition that would, in the investigator's judgement, interfere with full participation in the study, including administration of pirtobrutinib and attending required study visits (if outpatient); pose a significant risk to the participant; or interfere with interpretation of study data.\nInability of the participant to swallow and retain oral medication. Or, if there is clinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal (GI) absorption of the study drug.\nPatients who experienced a major bleeding event or grade \u2265 3 arrhythmia on prior treatment with a BTK inhibitor. NOTE: Major bleeding is defined as bleeding having one or more of the following features: potentially life-threatening bleeding with signs or symptoms of hemodynamic compromise; bleeding associated with a decrease in the hemoglobin level of at least 2g per deciliter; or bleeding in a critical area or organ (e.g., retroperitoneal, intraarticular, pericardial, epidural, or intracranial bleeding or intramuscular bleeding with compartment syndrome)\nMajor surgery within 4 weeks prior to enrollment.\nHistory of a previously diagnosed hereditary bleeding disorder.\nPatients requiring therapeutic anticoagulation with warfarin or another vitamin K antagonist.\nActive second malignancy unless in remission and with life expectancy \\> 2 years.\nVaccination with live vaccine within 28 days prior to randomization.\nHistory of stroke or intracranial hemorrhage within 6 months of enrollment.\nHistory of allogeneic or autologous stem cell transplant within 60 days of enrollment, presence of either of the following regardless of prior stem cell transplant timing: active graft vs. host disease; cytopenias from incomplete blood cell count recovery post-transplant.\nActive uncontrolled autoimmune cytopenia, including autoimmune hemolytic anemia or idiopathic thrombocytopenic purpura for which new therapy was introduced or existing therapy was escalated within the 4 weeks prior to study enrollment to maintain adequate blood counts.", "brief_summary": "This is a phase 2, open-label, randomized, multicenter clinical trial in patients with relapsed/refractory mantle cell lymphoma (R/R MCL) who meet the criteria for standard-of-care FDA label for CD19 CAR T-cell therapy with brexucabtagene autoleucel (brexu-cel).", "keywords": []}}
{"_id": "NCT06395012", "title": "A First-In-Human Study of LY3985297 in Healthy Participants", "text": "Summary: The main purpose of this study is to see if LY3985297, the study drug, is safe and well-tolerated when given as a single dose or as multiple doses either through an intravenous (into a vein) or a subcutaneous (under the skin) injection in healthy participants. Study will also evaluate how much of the study drug LY3985297 gets into the blood stream and how long it takes the body to remove it.\n\nThe study is conducted in two parts (part A and B), each part has a separate treatment cohort.\n\nThe study will last up to approximately 116 days for part A, and 145 days for part B, including the screening period.\n\nInclusion criteria: inclusion criteria: \n\n Participants must be overtly healthy, as determined by medical evaluation.\n Have a body mass index of 18.0 to 32.0 kilograms per square meter (kg/m\u00b2), inclusive, and a minimum body weight of 45.0 kg.\n Participants must be assigned male or female at birth and not of childbearing potential.\n Have normal blood pressure, pulse rate, electrocardiogram (ECG), clinical laboratory test results that are acceptable for the study.\n Have venous access sufficient to allow for blood sampling.\n\nFor Part A Cohorts 5, 6, and 7:\n\n Participants must be first-generation Japanese only, defined as the participant's biological parents, and all of the participant's biological grandparents must be of exclusive Japanese descent and born in Japan. Or\n Participants must be first-generation Chinese only, defined as the participant's biological parents, and all of the participant's biological grandparents must be of exclusive Chinese descent and born in China.\n\nExclusion criteria: exclusion criteria: \n\nHave a current or recent acute, active infection. For at least 30 days before screening and up to the randomization visit (Day 1).\nHad any surgical procedure (except for minor surgery requiring local or no anesthesia and without any complications or sequelae) within 12 weeks prior to screening or intend to during the study.\nHave a history of multiple or severe allergies, or an anaphylactic reaction, to prescription or nonprescription drugs or food.\nShow evidence of active or latent tuberculosis (TB).\nHave one of the following infections: hepatitis B, C virus or human immunodeficiency virus (HIV).", "metadata": {"brief_title": "A First-In-Human Study of LY3985297 in Healthy Participants", "phase": ["PHASE1"], "drugs_list": ["LY3985297", "Placebo"], "diseases_list": ["Healthy"], "enrollment": 153, "inclusion_criteria": "inclusion criteria: \n\n Participants must be overtly healthy, as determined by medical evaluation.\n Have a body mass index of 18.0 to 32.0 kilograms per square meter (kg/m\u00b2), inclusive, and a minimum body weight of 45.0 kg.\n Participants must be assigned male or female at birth and not of childbearing potential.\n Have normal blood pressure, pulse rate, electrocardiogram (ECG), clinical laboratory test results that are acceptable for the study.\n Have venous access sufficient to allow for blood sampling.\n\nFor Part A Cohorts 5, 6, and 7:\n\n Participants must be first-generation Japanese only, defined as the participant's biological parents, and all of the participant's biological grandparents must be of exclusive Japanese descent and born in Japan. Or\n Participants must be first-generation Chinese only, defined as the participant's biological parents, and all of the participant's biological grandparents must be of exclusive Chinese descent and born in China.", "exclusion_criteria": "exclusion criteria: \n\nHave a current or recent acute, active infection. For at least 30 days before screening and up to the randomization visit (Day 1).\nHad any surgical procedure (except for minor surgery requiring local or no anesthesia and without any complications or sequelae) within 12 weeks prior to screening or intend to during the study.\nHave a history of multiple or severe allergies, or an anaphylactic reaction, to prescription or nonprescription drugs or food.\nShow evidence of active or latent tuberculosis (TB).\nHave one of the following infections: hepatitis B, C virus or human immunodeficiency virus (HIV).", "brief_summary": "The main purpose of this study is to see if LY3985297, the study drug, is safe and well-tolerated when given as a single dose or as multiple doses either through an intravenous (into a vein) or a subcutaneous (under the skin) injection in healthy participants. Study will also evaluate how much of the study drug LY3985297 gets into the blood stream and how long it takes the body to remove it.\n\nThe study is conducted in two parts (part A and B), each part has a separate treatment cohort.\n\nThe study will last up to approximately 116 days for part A, and 145 days for part B, including the screening period.", "keywords": []}}
{"_id": "NCT05784246", "title": "A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis", "text": "Summary: The main purpose of this study is to investigate efficacy, pharmacokinetics and safety of the drug in pediatric participants with moderately to severely active ulcerative colitis (UC).\n\nInclusion criteria: inclusion criteria: \n\n Males or females weighing \u226510 kg and \u22652 and \\<18 years old at the time of consent for screening.\n Have moderate to severe UC.\n Have failed corticosteroids, biologics, (for example, anti-tumor necrosis factor (TNF) antibodies or anti-integrin antibodies), immunomodulators (for example, azathioprine, thiopurines or methotrexate) or Janus Kinase (JAK)-Inhibitor treatment.\n Have UC at least 3 months in duration before baseline, which includes endoscopic evidence of UC corroborated by a histopathology report.\n\nExclusion criteria: exclusion criteria: \n\nHave Crohn's disease, Inflammatory Bowel Disease Unclassified, ulcerative proctitis or primary sclerosing cholangitis.\nHave immune deficiency syndrome.\nPrevious bowel resection or intestinal surgery.\nEvidence of toxic megacolon.\nHistory or current evidence of cancer of the gastrointestinal tract.", "metadata": {"brief_title": "A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis", "phase": ["PHASE3"], "drugs_list": ["Mirikizumab IV", "Mirikizumab SC"], "diseases_list": ["Ulcerative Colitis"], "enrollment": 60, "inclusion_criteria": "inclusion criteria: \n\n Males or females weighing \u226510 kg and \u22652 and \\<18 years old at the time of consent for screening.\n Have moderate to severe UC.\n Have failed corticosteroids, biologics, (for example, anti-tumor necrosis factor (TNF) antibodies or anti-integrin antibodies), immunomodulators (for example, azathioprine, thiopurines or methotrexate) or Janus Kinase (JAK)-Inhibitor treatment.\n Have UC at least 3 months in duration before baseline, which includes endoscopic evidence of UC corroborated by a histopathology report.", "exclusion_criteria": "exclusion criteria: \n\nHave Crohn's disease, Inflammatory Bowel Disease Unclassified, ulcerative proctitis or primary sclerosing cholangitis.\nHave immune deficiency syndrome.\nPrevious bowel resection or intestinal surgery.\nEvidence of toxic megacolon.\nHistory or current evidence of cancer of the gastrointestinal tract.", "brief_summary": "The main purpose of this study is to investigate efficacy, pharmacokinetics and safety of the drug in pediatric participants with moderately to severely active ulcerative colitis (UC).", "keywords": []}}
{"_id": "NCT05395481", "title": "A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)", "text": "Summary: The main purpose of this study is to evaluate the safety and tolerability of the study drug LY3849891 in participants with metabolic dysfunction-associated steatotic liver disease (MASLD) who have the patatin-like phospholipase domain-containing protein 3 (PNPLA3) I148M genotype. Blood tests and magnetic resonance imaging of the liver will be performed to determine the effects of LY3849891 on MASLD and assessment of resolution of liver fibroinflammation. Blood tests will also determine how long it takes the body to eliminate LY3849891. This is a 2-part study and may last up to 32 weeks for each participant and may include 12 visits in parts A and B.\n\nInclusion criteria: inclusion criteria: \n\n Participants must have a body mass index (BMI) within the range greater than or equal to (\u2265) 25 and less than (\\<) 50 kilogram per square meter (kg/m\u00b2) inclusive\n Participants must have liver fat content \u226510% in Part A and \u22658% for Part B as determined by MRI-PDFF\n Participants must be carriers of the PNPLA3 I148M allele\n Participants with or without type 2 diabetes mellitus (T2DM)\n\n  o For participants with T2DM, hemoglobin A1c (HbA1c) \\<8% in Part A and \\<9% in Part B\n Male participants agree to use an effective method of contraception for the duration of the study and for 90 days after the last dose of study intervention\n Women not of childbearing potential may participate and include those who are: infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy, or tubal ligation), congenital anomaly such as Mullerian agenesis; or those who are postmenopausal\n\nExclusion criteria: exclusion criteria: \n\nParticipants must not have known or suspected alcohol abuse (\\>14 units/week for women and \\>21 units/week for men) or active substance abuse\nParticipants must not have evidence of cirrhosis or other forms of liver disease\nParticipants must not have heart attack, stroke, or hospitalization for congestive heart failure in the past 3 months\nParticipants must not have active cancer within the last 5 years\nParticipants must not have uncontrolled high blood pressure\nParticipants must not have renal impairment with estimated glomerular filtration rate (eGFR) \\<60 milliliter per minute per 1.73 square meter (ml/min/1.73m\u00b2)\nParticipants must not have a diagnosis of type 1 diabetes\nParticipants must not have a contraindication to MRI examinations, such as persons with cardiac pacemaker and implants made out of metal (for example, cochlear implant, nerve stimulators, magnetic vascular clips, and metallic heart valve) or other contraindications for MRI", "metadata": {"brief_title": "A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)", "phase": ["PHASE1"], "drugs_list": ["LY3849891", "Placebo"], "diseases_list": ["Metabolic Dysfunction-Associated Steatohepatitis (MASH)", "Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)"], "enrollment": 176, "inclusion_criteria": "inclusion criteria: \n\n Participants must have a body mass index (BMI) within the range greater than or equal to (\u2265) 25 and less than (\\<) 50 kilogram per square meter (kg/m\u00b2) inclusive\n Participants must have liver fat content \u226510% in Part A and \u22658% for Part B as determined by MRI-PDFF\n Participants must be carriers of the PNPLA3 I148M allele\n Participants with or without type 2 diabetes mellitus (T2DM)\n\n  o For participants with T2DM, hemoglobin A1c (HbA1c) \\<8% in Part A and \\<9% in Part B\n Male participants agree to use an effective method of contraception for the duration of the study and for 90 days after the last dose of study intervention\n Women not of childbearing potential may participate and include those who are: infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy, or tubal ligation), congenital anomaly such as Mullerian agenesis; or those who are postmenopausal", "exclusion_criteria": "exclusion criteria: \n\nParticipants must not have known or suspected alcohol abuse (\\>14 units/week for women and \\>21 units/week for men) or active substance abuse\nParticipants must not have evidence of cirrhosis or other forms of liver disease\nParticipants must not have heart attack, stroke, or hospitalization for congestive heart failure in the past 3 months\nParticipants must not have active cancer within the last 5 years\nParticipants must not have uncontrolled high blood pressure\nParticipants must not have renal impairment with estimated glomerular filtration rate (eGFR) \\<60 milliliter per minute per 1.73 square meter (ml/min/1.73m\u00b2)\nParticipants must not have a diagnosis of type 1 diabetes\nParticipants must not have a contraindication to MRI examinations, such as persons with cardiac pacemaker and implants made out of metal (for example, cochlear implant, nerve stimulators, magnetic vascular clips, and metallic heart valve) or other contraindications for MRI", "brief_summary": "The main purpose of this study is to evaluate the safety and tolerability of the study drug LY3849891 in participants with metabolic dysfunction-associated steatotic liver disease (MASLD) who have the patatin-like phospholipase domain-containing protein 3 (PNPLA3) I148M genotype. Blood tests and magnetic resonance imaging of the liver will be performed to determine the effects of LY3849891 on MASLD and assessment of resolution of liver fibroinflammation. Blood tests will also determine how long it takes the body to eliminate LY3849891. This is a 2-part study and may last up to 32 weeks for each participant and may include 12 visits in parts A and B.", "keywords": ["Hepatic fibrosis", "Biomarkers", "Magnetic resonance imaging", "Pharmacokinetics", "Liver fat"]}}
{"_id": "NCT06914895", "title": "A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight", "text": "Summary: The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 49 weeks.\n\nInclusion criteria: inclusion criteria: \n\n Have type 1 diabetes and on insulin treatment for at least one year prior to screening\n Have an HbA1c value of 7.0% to 10.5% inclusive, at screening\n Have a body mass index (BMI) of \u226525 kilograms per square meter (kg/m2) at screening\n Are of stable weight for at least 90 days prior to screening and agree to not start an intensive diet or exercise program during the study\n\nExclusion criteria: exclusion criteria: \n\nHave experienced two or more events requiring hospitalization due to poor glucose control (hyperglycemia or (diabetic ketoacidosis (DKA)) during the period of 180 days prior to screening and until randomization.\nHave experienced one or more events of severe hypoglycemia during the period of 90 days prior to screening and until randomization.\nAre currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema\nHave had chronic or acute pancreatitis\nHave used any weight loss drugs or alternative remedies, including herbal or nutritional supplements, within 90 days prior to screening", "metadata": {"brief_title": "A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight", "phase": ["PHASE3"], "drugs_list": ["Tirzepatide", "Placebo"], "diseases_list": ["Type 1 Diabetes", "Obesity", "Overweight"], "enrollment": 905, "inclusion_criteria": "inclusion criteria: \n\n Have type 1 diabetes and on insulin treatment for at least one year prior to screening\n Have an HbA1c value of 7.0% to 10.5% inclusive, at screening\n Have a body mass index (BMI) of \u226525 kilograms per square meter (kg/m2) at screening\n Are of stable weight for at least 90 days prior to screening and agree to not start an intensive diet or exercise program during the study", "exclusion_criteria": "exclusion criteria: \n\nHave experienced two or more events requiring hospitalization due to poor glucose control (hyperglycemia or (diabetic ketoacidosis (DKA)) during the period of 180 days prior to screening and until randomization.\nHave experienced one or more events of severe hypoglycemia during the period of 90 days prior to screening and until randomization.\nAre currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema\nHave had chronic or acute pancreatitis\nHave used any weight loss drugs or alternative remedies, including herbal or nutritional supplements, within 90 days prior to screening", "brief_summary": "The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 49 weeks.", "keywords": []}}
{"_id": "NCT06400472", "title": "A Study of LY4170156 in Participants With Selected Advanced Solid Tumors", "text": "Summary: The purpose of this study is to find out whether the study drug, LY4170156, is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.\n\nInclusion criteria: inclusion criteria: \n\n Have one of the following solid tumor cancers:\n\n   Cohort A1: Ovarian (epithelial ovarian, primary peritoneal, and fallopian tube) cancer, endometrial cancer, cervical cancer, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), pancreatic, and colorectal cancer (CRC)\n   Cohort A2/A3/A4/A5/B1/B2: Ovarian (epithelial ovarian, primary peritoneal, and fallopian tube) cancer\n   Cohort C1/C2: Endometrial cancer, cervical cancer, NSCLC, TNBC, CRC or pancreatic cancer\n\nExclusion criteria: exclusion criteria: \n\nIndividual with known or suspected uncontrolled central nervous system (CNS) metastases\nIndividual with history of carcinomatous meningitis\nIndividual with active uncontrolled systemic bacterial, viral, fungal, or parasitic infection\nIndividual with evidence of corneal keratopathy or history of corneal transplant\nAny serious unresolved toxicities from prior therapy\nSignificant cardiovascular disease\nProlongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) \u2265 470 milliseconds (ms)\nHistory of pneumonitis/interstitial lung disease\nIndividuals who are pregnant, breastfeeding or plan to breastfeed during study or within 30 days of last dose of study intervention", "metadata": {"brief_title": "A Study of LY4170156 in Participants With Selected Advanced Solid Tumors", "phase": ["PHASE1"], "drugs_list": ["LY4170156", "Bevacizumab", "carboplatin"], "diseases_list": ["Ovarian Neoplasms", "Endometrial Neoplasms", "Uterine Cervical Neoplasms", "Carcinoma, Non-Small-Cell Lung", "Triple Negative Breast Neoplasms", "Pancreatic Neoplasm", "Colorectal Neoplasms"], "enrollment": 360, "inclusion_criteria": "inclusion criteria: \n\n Have one of the following solid tumor cancers:\n\n   Cohort A1: Ovarian (epithelial ovarian, primary peritoneal, and fallopian tube) cancer, endometrial cancer, cervical cancer, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), pancreatic, and colorectal cancer (CRC)\n   Cohort A2/A3/A4/A5/B1/B2: Ovarian (epithelial ovarian, primary peritoneal, and fallopian tube) cancer\n   Cohort C1/C2: Endometrial cancer, cervical cancer, NSCLC, TNBC, CRC or pancreatic cancer", "exclusion_criteria": "exclusion criteria: \n\nIndividual with known or suspected uncontrolled central nervous system (CNS) metastases\nIndividual with history of carcinomatous meningitis\nIndividual with active uncontrolled systemic bacterial, viral, fungal, or parasitic infection\nIndividual with evidence of corneal keratopathy or history of corneal transplant\nAny serious unresolved toxicities from prior therapy\nSignificant cardiovascular disease\nProlongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) \u2265 470 milliseconds (ms)\nHistory of pneumonitis/interstitial lung disease\nIndividuals who are pregnant, breastfeeding or plan to breastfeed during study or within 30 days of last dose of study intervention", "brief_summary": "The purpose of this study is to find out whether the study drug, LY4170156, is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.", "keywords": ["Folate receptor alpha", "NSCLC", "Ovarian cancer", "Cervical cancer", "Endometrial cancer", "Solid tumor", "Lung cancer", "Breast cancer", "Pancreatic cancer", "Colorectal cancer", "Anti-drug conjugate", "Phase I", "Chemotherapy"]}}
{"_id": "NCT06602219", "title": "A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis", "text": "Summary: The main purpose of this study is to assess the safety and efficacy of LY4100511 in adult participants with moderate-to-severe plaque psoriasis.\n\nInclusion criteria: inclusion criteria: \n\n Clinical diagnosis of plaque psoriasis for 6 months before the baseline day 1 randomization\n Must have a body mass index (BMI) of 18 to 40 kilogram/square meter (kg/m2) (inclusive).\n Must be willing to discontinue topical and/or systemic therapies for psoriasis before the first dose of study intervention.\n Must agree to avoid prolonged exposure to the sun and to refrain from the use of tanning booths, sun lamps, and other sources of ultraviolet light during the study\n\nExclusion criteria: exclusion criteria: \n\nHave had a clinically significant flare of psoriasis during the 12 weeks before the baseline, as assessed by the investigator.\nHave a history of erythrodermic psoriasis, generalized or localized pustular psoriasis, predominantly guttate psoriasis, or medication-induced or medication-exacerbated psoriasis.\nHave any known or suspected diagnosis of inflammatory conditions other than psoriasis and psoriatic arthritis, including but not limited to rheumatoid arthritis, sarcoidosis, IBD (Crohn's disease or ulcerative colitis), or systemic lupus erythematosus.\nHave a diagnosis of psoriatic arthritis requiring, or are currently receiving, systemic immunosuppressant medical treatment (including corticosteroids, immunosuppressants, and biologics).\nHave a current or recent acute, active infection. Participant must have no symptoms or signs of confirmed or suspected infection and must have completed any appropriate anti-infective treatment for at least 30 days before screening and up to randomization/baseline.", "metadata": {"brief_title": "A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis", "phase": ["PHASE2"], "drugs_list": ["LY4100511", "Placebo"], "diseases_list": ["Plaque Psoriasis"], "enrollment": 220, "inclusion_criteria": "inclusion criteria: \n\n Clinical diagnosis of plaque psoriasis for 6 months before the baseline day 1 randomization\n Must have a body mass index (BMI) of 18 to 40 kilogram/square meter (kg/m2) (inclusive).\n Must be willing to discontinue topical and/or systemic therapies for psoriasis before the first dose of study intervention.\n Must agree to avoid prolonged exposure to the sun and to refrain from the use of tanning booths, sun lamps, and other sources of ultraviolet light during the study", "exclusion_criteria": "exclusion criteria: \n\nHave had a clinically significant flare of psoriasis during the 12 weeks before the baseline, as assessed by the investigator.\nHave a history of erythrodermic psoriasis, generalized or localized pustular psoriasis, predominantly guttate psoriasis, or medication-induced or medication-exacerbated psoriasis.\nHave any known or suspected diagnosis of inflammatory conditions other than psoriasis and psoriatic arthritis, including but not limited to rheumatoid arthritis, sarcoidosis, IBD (Crohn's disease or ulcerative colitis), or systemic lupus erythematosus.\nHave a diagnosis of psoriatic arthritis requiring, or are currently receiving, systemic immunosuppressant medical treatment (including corticosteroids, immunosuppressants, and biologics).\nHave a current or recent acute, active infection. Participant must have no symptoms or signs of confirmed or suspected infection and must have completed any appropriate anti-infective treatment for at least 30 days before screening and up to randomization/baseline.", "brief_summary": "The main purpose of this study is to assess the safety and efficacy of LY4100511 in adult participants with moderate-to-severe plaque psoriasis.", "keywords": []}}
{"_id": "NCT03997981", "title": "Chemotherapy Induced Peripheral Neuropathy Natural History Study (EPIPHANY)", "text": "Summary: This is a prospective natural history study of CIPN in approximately 200 participants receiving taxanes (paclitaxel, docetaxel) for breast cancer, bortezomib for multiple myeloma, oxaliplatin-based regimens for colorectal cancer, or vincristine for lymphoma.. Demographic data, medical history, electronic PROs, ClinROs blood biomarkers including NF-L, PGx DNA analyses and Bedside-QST will be assessed at Baseline. The Observation Period will initiate with the first dose of chemotherapy and conclude with the last dose of chemotherapy. During the Observation Period, participants will be evaluated for the development of CIPN using PROs and ClinROs. Blood biomarkers and Bedside-QST will be measured at various timepoints corresponding with treatment regimen schedules throughout the observation period. The Post Chemotherapy Follow-up Period will begin with the first visit after the last dose of chemotherapy and conclude 6 months after the last dose of chemotherapy. During the Post Chemotherapy Follow-up Period, participants will be evaluated for CIPN using PROs and ClinROs. Blood biomarkers and Bedside-QST will also be measured at the beginning and at the end of the Post-Chemotherapy Follow-up Period. PROs will be assessed electronically on a monthly basis.\n\nInclusion criteria: inclusion criteria: \n\nAll of the following criteria must be met in order to be enrolled in the study:\n\n Age \u226518 years\n Life expectancy \u22656 months\n Participants with Common Terminology Criteria for Adverse Events (CTCAE) Grade 0 CIPN (exception, patients with multiple myeloma treated with bortezomib, CTCAE Grade \\<=1)\n Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n Breast cancer only:\n\n   Breast cancer beginning treatment with paclitaxel or docetaxel with curative intent (i.e., not metastatic disease beyond regional lymph nodes)\n   Planned minimum of 6 cycles of chemotherapy\n Lymphoma only:\n\n   Incident lymphoma initiating treatment with vincristine\n   Planned minimum of 4 cycles of chemotherapy\n Oxaliplatin-based regimens, Stage III colorectal cancer: Total of 6 months (planned minimum of 12 cycles). May consider Stage IV with minimal metastatic confirmed with Sponsor prior to enrollment\n Bortezomib use in untreated multiple myeloma: Total of 4 months (planned minimum of 9 cycles)\n Written informed consent given\n Enrollment must be completed prior to receiving the first dose of chemotherapy\n\nExclusion criteria: exclusion criteria: \n\nPatients meeting ANY of the following criteria are not eligible for participation:\n\nEvidence of central nervous system metastases\nEvidence of clinically significant peripheral neuropathy (CTCAE \\>2) as defined by patient report of frequent numbness or tingling in the hands or feet\nAny uncontrolled serious illness or medical condition that would impact the conduct of the current study\nPrevious exposure to neurotoxic chemotherapy drugs\nPre-existing neurodegenerative disease (Parkinson's, Alzheimer's, Huntington's, etc.), neuromuscular disorder (multiple sclerosis, ALS, polio, hereditary neuromuscular disease) or history of stoke or history of traumatic brain injury\nGeneral anesthesia less than one month prior to the first dose of neurotoxic chemotherapy", "metadata": {"brief_title": "Chemotherapy Induced Peripheral Neuropathy Natural History Study (EPIPHANY)", "phase": {}, "drugs_list": [], "diseases_list": ["Chemotherapy-induced Peripheral Neuropathy"], "enrollment": 200, "inclusion_criteria": "inclusion criteria: \n\nAll of the following criteria must be met in order to be enrolled in the study:\n\n Age \u226518 years\n Life expectancy \u22656 months\n Participants with Common Terminology Criteria for Adverse Events (CTCAE) Grade 0 CIPN (exception, patients with multiple myeloma treated with bortezomib, CTCAE Grade \\<=1)\n Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n Breast cancer only:\n\n   Breast cancer beginning treatment with paclitaxel or docetaxel with curative intent (i.e., not metastatic disease beyond regional lymph nodes)\n   Planned minimum of 6 cycles of chemotherapy\n Lymphoma only:\n\n   Incident lymphoma initiating treatment with vincristine\n   Planned minimum of 4 cycles of chemotherapy\n Oxaliplatin-based regimens, Stage III colorectal cancer: Total of 6 months (planned minimum of 12 cycles). May consider Stage IV with minimal metastatic confirmed with Sponsor prior to enrollment\n Bortezomib use in untreated multiple myeloma: Total of 4 months (planned minimum of 9 cycles)\n Written informed consent given\n Enrollment must be completed prior to receiving the first dose of chemotherapy", "exclusion_criteria": "exclusion criteria: \n\nPatients meeting ANY of the following criteria are not eligible for participation:\n\nEvidence of central nervous system metastases\nEvidence of clinically significant peripheral neuropathy (CTCAE \\>2) as defined by patient report of frequent numbness or tingling in the hands or feet\nAny uncontrolled serious illness or medical condition that would impact the conduct of the current study\nPrevious exposure to neurotoxic chemotherapy drugs\nPre-existing neurodegenerative disease (Parkinson's, Alzheimer's, Huntington's, etc.), neuromuscular disorder (multiple sclerosis, ALS, polio, hereditary neuromuscular disease) or history of stoke or history of traumatic brain injury\nGeneral anesthesia less than one month prior to the first dose of neurotoxic chemotherapy", "brief_summary": "This is a prospective natural history study of CIPN in approximately 200 participants receiving taxanes (paclitaxel, docetaxel) for breast cancer, bortezomib for multiple myeloma, oxaliplatin-based regimens for colorectal cancer, or vincristine for lymphoma.. Demographic data, medical history, electronic PROs, ClinROs blood biomarkers including NF-L, PGx DNA analyses and Bedside-QST will be assessed at Baseline. The Observation Period will initiate with the first dose of chemotherapy and conclude with the last dose of chemotherapy. During the Observation Period, participants will be evaluated for the development of CIPN using PROs and ClinROs. Blood biomarkers and Bedside-QST will be measured at various timepoints corresponding with treatment regimen schedules throughout the observation period. The Post Chemotherapy Follow-up Period will begin with the first visit after the last dose of chemotherapy and conclude 6 months after the last dose of chemotherapy. During the Post Chemotherapy Follow-up Period, participants will be evaluated for CIPN using PROs and ClinROs. Blood biomarkers and Bedside-QST will also be measured at the beginning and at the end of the Post-Chemotherapy Follow-up Period. PROs will be assessed electronically on a monthly basis.", "keywords": ["CIPN"]}}
{"_id": "NCT06339008", "title": "A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)", "text": "Summary: The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with perennial allergic rhinitis. The study will last about 18 months\n\nInclusion criteria: inclusion criteria: \n\n Physician-diagnosed PAR.\n Has a positive skin prick test (SPT) with indoor allergens and/or positive antigen-specific serum immunoglobulin E (IgE) for indoor allergens \u22650.70 kU/L, utilizing a validated assay (central laboratory).\n A dermatographic participant who has a known history of dermatographism or identified during the SPT may participate in this study with a positive serum IgE test.\n Participants who have concomitant asthma must be stable in the 3 months prior to screening using permitted regular asthma treatment.\n\nExclusion criteria: exclusion criteria: \n\nHave received a dose of lebrikizumab.\nIs currently on allergen immunotherapy. However, individuals who discontinued subcutaneous or sublingual immunotherapy (SCIT/SLIT) for \u22653 years prior to randomization are eligible, if they were not on a maintenance allergen immunotherapy (AIT) regimen.\nHave received treatment with any rescue medication during the screening and/or run-in period.\nHave received treatment with any biologic or systemic immunosuppressants for inflammatory disease or autoimmune disease prior to the baseline visit:\n\n  1. B cell-depleting biologics, including rituximab, within 6 months.\n  2. other biologics within 5 half-lives (if known) or 8 weeks, whichever is longer.\n  3. Systemic immunosuppressants within 4 weeks prior to baseline.\nHave a history of seasonal worsening of AR and if the seasonal worsening is expected during the 4-week run-in period, the first 16 weeks after randomization, or during the last 4 weeks of the maintenance period.\nAnticipates significant changes in their daily environmental exposure\nHas a known history of recurrent acute or chronic sinusitis,\nFemale participant who is pregnant, breastfeeding or is planning to become pregnant or to breastfeed during the study.", "metadata": {"brief_title": "A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)", "phase": ["PHASE3"], "drugs_list": ["LY3650150", "Placebo", "Standard therapy for INCS"], "diseases_list": ["Perennial Allergic Rhinitis (PAR)"], "enrollment": 450, "inclusion_criteria": "inclusion criteria: \n\n Physician-diagnosed PAR.\n Has a positive skin prick test (SPT) with indoor allergens and/or positive antigen-specific serum immunoglobulin E (IgE) for indoor allergens \u22650.70 kU/L, utilizing a validated assay (central laboratory).\n A dermatographic participant who has a known history of dermatographism or identified during the SPT may participate in this study with a positive serum IgE test.\n Participants who have concomitant asthma must be stable in the 3 months prior to screening using permitted regular asthma treatment.", "exclusion_criteria": "exclusion criteria: \n\nHave received a dose of lebrikizumab.\nIs currently on allergen immunotherapy. However, individuals who discontinued subcutaneous or sublingual immunotherapy (SCIT/SLIT) for \u22653 years prior to randomization are eligible, if they were not on a maintenance allergen immunotherapy (AIT) regimen.\nHave received treatment with any rescue medication during the screening and/or run-in period.\nHave received treatment with any biologic or systemic immunosuppressants for inflammatory disease or autoimmune disease prior to the baseline visit:\n\n  1. B cell-depleting biologics, including rituximab, within 6 months.\n  2. other biologics within 5 half-lives (if known) or 8 weeks, whichever is longer.\n  3. Systemic immunosuppressants within 4 weeks prior to baseline.\nHave a history of seasonal worsening of AR and if the seasonal worsening is expected during the 4-week run-in period, the first 16 weeks after randomization, or during the last 4 weeks of the maintenance period.\nAnticipates significant changes in their daily environmental exposure\nHas a known history of recurrent acute or chronic sinusitis,\nFemale participant who is pregnant, breastfeeding or is planning to become pregnant or to breastfeed during the study.", "brief_summary": "The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with perennial allergic rhinitis. The study will last about 18 months", "keywords": []}}
{"_id": "NCT04662255", "title": "Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)", "text": "Summary: This is a study for participants with a type of blood cancer called mantle cell lymphoma (MCL). The main purpose is to compare pirtobrutinib (LOXO-305) to other drugs that work in a similar way that have already been approved by the United States Food and Drug Administration (US FDA). Participation could last up to two years, and possibly longer, if the disease does not progress.\n\nInclusion criteria: inclusion criteria: \n\n Confirmed MCL diagnosis\n Previously treated with at least one prior line of systemic therapy for MCL\n Measurable disease per Lugano criteria\n Eastern Cooperative Oncology Group (ECOG) 0-2\n Absolute neutrophil count \u2265 0.75 \u00d7 109/L without granulocyte-colony stimulating factor support within 7 days of screening\n Hemoglobin \u2265 8 g/dL not requiring transfusion support or growth factors within 7 days of screening\n Platelets \u2265 50 \u00d7 109/L not requiring transfusion support or growth factors within 7 days of screening.\n AST and ALT \u2264 3.0 x upper limit of normal (ULN)\n Total bilirubin \u2264 1.5 x ULN.\n Creatinine clearance of \u2265 30 mL/min according to Cockcroft/Gault Formula\n\nExclusion criteria: exclusion criteria: \n\nPrior treatment with an approved or investigational BTK inhibitor\nHistory of bleeding diathesis\nHistory of stroke or intracranial hemorrhage within 6 months of randomization\nHistory of allogeneic or autologous stem cell transplant (SCT) or chimeric antigen receptor modified T-cell (CAR-T) therapy within 60 days of randomization\nClinically significant cardiovascular disease\nProlonged QT interval corrected using Fridericia's formula (QTcF) \\> 470 ms on 2/3 consecutive ECGs, and mean QTcF\\>470 ms on all 3 ECGs\nKnown HIV infection or active HBV, HCV, or CMV infections. (Certain participants with controlled HBV infections may still be eligible)\nClinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal (GI) absorption\nOngoing chronic treatment with strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers which cannot be stopped within 3-5 half lives of the CYP3A inhibitor therapy prior to start of study drug treatment.\nPatients requiring therapeutic anticoagulation with warfarin or another Vitamin K antagonist.\nVaccination with live vaccine within 28 days prior to randomization", "metadata": {"brief_title": "Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)", "phase": ["PHASE3"], "drugs_list": ["Pirtobrutinib", "Ibrutinib", "Acalabrutinib", "Zanubrutinib"], "diseases_list": ["Lymphoma, Mantle-Cell"], "enrollment": 500, "inclusion_criteria": "inclusion criteria: \n\n Confirmed MCL diagnosis\n Previously treated with at least one prior line of systemic therapy for MCL\n Measurable disease per Lugano criteria\n Eastern Cooperative Oncology Group (ECOG) 0-2\n Absolute neutrophil count \u2265 0.75 \u00d7 109/L without granulocyte-colony stimulating factor support within 7 days of screening\n Hemoglobin \u2265 8 g/dL not requiring transfusion support or growth factors within 7 days of screening\n Platelets \u2265 50 \u00d7 109/L not requiring transfusion support or growth factors within 7 days of screening.\n AST and ALT \u2264 3.0 x upper limit of normal (ULN)\n Total bilirubin \u2264 1.5 x ULN.\n Creatinine clearance of \u2265 30 mL/min according to Cockcroft/Gault Formula", "exclusion_criteria": "exclusion criteria: \n\nPrior treatment with an approved or investigational BTK inhibitor\nHistory of bleeding diathesis\nHistory of stroke or intracranial hemorrhage within 6 months of randomization\nHistory of allogeneic or autologous stem cell transplant (SCT) or chimeric antigen receptor modified T-cell (CAR-T) therapy within 60 days of randomization\nClinically significant cardiovascular disease\nProlonged QT interval corrected using Fridericia's formula (QTcF) \\> 470 ms on 2/3 consecutive ECGs, and mean QTcF\\>470 ms on all 3 ECGs\nKnown HIV infection or active HBV, HCV, or CMV infections. (Certain participants with controlled HBV infections may still be eligible)\nClinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal (GI) absorption\nOngoing chronic treatment with strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers which cannot be stopped within 3-5 half lives of the CYP3A inhibitor therapy prior to start of study drug treatment.\nPatients requiring therapeutic anticoagulation with warfarin or another Vitamin K antagonist.\nVaccination with live vaccine within 28 days prior to randomization", "brief_summary": "This is a study for participants with a type of blood cancer called mantle cell lymphoma (MCL). The main purpose is to compare pirtobrutinib (LOXO-305) to other drugs that work in a similar way that have already been approved by the United States Food and Drug Administration (US FDA). Participation could last up to two years, and possibly longer, if the disease does not progress.", "keywords": ["Bruton's Tyrosine Kinase Inhibitor", "BTKi", "Hematologic Disease", "Lymphoma, non-Hodgkin's", "Lymphoma, B-Cell", "Lymphoma", "pirtobrutinib"]}}
{"_id": "NCT06153355", "title": "A First-In-Human Study of LY3839840 in Healthy Participants", "text": "Summary: The main purpose of this first-in-human study to investigate the safety of LY3839840 in single and multiple doses, and how it's processed in the body when given in different amounts.\n\nInclusion criteria: inclusion criteria: \n\nHealthy men and women. Women may only be included if they are of nonchildbearing potential\n\nFor Part C:\n\n\u2022 Part C of the study includes Chinese participants only. To qualify, the participants must be considered as native Chinese, defined as all the participant's biological grandparents being of Chinese origin\n\nFor Part D:\n\n Part D of the study includes Japanese participants only. To qualify, the participants must be first-generation Japanese, defined as the participant's biological parents, and all the participant's biological grandparents, being of exclusive Japanese descent, and being born in Japan\n Participants who are healthy as determined through medical evaluation including medical history, physical examination, laboratory tests, vital signs, and 12-lead (electrocardiogram ECG)\n Have a body mass index (BMI) of greater than or equal to 18 to less than or equal to 35 kilograms per square meter (kg/m\u00b2). For Parts C and D: BMI greater than or equal to 18 to less than or equal to 29 kilograms per square meter (kg/m\u00b2)\n Participants who have laboratory tests within the normal reference range for the population or CRU or have results with acceptable deviations that are judged by the investigator not to be clinically significant\n Have venous access sufficient to allow for blood sampling\n\nExclusion criteria: exclusion criteria: \n\nHave known allergies to LY3839840, related compounds, or any components of the formulation\nHave a history or presence of multiple or severe allergies, anaphylactic reaction to prescription or nonprescription drugs, or history of significant atopy\nHave a significant history of or current rheumatologic, cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine (such as Cushing syndrome, hyperthyroidism, hyperaldosteronism), hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the investigational medicinal product; or of interfering with the interpretation of data\nHave had any significant infections within 3 months prior to the screening visit, or develop any of these infections before the randomization visit.\nHave received \u22651 live vaccine within 28 days of screening, or intend to during the study, or \u226428 days after the study\nHad any surgical procedure (except for minor surgery requiring local or no anesthesia and without any complications or sequelae) within 12 weeks prior to screening, or intend to during the study, or \u226428 days after the study\nHad any malignancy within the past 5 years. Exceptions: successfully treated basal cell skin carcinoma or squamous cell skin carcinoma with no evidence of recurrence or metastatic disease within the past 3 years\nHave a history of a primary immunodeficiency, splenectomy, or any underlying condition that predisposes the participant to infection that, in the opinion of the sponsor or investigator, poses an unacceptable risk to the participant\nHave used, or intend to use, prescription or nonprescription medication within 14 days prior to dosing (or 5 half-lives - whichever is longer)\nAre currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study\nHave participated in a clinical study involving an investigational product within the last 30 days of the final drug administration (or 5 half-lives - whichever is longer)\nShow evidence of active or latent TB\nAre females who are lactating or have a positive pregnancy test at screening or Day -1\nBlood donation of \u2265450 mL, or participation in a clinical study that required a blood volume of \u2265400 mL since the last study visit within the past 120 days", "metadata": {"brief_title": "A First-In-Human Study of LY3839840 in Healthy Participants", "phase": ["PHASE1"], "drugs_list": ["LY3839840", "Placebo", "Midazolam"], "diseases_list": ["Healthy"], "enrollment": 178, "inclusion_criteria": "inclusion criteria: \n\nHealthy men and women. Women may only be included if they are of nonchildbearing potential\n\nFor Part C:\n\n\u2022 Part C of the study includes Chinese participants only. To qualify, the participants must be considered as native Chinese, defined as all the participant's biological grandparents being of Chinese origin\n\nFor Part D:\n\n Part D of the study includes Japanese participants only. To qualify, the participants must be first-generation Japanese, defined as the participant's biological parents, and all the participant's biological grandparents, being of exclusive Japanese descent, and being born in Japan\n Participants who are healthy as determined through medical evaluation including medical history, physical examination, laboratory tests, vital signs, and 12-lead (electrocardiogram ECG)\n Have a body mass index (BMI) of greater than or equal to 18 to less than or equal to 35 kilograms per square meter (kg/m\u00b2). For Parts C and D: BMI greater than or equal to 18 to less than or equal to 29 kilograms per square meter (kg/m\u00b2)\n Participants who have laboratory tests within the normal reference range for the population or CRU or have results with acceptable deviations that are judged by the investigator not to be clinically significant\n Have venous access sufficient to allow for blood sampling", "exclusion_criteria": "exclusion criteria: \n\nHave known allergies to LY3839840, related compounds, or any components of the formulation\nHave a history or presence of multiple or severe allergies, anaphylactic reaction to prescription or nonprescription drugs, or history of significant atopy\nHave a significant history of or current rheumatologic, cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine (such as Cushing syndrome, hyperthyroidism, hyperaldosteronism), hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the investigational medicinal product; or of interfering with the interpretation of data\nHave had any significant infections within 3 months prior to the screening visit, or develop any of these infections before the randomization visit.\nHave received \u22651 live vaccine within 28 days of screening, or intend to during the study, or \u226428 days after the study\nHad any surgical procedure (except for minor surgery requiring local or no anesthesia and without any complications or sequelae) within 12 weeks prior to screening, or intend to during the study, or \u226428 days after the study\nHad any malignancy within the past 5 years. Exceptions: successfully treated basal cell skin carcinoma or squamous cell skin carcinoma with no evidence of recurrence or metastatic disease within the past 3 years\nHave a history of a primary immunodeficiency, splenectomy, or any underlying condition that predisposes the participant to infection that, in the opinion of the sponsor or investigator, poses an unacceptable risk to the participant\nHave used, or intend to use, prescription or nonprescription medication within 14 days prior to dosing (or 5 half-lives - whichever is longer)\nAre currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study\nHave participated in a clinical study involving an investigational product within the last 30 days of the final drug administration (or 5 half-lives - whichever is longer)\nShow evidence of active or latent TB\nAre females who are lactating or have a positive pregnancy test at screening or Day -1\nBlood donation of \u2265450 mL, or participation in a clinical study that required a blood volume of \u2265400 mL since the last study visit within the past 120 days", "brief_summary": "The main purpose of this first-in-human study to investigate the safety of LY3839840 in single and multiple doses, and how it's processed in the body when given in different amounts.", "keywords": []}}
{"_id": "NCT06220669", "title": "A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis", "text": "Summary: The main purpose of this study is to evaluate the safety and efficacy of LY3541860 in adult participants with multiple sclerosis that gets worse and gets better. The study will last about 9 months with additional 6 months follow-up.\n\nInclusion criteria: inclusion criteria: \n\n Participants must meet criteria for relapsing forms of multiple sclerosis, including relapsing-remitting multiple sclerosis based on the 2017 revision of the McDonald diagnostic criteria (Thompson et al. 2018) with a relapsing course (RMS) activity according to Klineova and Lublin 2018.\n Participants must have 1 of these:\n\n   at least 1 documented relapse within the previous year\n   at least 2 documented relapses within the previous 2 years, or\n   at least 1 active GdE brain lesion on an MRI scan in the past 180 days prior to screening.\n Have an Expanded Disability Status Scale (EDSS) score of less than or equal to (\u2264) 5.5 at screening and randomization.\n\nExclusion criteria: exclusion criteria: \n\nHave had a diagnosis of:\n\n  primary progressive multiple sclerosis (MS) according to the 2017 revision of McDonald diagnostic criteria (Thompson et al. 2018), or\n  nonactive secondary progressive MS ( Klineova and Lublin 2018).\nMeet criteria for neuromyelitis optica spectrum disorder (Wingerchuk and Lucchinetti 2022).\nHave a history of clinically significant central nervous system (CNS) disease.\nHave had a confirmed relapse with systemic corticosteroid administration \\<30 days prior to randomization.\nHave more than 20 active GdE brain lesions on screening MRI scan.\nHave received any of these medications or treatments.\nHave a current or recent acute, active infection.\nHave current serious or unstable illnesses.\nHave any other clinically important abnormality at screening or baseline.", "metadata": {"brief_title": "A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis", "phase": ["PHASE2"], "drugs_list": ["LY3541860", "Placebo"], "diseases_list": ["Multiple Sclerosis"], "enrollment": 200, "inclusion_criteria": "inclusion criteria: \n\n Participants must meet criteria for relapsing forms of multiple sclerosis, including relapsing-remitting multiple sclerosis based on the 2017 revision of the McDonald diagnostic criteria (Thompson et al. 2018) with a relapsing course (RMS) activity according to Klineova and Lublin 2018.\n Participants must have 1 of these:\n\n   at least 1 documented relapse within the previous year\n   at least 2 documented relapses within the previous 2 years, or\n   at least 1 active GdE brain lesion on an MRI scan in the past 180 days prior to screening.\n Have an Expanded Disability Status Scale (EDSS) score of less than or equal to (\u2264) 5.5 at screening and randomization.", "exclusion_criteria": "exclusion criteria: \n\nHave had a diagnosis of:\n\n  primary progressive multiple sclerosis (MS) according to the 2017 revision of McDonald diagnostic criteria (Thompson et al. 2018), or\n  nonactive secondary progressive MS ( Klineova and Lublin 2018).\nMeet criteria for neuromyelitis optica spectrum disorder (Wingerchuk and Lucchinetti 2022).\nHave a history of clinically significant central nervous system (CNS) disease.\nHave had a confirmed relapse with systemic corticosteroid administration \\<30 days prior to randomization.\nHave more than 20 active GdE brain lesions on screening MRI scan.\nHave received any of these medications or treatments.\nHave a current or recent acute, active infection.\nHave current serious or unstable illnesses.\nHave any other clinically important abnormality at screening or baseline.", "brief_summary": "The main purpose of this study is to evaluate the safety and efficacy of LY3541860 in adult participants with multiple sclerosis that gets worse and gets better. The study will last about 9 months with additional 6 months follow-up.", "keywords": ["Relapsing remitting multiple sclerosis, Clinically isolated syndrome, Secondary progressive multiple sclerosis with disease activity."]}}
{"_id": "NCT06657768", "title": "A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)", "text": "Summary: The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY4006895. Part A will administer a single-ascending dose in healthy participants or Part B will administer multiple-ascending doses in participants with early symptomatic Alzheimer's Disease (AD).\n\nBlood tests will be performed to check how much LY4006895 gets into the bloodstream and how long it takes the body to eliminate it.\n\nThis is a 2-part study and will last approximately 29 weeks for Part A and 61 weeks for Part B, including a screening period for each part.\n\nInclusion criteria: inclusion criteria: \n\n \n\nExclusion criteria: exclusion criteria: \n\n ", "metadata": {"brief_title": "A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)", "phase": ["PHASE1"], "drugs_list": ["LY4006895", "Placebo"], "diseases_list": ["Alzheimer Disease", "Healthy"], "enrollment": 68, "inclusion_criteria": "inclusion criteria: \n\n ", "exclusion_criteria": "exclusion criteria: \n\n ", "brief_summary": "The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY4006895. Part A will administer a single-ascending dose in healthy participants or Part B will administer multiple-ascending doses in participants with early symptomatic Alzheimer's Disease (AD).\n\nBlood tests will be performed to check how much LY4006895 gets into the bloodstream and how long it takes the body to eliminate it.\n\nThis is a 2-part study and will last approximately 29 weeks for Part A and 61 weeks for Part B, including a screening period for each part.", "keywords": []}}
{"_id": "NCT06238479", "title": "A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors", "text": "Summary: The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with select advanced or metastatic solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.\n\nInclusion criteria: inclusion criteria: \n\n Have one of the following solid tumor cancers:\n\n   Cohort A1: urothelial carcinoma, triple negative breast cancer, non-small cell lung cancer, esophageal cancer, pancreatic cancer, ovarian cancer, cervical cancer (squamous cell carcinoma), head and neck squamous cell carcinoma or prostate cancer\n   Cohort A2/B1/B2: urothelial carcinoma\n   Cohort C1: triple negative breast cancer\n   Cohort C2: non-small cell lung cancer\n   Cohort C3: ovarian or fallopian tube cancer\n   Cohort C4: cervical cancer\n   Cohort C5: head and neck squamous cell carcinoma\n Prior Systemic Therapy Criteria:\n\n   Cohort A1/C1-5: Individual has received all standard therapies for which the participant was deemed to be an appropriate candidate by the treating investigator; OR there is no standard therapy available for the disease. There is no restriction on number of prior therapies\n   Cohort A2/B1/B2: Individual must have received at least one prior regimen in the advanced or metastatic setting. There is no restriction on number of prior therapies.\n Prior enfortumab vedotin specific requirements:\n\n   Cohorts A1/A2/C1-5: prior treatment with enfortumab vedotin is allowed, but not required\n   Cohort B1: individual must be enfortumab vedotin naive in the advanced/metastatic setting\n   Cohort B2: individual must have received enfortumab vedotin in the metastatic/advanced setting.\n Measurability of disease\n\n   Cohort A1: measurable or non-measurable disease as defined by Response Evaluation Criteria in Solid Tumors v1.1 (RECIST 1.1)\n   Cohorts A2, B1, B2, C1-5: measurable disease required as defined by RECIST v1.1\n Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n Have adequate archival tumor tissue sample available or undergo a screening biopsy if allowed per country specific regulations\n\nExclusion criteria: exclusion criteria: \n\nIndividual with known or suspected uncontrolled CNS metastases\nIndividual with uncontrolled hypercalcemia\nIndividual with uncontrolled diabetes\nIndividual with evidence of corneal keratopathy or history of corneal transplant\nAny serious unresolved toxicities from prior therapy\nSignificant cardiovascular disease\nCurrent of history of intestinal obstruction in the previous 3 months\nRecent thromboembolic event or bleeding disorder\nProlongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) \u2265 470 ms\nHistory of pneumonitis/interstitial lung disease\nHistory of Grade \u22653 skin toxicity when receiving enfortumab vedotin\nIndividuals who are pregnant, breastfeeding or plan to breastfeed during study or within 30 days of last dose of study intervention\nIndividual with active uncontrolled infection", "metadata": {"brief_title": "A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors", "phase": ["PHASE1"], "drugs_list": ["LY4101174"], "diseases_list": ["Metastatic Solid Tumor", "Recurrent Solid Tumor", "Advanced Solid Tumor", "Urinary Bladder Neoplasm", "Triple Negative Breast Cancer", "Non-small Cell Lung Cancer", "Esophageal Cancer", "Pancreatic Cancer", "Ovarian Cancer", "Cervical Cancer", "Head and Neck Squamous Cell Carcinoma", "Prostate Cancer", "Renal Pelvis Cancer", "Bladder Cancer"], "enrollment": 490, "inclusion_criteria": "inclusion criteria: \n\n Have one of the following solid tumor cancers:\n\n   Cohort A1: urothelial carcinoma, triple negative breast cancer, non-small cell lung cancer, esophageal cancer, pancreatic cancer, ovarian cancer, cervical cancer (squamous cell carcinoma), head and neck squamous cell carcinoma or prostate cancer\n   Cohort A2/B1/B2: urothelial carcinoma\n   Cohort C1: triple negative breast cancer\n   Cohort C2: non-small cell lung cancer\n   Cohort C3: ovarian or fallopian tube cancer\n   Cohort C4: cervical cancer\n   Cohort C5: head and neck squamous cell carcinoma\n Prior Systemic Therapy Criteria:\n\n   Cohort A1/C1-5: Individual has received all standard therapies for which the participant was deemed to be an appropriate candidate by the treating investigator; OR there is no standard therapy available for the disease. There is no restriction on number of prior therapies\n   Cohort A2/B1/B2: Individual must have received at least one prior regimen in the advanced or metastatic setting. There is no restriction on number of prior therapies.\n Prior enfortumab vedotin specific requirements:\n\n   Cohorts A1/A2/C1-5: prior treatment with enfortumab vedotin is allowed, but not required\n   Cohort B1: individual must be enfortumab vedotin naive in the advanced/metastatic setting\n   Cohort B2: individual must have received enfortumab vedotin in the metastatic/advanced setting.\n Measurability of disease\n\n   Cohort A1: measurable or non-measurable disease as defined by Response Evaluation Criteria in Solid Tumors v1.1 (RECIST 1.1)\n   Cohorts A2, B1, B2, C1-5: measurable disease required as defined by RECIST v1.1\n Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n Have adequate archival tumor tissue sample available or undergo a screening biopsy if allowed per country specific regulations", "exclusion_criteria": "exclusion criteria: \n\nIndividual with known or suspected uncontrolled CNS metastases\nIndividual with uncontrolled hypercalcemia\nIndividual with uncontrolled diabetes\nIndividual with evidence of corneal keratopathy or history of corneal transplant\nAny serious unresolved toxicities from prior therapy\nSignificant cardiovascular disease\nCurrent of history of intestinal obstruction in the previous 3 months\nRecent thromboembolic event or bleeding disorder\nProlongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) \u2265 470 ms\nHistory of pneumonitis/interstitial lung disease\nHistory of Grade \u22653 skin toxicity when receiving enfortumab vedotin\nIndividuals who are pregnant, breastfeeding or plan to breastfeed during study or within 30 days of last dose of study intervention\nIndividual with active uncontrolled infection", "brief_summary": "The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with select advanced or metastatic solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.", "keywords": ["Bladder Cancer", "Bladder Neoplasm", "Bladder Urothelial Carcinoma", "Urinary Bladder Cancer", "Urinary Tract Cancer", "Urothelial Neoplasms", "Renal Pelvis Cancer", "Ureter Cancer", "Nectin-4", "Antibody Drug Conjugate (ADC)"]}}
{"_id": "NCT06383390", "title": "The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)", "text": "Summary: The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\\^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.\n\nInclusion criteria: inclusion criteria: \n\n Participants may be without type 2 diabetes (T2D), or with T2D if their hemoglobin A1c (HbA1c) is 10% or lower\n Participants have established atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD), as evidenced at least one of the following:\n\n   Coronary artery disease\n   Cerebrovascular disease\n   Peripheral arterial disease\n   Chronic kidney disease defined as:\n\n     eGFR \\<45 millilitres/minute/1.73 meter squared (mL/min/1.73m\\^2) and UACR \\>30 milligram/gram (mg/g) (0.030 mg/mg)\n     eGFR \\<60 mL/min/1.73 m\\^2 and UACR \\>100 mg/g (0.100 mg/mg), or\n     eGFR \\<75 mL/min/1.73 m\\^2 and UACR \\>300 mg/g (0.300 mg/mg) (eGFR is calculated by central lab based on Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine-cystatin c equation as determined by central lab)\n A Body Mass Index of \u226527.0 kilograms per meter squared (kg/m\\^2)\n\nExclusion criteria: exclusion criteria: \n\nDiabetes related:\n\nParticipants have Type 1 Diabetes or any history of diabetic ketoacidosis\n\nCV related:\n\nParticipants have any of the following cardiovascular conditions \u2264 90 days prior to randomization:\n\n  Myocardial infarction\n  Acute coronary syndrome\n  Stroke, or\n  Coronary, peripheral, or carotid artery arterial revascularization procedure.\nHave acute decompensated heart failure requiring hospitalization.\nHave New York Heart Association (NYHA) Classification Class IV heart failure at screening\n\nKidney related:\n\nParticipants have an eGFR \\<20 mL/min/1.73 m\\^2 at screening\nHave UACR \\>5000 mg/g (5.000 mg/mg) at screening\nHave received any form of dialysis \u2264 90 days from the date of randomization\nHave either undergone a kidney transplant or have a transplant procedure scheduled\n\nOther medical conditions:\n\nParticipants have had or plan to have a surgical treatment for obesity,\nHave a history of chronic or acute pancreatitis\nHave a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) syndrome type 2\nHave a known clinically significant gastric emptying abnormality, such as severe gastroparesis or gastric outlet obstruction", "metadata": {"brief_title": "The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)", "phase": ["PHASE3"], "drugs_list": ["Retatrutide", "Placebo"], "diseases_list": ["Atherosclerotic Cardiovascular Disease (ASCVD)", "Chronic Kidney Disease (CKD)"], "enrollment": 10000, "inclusion_criteria": "inclusion criteria: \n\n Participants may be without type 2 diabetes (T2D), or with T2D if their hemoglobin A1c (HbA1c) is 10% or lower\n Participants have established atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD), as evidenced at least one of the following:\n\n   Coronary artery disease\n   Cerebrovascular disease\n   Peripheral arterial disease\n   Chronic kidney disease defined as:\n\n     eGFR \\<45 millilitres/minute/1.73 meter squared (mL/min/1.73m\\^2) and UACR \\>30 milligram/gram (mg/g) (0.030 mg/mg)\n     eGFR \\<60 mL/min/1.73 m\\^2 and UACR \\>100 mg/g (0.100 mg/mg), or\n     eGFR \\<75 mL/min/1.73 m\\^2 and UACR \\>300 mg/g (0.300 mg/mg) (eGFR is calculated by central lab based on Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine-cystatin c equation as determined by central lab)\n A Body Mass Index of \u226527.0 kilograms per meter squared (kg/m\\^2)", "exclusion_criteria": "exclusion criteria: \n\nDiabetes related:\n\nParticipants have Type 1 Diabetes or any history of diabetic ketoacidosis\n\nCV related:\n\nParticipants have any of the following cardiovascular conditions \u2264 90 days prior to randomization:\n\n  Myocardial infarction\n  Acute coronary syndrome\n  Stroke, or\n  Coronary, peripheral, or carotid artery arterial revascularization procedure.\nHave acute decompensated heart failure requiring hospitalization.\nHave New York Heart Association (NYHA) Classification Class IV heart failure at screening\n\nKidney related:\n\nParticipants have an eGFR \\<20 mL/min/1.73 m\\^2 at screening\nHave UACR \\>5000 mg/g (5.000 mg/mg) at screening\nHave received any form of dialysis \u2264 90 days from the date of randomization\nHave either undergone a kidney transplant or have a transplant procedure scheduled\n\nOther medical conditions:\n\nParticipants have had or plan to have a surgical treatment for obesity,\nHave a history of chronic or acute pancreatitis\nHave a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) syndrome type 2\nHave a known clinically significant gastric emptying abnormality, such as severe gastroparesis or gastric outlet obstruction", "brief_summary": "The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\\^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.", "keywords": ["Cardiovascular Disease", "Kidney Disease", "Major Adverse Cardiovascular Events (MACE)", "Renal Outcomes", "Cardiovascular Risk Reduction", "Kidney Disease Progression", "Cardiometabolic Risk Factors", "Cardiovascular Outcomes", "Kidney Outcomes", "Type 2 Diabetes", "Heart Disease", "Coronary Artery Disease", "Cerebrovascular Disease", "Peripheral Arterial Disease", "Nonfatal Myocardial Infarction (MI)", "Nonfatal Stroke", "Cardiovascular (CV) Death", "Hospitalization or Urgent Visit Due to Heart Failure (HF)", "Renal Death", "End Stage Kidney Disease (ESKD)"]}}
{"_id": "NCT04844606", "title": "A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)", "text": "Summary: The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in pediatric participants with ulcerative colitis (UC) or Crohn's disease (CD). The study will last about 172 weeks and may include up to 44 visits.\n\nInclusion criteria: inclusion criteria: \n\n Participants from originating studies (I6T-MC-AMBA \\[NCT05784246\\], I6T-MC-AMBU \\[NCT04004611\\], I6T-MC-AMAM \\[NCT03926130\\]) , I6T-MC-AMAY \\[NCT05509777\\]) who would, in the opinion of the investigator, derive clinical benefit from further treatment with mirikizumab\n Participants from prior studies who have completed assessments and procedures at last visit of originating study and remain on study drug treatment.\n Female participants must agree to contraception requirements.\n\nExclusion criteria: exclusion criteria: \n\nParticipants must not have developed a serious adverse event (SAE) or Adverse Event (AE) in originating study or developed other condition before first visit of Study AMAZ that continued treatment with mirikizumab would present an unreasonable risk for the participant.\nParticipants must not have had permanently or temporarily stopped study drug in the originating study, such that restarting mirikizumab would pose an unacceptable risk for the participant in Study AMAZ.\nParticipants must not have an unstable or uncontrolled illness that would potentially affect participant safety.\nParticipants must not be enrolled in the study if, for any reason, being in the study would compromise the participant's safety or confound data interpretation.\nParticipants must not have adenomatous polyps that have not been removed.\nParticipants must not be pregnant or breastfeeding.", "metadata": {"brief_title": "A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)", "phase": ["PHASE3"], "drugs_list": ["Mirikizumab", "Mirikizumab"], "diseases_list": ["Ulcerative Colitis", "Ulcerative Colitis Chronic", "Inflammatory Bowel Diseases", "Crohn's Disease"], "enrollment": 150, "inclusion_criteria": "inclusion criteria: \n\n Participants from originating studies (I6T-MC-AMBA \\[NCT05784246\\], I6T-MC-AMBU \\[NCT04004611\\], I6T-MC-AMAM \\[NCT03926130\\]) , I6T-MC-AMAY \\[NCT05509777\\]) who would, in the opinion of the investigator, derive clinical benefit from further treatment with mirikizumab\n Participants from prior studies who have completed assessments and procedures at last visit of originating study and remain on study drug treatment.\n Female participants must agree to contraception requirements.", "exclusion_criteria": "exclusion criteria: \n\nParticipants must not have developed a serious adverse event (SAE) or Adverse Event (AE) in originating study or developed other condition before first visit of Study AMAZ that continued treatment with mirikizumab would present an unreasonable risk for the participant.\nParticipants must not have had permanently or temporarily stopped study drug in the originating study, such that restarting mirikizumab would pose an unacceptable risk for the participant in Study AMAZ.\nParticipants must not have an unstable or uncontrolled illness that would potentially affect participant safety.\nParticipants must not be enrolled in the study if, for any reason, being in the study would compromise the participant's safety or confound data interpretation.\nParticipants must not have adenomatous polyps that have not been removed.\nParticipants must not be pregnant or breastfeeding.", "brief_summary": "The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in pediatric participants with ulcerative colitis (UC) or Crohn's disease (CD). The study will last about 172 weeks and may include up to 44 visits.", "keywords": ["Pediatric Ulcerative Colitis", "Pediatric Crohn's Disease", "Pediatric UC", "Pediatric CD"]}}
{"_id": "NCT06606106", "title": "A Study of LY3537031 in Overweight, Obese, and Healthy Participants", "text": "Summary: This is a 3-part study that includes a Part A, Part B, and Part C. Part A will study the safety and tolerability of the study drug known as LY3537031 in participants who are overweight and obese. Part B and Part C will study the safety and tolerability of LY3537031 in healthy participants. Part C will contain only Japanese and Chinese healthy participants.\n\nBlood tests will be performed to check how much LY3537031 gets into the bloodstream and how long it takes the body to eliminate it. Body weight will be measured. The study will last approximately 20 weeks excluding a screening period.\n\nInclusion criteria: inclusion criteria: \n\n Have a BMI within the range of:\n\n   Part A: 27.0 to 45.0 kilogram per square meter (kg/m\u00b2)\n   Part B: 22.0 to 26.9 kg/m\u00b2\n Parts B and C: Weigh 60 kg (80 lbs) or more at screening\n Have no significant (not more than 5%) self-reported weight gain or loss in the past 3 months prior to screening\n Have a thyroid stimulating hormone (TSH) value within normal local laboratory ranges.\n\nExclusion criteria: exclusion criteria: \n\nHave undergone any form of bariatric surgery\nParticipants who are lactating\nHave taken medications that promote weight loss within 90 days before screening\nHave a serum calcitonin level (at screening) of greater than or equal to 35 nanograms per liter (ng/L) (35 picograms per milliliter (pg/mL))", "metadata": {"brief_title": "A Study of LY3537031 in Overweight, Obese, and Healthy Participants", "phase": ["PHASE1"], "drugs_list": ["LY3537031", "Placebo"], "diseases_list": ["Healthy", "Obesity"], "enrollment": 230, "inclusion_criteria": "inclusion criteria: \n\n Have a BMI within the range of:\n\n   Part A: 27.0 to 45.0 kilogram per square meter (kg/m\u00b2)\n   Part B: 22.0 to 26.9 kg/m\u00b2\n Parts B and C: Weigh 60 kg (80 lbs) or more at screening\n Have no significant (not more than 5%) self-reported weight gain or loss in the past 3 months prior to screening\n Have a thyroid stimulating hormone (TSH) value within normal local laboratory ranges.", "exclusion_criteria": "exclusion criteria: \n\nHave undergone any form of bariatric surgery\nParticipants who are lactating\nHave taken medications that promote weight loss within 90 days before screening\nHave a serum calcitonin level (at screening) of greater than or equal to 35 nanograms per liter (ng/L) (35 picograms per milliliter (pg/mL))", "brief_summary": "This is a 3-part study that includes a Part A, Part B, and Part C. Part A will study the safety and tolerability of the study drug known as LY3537031 in participants who are overweight and obese. Part B and Part C will study the safety and tolerability of LY3537031 in healthy participants. Part C will contain only Japanese and Chinese healthy participants.\n\nBlood tests will be performed to check how much LY3537031 gets into the bloodstream and how long it takes the body to eliminate it. Body weight will be measured. The study will last approximately 20 weeks excluding a screening period.", "keywords": []}}
{"_id": "NCT06292013", "title": "A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)", "text": "Summary: The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke. The study drug will be administered subcutaneously (SC) (under the skin).\n\nInclusion criteria: inclusion criteria: \n\n Have Lipoprotein(a) \\[Lp(a)\\] \u2265175 nanomoles per liter (nmol/L).\n Meet criteria of either 2a or 2b:\n\n  2a: Individuals 18 years of age or older with established atherosclerotic cardiovascular disease (ASCVD) with an event or revascularization.\n\n  2b: Individuals 55 years of age or older who are at risk for a first cardiovascular (CV) event and either: Documented coronary artery disease (CAD), carotid stenosis, or peripheral artery disease (PAD) without history of event or revascularization; known familial hypercholesteremia; or a combination of high-risk factors.\n\nExclusion criteria: exclusion criteria: \n\nHave had a major cardiovascular event or surgery, such as myocardial infarction (MI), stroke or coronary or peripheral revascularization, \\< 60 days before screening\nHave uncontrolled hypertension\nHave New York Heart Association class IV heart failure.\nHave lipoprotein apheresis within 90 days of screening, or planned lipoprotein apheresis during the study.\nHave severe renal failure, defined as\n\n  Estimated glomerular rate (eGFR) \\<15 milliliters per minute per 1.73 meters squared (mL/min/1.73m2) at screening Visit 1, or ongoing dialysis.\nHave a diagnosis of active nephrotic syndrome, or urine albumin-creatinine ratio (UACR) of \u22655000 mg/g at screening Visit 1.\nHave acute or chronic hepatitis, known cirrhosis, signs and symptoms of any other liver disease other than metabolic-associated steatotic liver disease, or exclusionary laboratory results as determined by the central laboratory during screening.", "metadata": {"brief_title": "A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)", "phase": ["PHASE3"], "drugs_list": ["Lepodisiran Sodium", "Placebo"], "diseases_list": ["Atherosclerotic Cardiovascular Disease (ASCVD)", "Elevated Lp(a)"], "enrollment": 12500, "inclusion_criteria": "inclusion criteria: \n\n Have Lipoprotein(a) \\[Lp(a)\\] \u2265175 nanomoles per liter (nmol/L).\n Meet criteria of either 2a or 2b:\n\n  2a: Individuals 18 years of age or older with established atherosclerotic cardiovascular disease (ASCVD) with an event or revascularization.\n\n  2b: Individuals 55 years of age or older who are at risk for a first cardiovascular (CV) event and either: Documented coronary artery disease (CAD), carotid stenosis, or peripheral artery disease (PAD) without history of event or revascularization; known familial hypercholesteremia; or a combination of high-risk factors.", "exclusion_criteria": "exclusion criteria: \n\nHave had a major cardiovascular event or surgery, such as myocardial infarction (MI), stroke or coronary or peripheral revascularization, \\< 60 days before screening\nHave uncontrolled hypertension\nHave New York Heart Association class IV heart failure.\nHave lipoprotein apheresis within 90 days of screening, or planned lipoprotein apheresis during the study.\nHave severe renal failure, defined as\n\n  Estimated glomerular rate (eGFR) \\<15 milliliters per minute per 1.73 meters squared (mL/min/1.73m2) at screening Visit 1, or ongoing dialysis.\nHave a diagnosis of active nephrotic syndrome, or urine albumin-creatinine ratio (UACR) of \u22655000 mg/g at screening Visit 1.\nHave acute or chronic hepatitis, known cirrhosis, signs and symptoms of any other liver disease other than metabolic-associated steatotic liver disease, or exclusionary laboratory results as determined by the central laboratory during screening.", "brief_summary": "The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke. The study drug will be administered subcutaneously (SC) (under the skin).", "keywords": ["ASCVD", "LY3819469", "lepodisiran"]}}
{"_id": "NCT06413706", "title": "A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy", "text": "Summary: The purpose of this study is to measure the benefit of adding abemaciclib to the chemotherapy, temozolomide, for newly diagnosed high-grade glioma following radiotherapy.\n\nYour participation could last approximately 11 months and possibly longer depending upon how you and your tumor respond.\n\nInclusion criteria: inclusion criteria: \n\n Biopsy proven high-grade glioma (HGG) as defined by 2016 World Health Organization (WHO) Classification Criteria, Grade 3-4 including:\n Anaplastic astrocytoma\n Anaplastic ganglioglioma\n Anaplastic oligodendroglioma.\n Anaplastic pleomorphic xanthoastrocytoma,\n Glioblastoma\n\nOR as defined by the 2021 WHO Classification Criteria as molecularly characterized:\n\n Non-pontine diffuse midline glioma, H3 K27-altered,\n Diffuse hemispheric glioma, H3 G34-mutant\n Diffuse pediatric HGG, H3/IDH-wildtype\n Infant-type hemispheric glioma\n High-grade astrocytoma with piloid features\n High-grade pleomorphic xanthoastrocytoma\n IDH-mutant diffuse glioma with homozygous cyclin- dependent kinase inhibitor 2A/B (CDKN2A/B) deletion,\n IDH-mutant and 1p/19q co-deleted oligodendroglioma\n IDH-mutant astrocytoma with homozygous CDKN2A/B deletion\n Contraceptive use should be consistent with local regulations for participants in clinical studies.\n Radiotherapy initiated within 6 weeks (+1 week) of diagnosis and administered over 6 weeks (\u00b11 week). Participants \\<3 years of age, considered not suitable for radiotherapy may be eligible.\n Minimum of 4 weeks between completion of radiation and Cycle 1 Day 1 (C1D1).\n Maximum of 8 weeks between completion of radiation and C1D1. Exceptional circumstances can be discussed with the medical monitor.\n Acute effects of prior therapies must be Grade \u22641 unless deemed clinically insignificant by the investigator.\n Adequate hematologic and organ function \u22647 days prior to C1D1\n Life expectancy of \u22658 weeks and deemed likely to complete at least 1 cycle of treatment.\n A performance score of \u226560 using:\n\n  1. Lansky scale for participants \\<16 years\n  2. Karnofsky scale for participants \u226516 years\n Able to swallow and/or have a gastric/nasogastric tube.\n Any current systemic steroid use dose must be stable or decreasing at least 7 days prior to C1D1.\n Able and willing to adhere to study procedures, including frequent blood draws and MRI.\n At least 28 days since any major surgery, laparoscopic procedure, or a significant traumatic injury.\n Has a body surface area (BSA) of \u22650.2 m2.\n\nExclusion criteria: exclusion criteria: \n\nParticipants are excluded if any of the following apply:\n\nDiffuse Intrinsic Pontine Glioma (DIPG) or diffuse midline glioma located in the pons.\nRecurrent or refractory HGG including any recurrence/progression during/after radiotherapy.\nSecondary HGG, defined as a previously treated low-grade glioma that now meets high- grade criteria, or that resulted from a previously treated malignancy.\nHave known pathogenic somatic mutations appropriate for an anaplastic lymphoma kinase (ALK), B-rapidly accelerated fibrosarcoma (BRAF), or neurotrophic tyrosine receptor kinase (NTRK ) inhibitor, in regions where these therapies are available and deemed appropriate by the investigator.\nPrior HGG treatment (including bevacizumab), except for surgery and radiotherapy (with or without concomitant temozolomide).\nCurrent enrollment in another trial deemed incompatible with this study.\nTreatment with an investigational product within the last 30 days or 5 half-lives (whichever is longer).\nPrior malignancy within the previous 3 years that, per the investigator and the medical monitor, may affect interpretation of study results.\nA preexisting medical condition(s) that, per the investigator, would preclude study participation.\nAny serious, active, systemic infection requiring IV antibiotic, antifungal, or antiviral therapy, including acute hepatitis B or C, or Human Immunodeficiency Virus at C1D1.\nIntolerability or hypersensitivity such as urticaria, anaphylaxis, toxic necrolysis, and/or Stevens-Johnson syndrome to temozolomide, and/or abemaciclib, their excipients, or dacarbazine.\nReceived a live virus vaccine within 28 days of C1D1.\nPregnant, breastfeeding, or intend to become pregnant during the study.", "metadata": {"brief_title": "A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy", "phase": ["PHASE2"], "drugs_list": ["Abemaciclib", "Temozolomide"], "diseases_list": ["Glioma"], "enrollment": 45, "inclusion_criteria": "inclusion criteria: \n\n Biopsy proven high-grade glioma (HGG) as defined by 2016 World Health Organization (WHO) Classification Criteria, Grade 3-4 including:\n Anaplastic astrocytoma\n Anaplastic ganglioglioma\n Anaplastic oligodendroglioma.\n Anaplastic pleomorphic xanthoastrocytoma,\n Glioblastoma\n\nOR as defined by the 2021 WHO Classification Criteria as molecularly characterized:\n\n Non-pontine diffuse midline glioma, H3 K27-altered,\n Diffuse hemispheric glioma, H3 G34-mutant\n Diffuse pediatric HGG, H3/IDH-wildtype\n Infant-type hemispheric glioma\n High-grade astrocytoma with piloid features\n High-grade pleomorphic xanthoastrocytoma\n IDH-mutant diffuse glioma with homozygous cyclin- dependent kinase inhibitor 2A/B (CDKN2A/B) deletion,\n IDH-mutant and 1p/19q co-deleted oligodendroglioma\n IDH-mutant astrocytoma with homozygous CDKN2A/B deletion\n Contraceptive use should be consistent with local regulations for participants in clinical studies.\n Radiotherapy initiated within 6 weeks (+1 week) of diagnosis and administered over 6 weeks (\u00b11 week). Participants \\<3 years of age, considered not suitable for radiotherapy may be eligible.\n Minimum of 4 weeks between completion of radiation and Cycle 1 Day 1 (C1D1).\n Maximum of 8 weeks between completion of radiation and C1D1. Exceptional circumstances can be discussed with the medical monitor.\n Acute effects of prior therapies must be Grade \u22641 unless deemed clinically insignificant by the investigator.\n Adequate hematologic and organ function \u22647 days prior to C1D1\n Life expectancy of \u22658 weeks and deemed likely to complete at least 1 cycle of treatment.\n A performance score of \u226560 using:\n\n  1. Lansky scale for participants \\<16 years\n  2. Karnofsky scale for participants \u226516 years\n Able to swallow and/or have a gastric/nasogastric tube.\n Any current systemic steroid use dose must be stable or decreasing at least 7 days prior to C1D1.\n Able and willing to adhere to study procedures, including frequent blood draws and MRI.\n At least 28 days since any major surgery, laparoscopic procedure, or a significant traumatic injury.\n Has a body surface area (BSA) of \u22650.2 m2.", "exclusion_criteria": "exclusion criteria: \n\nParticipants are excluded if any of the following apply:\n\nDiffuse Intrinsic Pontine Glioma (DIPG) or diffuse midline glioma located in the pons.\nRecurrent or refractory HGG including any recurrence/progression during/after radiotherapy.\nSecondary HGG, defined as a previously treated low-grade glioma that now meets high- grade criteria, or that resulted from a previously treated malignancy.\nHave known pathogenic somatic mutations appropriate for an anaplastic lymphoma kinase (ALK), B-rapidly accelerated fibrosarcoma (BRAF), or neurotrophic tyrosine receptor kinase (NTRK ) inhibitor, in regions where these therapies are available and deemed appropriate by the investigator.\nPrior HGG treatment (including bevacizumab), except for surgery and radiotherapy (with or without concomitant temozolomide).\nCurrent enrollment in another trial deemed incompatible with this study.\nTreatment with an investigational product within the last 30 days or 5 half-lives (whichever is longer).\nPrior malignancy within the previous 3 years that, per the investigator and the medical monitor, may affect interpretation of study results.\nA preexisting medical condition(s) that, per the investigator, would preclude study participation.\nAny serious, active, systemic infection requiring IV antibiotic, antifungal, or antiviral therapy, including acute hepatitis B or C, or Human Immunodeficiency Virus at C1D1.\nIntolerability or hypersensitivity such as urticaria, anaphylaxis, toxic necrolysis, and/or Stevens-Johnson syndrome to temozolomide, and/or abemaciclib, their excipients, or dacarbazine.\nReceived a live virus vaccine within 28 days of C1D1.\nPregnant, breastfeeding, or intend to become pregnant during the study.", "brief_summary": "The purpose of this study is to measure the benefit of adding abemaciclib to the chemotherapy, temozolomide, for newly diagnosed high-grade glioma following radiotherapy.\n\nYour participation could last approximately 11 months and possibly longer depending upon how you and your tumor respond.", "keywords": ["Brain tumor", "Central nervous system (CNS) tumor", "Spinal cord tumor", "Cyclin-dependent kinase (CDK) 4/6 inhibitor"]}}
{"_id": "NCT06672549", "title": "A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)", "text": "Summary: The purpose of this pediatric, chronic weight management, Phase 3 Master Protocol (PWMP) is to create a framework to evaluate the safety and efficacy of pharmacologic agents for the treatment of obesity or overweight in pediatric participants.\n\nInclusion criteria: inclusion criteria: \n\n Have a history of at least 1 unsuccessful effort to lose sufficient body weight after participation in a structured lifestyle modification program (diet and exercise counseling for at least 3 months) prior to screening.\n Obesity as defined by BMI equal to or above the 95th percentile for age and sex (on age- and gender-specific growth chart \\[CDC-NCHS, 2022\\]); OR\n Applies to participant age between 12 and \\<18 years old. Overweight as defined by BMI equal to or above the 85th percentile but less than the 95th percentile for age and sex, on age- and sex-specific growth chart (CDC-NCHS, 2022), and at least 1 weight-related comorbidity,\n\n   hypertension\n   type 2 diabetes (T2D)\n   prediabetes\n   dyslipidemia\n   obstructive sleep apnea\n   metabolic dysfunction-associated steatohepatitis (MASH) or metabolic dysfunction-associated steatotic liver disease (MASLD)\n\nExclusion criteria: exclusion criteria: \n\nHave undergone or plan to undergo weight reduction procedure during the study, such as, but not limited to:\n\n  gastric bypass\n  sleeve gastrectomy\n  restrictive bariatric surgery, such as Lap-Band\u00ae gastric banding, or\n  any other procedure intended to result in weight reduction.\nHave a diagnosis that is a secondary cause of obesity or have a history of abrupt onset of obesity suggesting a secondary cause, such as hypothalamic, monogenetic, syndromic, or endocrine causes.\nHave a self-reported, or by parent or legal guardian where applicable, decrease in body weight greater than 5 kg (11 lbs) within 90 days before screening irrespective of medical records\nHave type 1 diabetes or history of ketoacidosis, or hyperosmolar state.\nHave HbA1c \\>9.0% (75 mmol/mol) as measured by central laboratory at screening.\nHave a family or personal history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia Syndrome Type 2.", "metadata": {"brief_title": "A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)", "phase": ["PHASE3"], "drugs_list": ["Orforglipron", "Placebo"], "diseases_list": ["Obesity", "Overweight"], "enrollment": 125, "inclusion_criteria": "inclusion criteria: \n\n Have a history of at least 1 unsuccessful effort to lose sufficient body weight after participation in a structured lifestyle modification program (diet and exercise counseling for at least 3 months) prior to screening.\n Obesity as defined by BMI equal to or above the 95th percentile for age and sex (on age- and gender-specific growth chart \\[CDC-NCHS, 2022\\]); OR\n Applies to participant age between 12 and \\<18 years old. Overweight as defined by BMI equal to or above the 85th percentile but less than the 95th percentile for age and sex, on age- and sex-specific growth chart (CDC-NCHS, 2022), and at least 1 weight-related comorbidity,\n\n   hypertension\n   type 2 diabetes (T2D)\n   prediabetes\n   dyslipidemia\n   obstructive sleep apnea\n   metabolic dysfunction-associated steatohepatitis (MASH) or metabolic dysfunction-associated steatotic liver disease (MASLD)", "exclusion_criteria": "exclusion criteria: \n\nHave undergone or plan to undergo weight reduction procedure during the study, such as, but not limited to:\n\n  gastric bypass\n  sleeve gastrectomy\n  restrictive bariatric surgery, such as Lap-Band\u00ae gastric banding, or\n  any other procedure intended to result in weight reduction.\nHave a diagnosis that is a secondary cause of obesity or have a history of abrupt onset of obesity suggesting a secondary cause, such as hypothalamic, monogenetic, syndromic, or endocrine causes.\nHave a self-reported, or by parent or legal guardian where applicable, decrease in body weight greater than 5 kg (11 lbs) within 90 days before screening irrespective of medical records\nHave type 1 diabetes or history of ketoacidosis, or hyperosmolar state.\nHave HbA1c \\>9.0% (75 mmol/mol) as measured by central laboratory at screening.\nHave a family or personal history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia Syndrome Type 2.", "brief_summary": "The purpose of this pediatric, chronic weight management, Phase 3 Master Protocol (PWMP) is to create a framework to evaluate the safety and efficacy of pharmacologic agents for the treatment of obesity or overweight in pediatric participants.", "keywords": []}}
{"_id": "NCT06280716", "title": "A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis", "text": "Summary: The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab with/without Topical Corticosteroid Treatment in Participants with Moderate-to-Severe Atopic Dermatitis. The study will last approximately 62 weeks.\n\nInclusion criteria: inclusion criteria: \n\n Have chronic AD that has been present for \u22651 year before the screening period or have chronic eczema and meet the AAD criteria.\n Have moderate-to-severe AD, including all of the following at the baseline: EASI score \u226516, IGA score \u22653 (scale of 0 to 4), \u226510% BSA of AD involvement.\n Have a documented history provided by a physician and/or investigator of inadequate response to existing topical medications within 6 months preceding screening as defined by at least 1 of the following:\n\n  1. Inability to achieve good disease control, defined as mild disease or better after use of at least a medium-potency TCS for at least 4 weeks, or for the maximum duration recommended by the product prescribing information, whichever is shorter. TCS may be used with or without TCIs and/or topical Janus kinase (JAK) inhibitors.\n  2. Participants who failed systemic therapies intended to treat AD within 6 months preceding screening, such as cyclosporine, MTX, azathioprine, and MMF, will also be considered as surrogates for having inadequate response to topical therapy.\n Adolescents body weight must be \u226540 kg at baseline.\n Males may participate in this trial and comply with specific local government study requirements. Females of childbearing potential and females not of childbearing potential may participate in this trial.\n\nExclusion criteria: exclusion criteria: \n\nHave received a dose of lebrikizumab in any prior lebrikizumab clinical study.\nHave a history of anaphylaxis or uncontrolled chronic disease that might require bursts of oral corticosteroids.\nHave a current or recent acute, active infection. For at least 30 days before screening and up to the randomization, participants must have no symptoms or signs of confirmed or suspected infection and must have completed any appropriate anti-infective treatment.\nHave had Serious, Opportunistic, Chronic and Recurring infection within 3 months prior to the screening or develops any of these infections before the randomization.\nHave active tuberculosis (TB) or latent tuberculosis infection (LTBI) that has not been treated with a complete course of appropriate therapy or such treatment is underway.\nHave a current infection with HBV, HCV, human immunodeficiency virus (HIV) infection.\nHave presence of skin comorbidities that may interfere with study assessments.\nHave a diagnosis or history of malignant disease within 5 years before screening, with the following exceptions:\n\n  1. basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years, and\n  2. cervical carcinoma in situ, with no evidence of recurrence within 5 years before screening visit.\nPregnant or breastfeeding women or women planning to become pregnant or breastfeed during the study.", "metadata": {"brief_title": "A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis", "phase": ["PHASE3"], "drugs_list": ["Placebo", "Lebrikizumab", "Topical Corticosteroid"], "diseases_list": ["Atopic Dermatitis"], "enrollment": 430, "inclusion_criteria": "inclusion criteria: \n\n Have chronic AD that has been present for \u22651 year before the screening period or have chronic eczema and meet the AAD criteria.\n Have moderate-to-severe AD, including all of the following at the baseline: EASI score \u226516, IGA score \u22653 (scale of 0 to 4), \u226510% BSA of AD involvement.\n Have a documented history provided by a physician and/or investigator of inadequate response to existing topical medications within 6 months preceding screening as defined by at least 1 of the following:\n\n  1. Inability to achieve good disease control, defined as mild disease or better after use of at least a medium-potency TCS for at least 4 weeks, or for the maximum duration recommended by the product prescribing information, whichever is shorter. TCS may be used with or without TCIs and/or topical Janus kinase (JAK) inhibitors.\n  2. Participants who failed systemic therapies intended to treat AD within 6 months preceding screening, such as cyclosporine, MTX, azathioprine, and MMF, will also be considered as surrogates for having inadequate response to topical therapy.\n Adolescents body weight must be \u226540 kg at baseline.\n Males may participate in this trial and comply with specific local government study requirements. Females of childbearing potential and females not of childbearing potential may participate in this trial.", "exclusion_criteria": "exclusion criteria: \n\nHave received a dose of lebrikizumab in any prior lebrikizumab clinical study.\nHave a history of anaphylaxis or uncontrolled chronic disease that might require bursts of oral corticosteroids.\nHave a current or recent acute, active infection. For at least 30 days before screening and up to the randomization, participants must have no symptoms or signs of confirmed or suspected infection and must have completed any appropriate anti-infective treatment.\nHave had Serious, Opportunistic, Chronic and Recurring infection within 3 months prior to the screening or develops any of these infections before the randomization.\nHave active tuberculosis (TB) or latent tuberculosis infection (LTBI) that has not been treated with a complete course of appropriate therapy or such treatment is underway.\nHave a current infection with HBV, HCV, human immunodeficiency virus (HIV) infection.\nHave presence of skin comorbidities that may interfere with study assessments.\nHave a diagnosis or history of malignant disease within 5 years before screening, with the following exceptions:\n\n  1. basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years, and\n  2. cervical carcinoma in situ, with no evidence of recurrence within 5 years before screening visit.\nPregnant or breastfeeding women or women planning to become pregnant or breastfeed during the study.", "brief_summary": "The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab with/without Topical Corticosteroid Treatment in Participants with Moderate-to-Severe Atopic Dermatitis. The study will last approximately 62 weeks.", "keywords": []}}
{"_id": "NCT04088396", "title": "A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)", "text": "Summary: The reason for this study is to see if the study drug baricitinib is safe and effective in participants from 1 year to less than 18 years old with systemic juvenile idiopathic arthritis (sJIA). Participants are assigned to 1 of 2 cohorts. In cohort 1, participants will receive baricitinib or tocilizumab reference. In cohort 2, participants will receive baricitinib.\n\nInclusion criteria: inclusion criteria: \n\n Participants must have a diagnosis of systemic Juvenile Idiopathic Arthritis (sJIA) as defined by International League of Associations for Rheumatology (ILAR) criteria with onset before the age of 16 years\n Participants must have at least 2 active joints at screening and baseline\n Cohort 1 (IL-6 inhibitor therapy naive): Participants who are at least 1 year and less than 18 years of age, except in countries that restrict use of tocilizumab in participants less than 2 years of age\n Cohort 2 (open-label baricitinib): Participants who are at least 1 year and less than 18 years of age\n\nExclusion criteria: exclusion criteria: \n\nParticipants must not have polyarticular JIA (positive or negative for rheumatoid factor), extended oligoarticular JIA, enthesitis-related JIA, or juvenile psoriatic arthritis\nParticipants must not have persistent oligoarticular arthritis as defined by the ILAR criteria\nParticipants must not have a history or presence of any autoimmune inflammatory condition other than JIA\nParticipants must not have active anterior uveitis or are receiving concurrent treatment for anterior uveitis\nParticipants must not have active fibromyalgia or other chronic pain conditions that, in the investigator's opinion, would make it difficult to appropriately assess disease activity for the purposes of this study\nParticipants must not have biologic features of Macrophage Activation Syndrome (MAS) over the past 12 weeks\nParticipants must not have a current or recent (\\<4 weeks prior to baseline) clinically serious infection\nParticipants must not have a positive test for hepatitis B virus\nParticipants must not have evidence of active tuberculosis (TB) or untreated latent TB", "metadata": {"brief_title": "A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)", "phase": ["PHASE3"], "drugs_list": ["Baricitinib", "Tocilizumab"], "diseases_list": ["Systemic Juvenile Idiopathic Arthritis"], "enrollment": 58, "inclusion_criteria": "inclusion criteria: \n\n Participants must have a diagnosis of systemic Juvenile Idiopathic Arthritis (sJIA) as defined by International League of Associations for Rheumatology (ILAR) criteria with onset before the age of 16 years\n Participants must have at least 2 active joints at screening and baseline\n Cohort 1 (IL-6 inhibitor therapy naive): Participants who are at least 1 year and less than 18 years of age, except in countries that restrict use of tocilizumab in participants less than 2 years of age\n Cohort 2 (open-label baricitinib): Participants who are at least 1 year and less than 18 years of age", "exclusion_criteria": "exclusion criteria: \n\nParticipants must not have polyarticular JIA (positive or negative for rheumatoid factor), extended oligoarticular JIA, enthesitis-related JIA, or juvenile psoriatic arthritis\nParticipants must not have persistent oligoarticular arthritis as defined by the ILAR criteria\nParticipants must not have a history or presence of any autoimmune inflammatory condition other than JIA\nParticipants must not have active anterior uveitis or are receiving concurrent treatment for anterior uveitis\nParticipants must not have active fibromyalgia or other chronic pain conditions that, in the investigator's opinion, would make it difficult to appropriately assess disease activity for the purposes of this study\nParticipants must not have biologic features of Macrophage Activation Syndrome (MAS) over the past 12 weeks\nParticipants must not have a current or recent (\\<4 weeks prior to baseline) clinically serious infection\nParticipants must not have a positive test for hepatitis B virus\nParticipants must not have evidence of active tuberculosis (TB) or untreated latent TB", "brief_summary": "The reason for this study is to see if the study drug baricitinib is safe and effective in participants from 1 year to less than 18 years old with systemic juvenile idiopathic arthritis (sJIA). Participants are assigned to 1 of 2 cohorts. In cohort 1, participants will receive baricitinib or tocilizumab reference. In cohort 2, participants will receive baricitinib.", "keywords": ["Systemic", "Fever", "Flare", "sJIA", "JIA"]}}
{"_id": "NCT06538116", "title": "A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease", "text": "Summary: The main purpose of this study is to look at how safe the study drug (mevidalen) is and whether it works to alleviate symptoms when given to people with mild to moderate Alzheimer Disease (AD) dementia. This is done by looking at participants: thinking and memory (cognition), everyday activities and sleep, AD symptoms, physical activity, irritability or anxiety. The study is expected to last approximately 26 weeks and may include up to 14 visits.\n\nInclusion criteria: inclusion criteria: \n\n Have gradual and progressive decline in memory function for greater than or equal to 6 months that is severe enough to interfere with activities of daily living.\n Have MMSE score of 13 to 24.\n Have eligibile plasma P-tau or historical evidence of AD pathology.\n Have a reliable study partner who will provide written informed consent to participate, is in frequent contact with the participant and will be available at designated times.\n Males with partners of childbearing potential must agree to abide with provided contraception guidance.\n\nExclusion criteria: exclusion criteria: \n\nAre individuals of childbearing potential.\nHave significant central nervous system or psychiatric disease, other than AD, that in the investigator's opinion may affect cognition or the ability to complete the study (e.g: head trauma, stroke, seizure disorder etc.,).\nHave cardiovascular-related risk factors or history that include uncontrolled hypertension, heart failure, stroke; or liver-related abnormalities.\nUse of moderate or strong CYP3A4 inhibitors or inducers.\nHave participated within the last 30 days in a clinical trial involving an investigational product.\nParticipant is, in the judgment of the investigator, actively suicidal and therefore deemed to be at significant risk for suicide.", "metadata": {"brief_title": "A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease", "phase": ["PHASE2"], "drugs_list": ["Mevidalen", "Placebo"], "diseases_list": ["Alzheimer Disease"], "enrollment": 300, "inclusion_criteria": "inclusion criteria: \n\n Have gradual and progressive decline in memory function for greater than or equal to 6 months that is severe enough to interfere with activities of daily living.\n Have MMSE score of 13 to 24.\n Have eligibile plasma P-tau or historical evidence of AD pathology.\n Have a reliable study partner who will provide written informed consent to participate, is in frequent contact with the participant and will be available at designated times.\n Males with partners of childbearing potential must agree to abide with provided contraception guidance.", "exclusion_criteria": "exclusion criteria: \n\nAre individuals of childbearing potential.\nHave significant central nervous system or psychiatric disease, other than AD, that in the investigator's opinion may affect cognition or the ability to complete the study (e.g: head trauma, stroke, seizure disorder etc.,).\nHave cardiovascular-related risk factors or history that include uncontrolled hypertension, heart failure, stroke; or liver-related abnormalities.\nUse of moderate or strong CYP3A4 inhibitors or inducers.\nHave participated within the last 30 days in a clinical trial involving an investigational product.\nParticipant is, in the judgment of the investigator, actively suicidal and therefore deemed to be at significant risk for suicide.", "brief_summary": "The main purpose of this study is to look at how safe the study drug (mevidalen) is and whether it works to alleviate symptoms when given to people with mild to moderate Alzheimer Disease (AD) dementia. This is done by looking at participants: thinking and memory (cognition), everyday activities and sleep, AD symptoms, physical activity, irritability or anxiety. The study is expected to last approximately 26 weeks and may include up to 14 visits.", "keywords": []}}
{"_id": "NCT06690996", "title": "A Study of LY4005130 in Healthy Participants", "text": "Summary: The purpose of this study is to evaluate how well LY4005130 is tolerated and what side effects may occur in healthy participants. The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm). Blood tests will be performed to check how much LY4005130 gets into the bloodstream and how long it takes the body to eliminate it.\n\nPart A for the single-ascending doses (SAD) of the study will last about 12 weeks with 9 visits. Part B for the multiple-ascending doses (MAD) of the study will either last about 16 weeks with 13 visits or 20 weeks with 12 visits not counting the time for screening.\n\nInclusion criteria: inclusion criteria: \n\n Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and 12-lead (electrocardiogram) ECG. If any values are outside the normal range and considered to be significant, for example, elevated white blood cell count, the respective test may be repeated once at the discretion of the investigator without consultation with the sponsor\n If enrolled as Japanese or Chinese, the entry requirements are as follows:\n\n   To qualify as a participant of first-generation Japanese origin, the participant, the participant's biological parents, and all of the participant's biological grandparents must be of exclusive Japanese descent and born in Japan\n   To qualify as Chinese for the purpose of this study, all 4 of the participant's biological grandparents must be of exclusive Chinese descent and born in China\n Have a body weight 45 kilogram (kg) or greater and body mass index greater than 18 and less than 32 kilogram per square meter (kg/m\u00b2)\n\nExclusion criteria: exclusion criteria: \n\nAre an individual of childbearing potential (IOCBP)\nHave known allergies to LY4005130, related compounds, or any components of the formulation\nHave received a live vaccine within 28 days of screening or intend to do so during the study or within 28 days after the study\n\n  Non-live or inactivated vaccinations are allowed\n  Bacillus Calmette Guerin vaccine must not have been administered within 12 months before screening\nHad a surgical procedure within 12 weeks before screening;\n\n  during the study, or\n  within 28 days after the study\nHave a history of allergy to medications that could be used to treat infusion reactions, or to the drug excipients\nHave a history or presence of multiple or severe allergies, anaphylactic reaction to prescription or nonprescription drugs, significant history of atopy, or a history of severe posttreatment hypersensitivity reactions. These reactions include, but are not limited to, erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, and exfoliative dermatitis\nHave a diagnosis or history of malignant disease within 5 years prior to screening, with the following exceptions\n\n  Basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years, or\n  Cervical carcinoma in situ, with no evidence of recurrence within the 5 years prior to screening\nHave had breast cancer within the past 10 years\nHave a history of a primary immunodeficiency, splenectomy, or any underlying condition that predisposes the participant to infection that, in the opinion of the sponsor or investigator, poses an unacceptable risk to the participant\nHave a current or recent acute, active infection", "metadata": {"brief_title": "A Study of LY4005130 in Healthy Participants", "phase": ["PHASE1"], "drugs_list": ["LY4005130", "LY4005130", "Placebo", "Placebo"], "diseases_list": ["Healthy"], "enrollment": 140, "inclusion_criteria": "inclusion criteria: \n\n Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and 12-lead (electrocardiogram) ECG. If any values are outside the normal range and considered to be significant, for example, elevated white blood cell count, the respective test may be repeated once at the discretion of the investigator without consultation with the sponsor\n If enrolled as Japanese or Chinese, the entry requirements are as follows:\n\n   To qualify as a participant of first-generation Japanese origin, the participant, the participant's biological parents, and all of the participant's biological grandparents must be of exclusive Japanese descent and born in Japan\n   To qualify as Chinese for the purpose of this study, all 4 of the participant's biological grandparents must be of exclusive Chinese descent and born in China\n Have a body weight 45 kilogram (kg) or greater and body mass index greater than 18 and less than 32 kilogram per square meter (kg/m\u00b2)", "exclusion_criteria": "exclusion criteria: \n\nAre an individual of childbearing potential (IOCBP)\nHave known allergies to LY4005130, related compounds, or any components of the formulation\nHave received a live vaccine within 28 days of screening or intend to do so during the study or within 28 days after the study\n\n  Non-live or inactivated vaccinations are allowed\n  Bacillus Calmette Guerin vaccine must not have been administered within 12 months before screening\nHad a surgical procedure within 12 weeks before screening;\n\n  during the study, or\n  within 28 days after the study\nHave a history of allergy to medications that could be used to treat infusion reactions, or to the drug excipients\nHave a history or presence of multiple or severe allergies, anaphylactic reaction to prescription or nonprescription drugs, significant history of atopy, or a history of severe posttreatment hypersensitivity reactions. These reactions include, but are not limited to, erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, and exfoliative dermatitis\nHave a diagnosis or history of malignant disease within 5 years prior to screening, with the following exceptions\n\n  Basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years, or\n  Cervical carcinoma in situ, with no evidence of recurrence within the 5 years prior to screening\nHave had breast cancer within the past 10 years\nHave a history of a primary immunodeficiency, splenectomy, or any underlying condition that predisposes the participant to infection that, in the opinion of the sponsor or investigator, poses an unacceptable risk to the participant\nHave a current or recent acute, active infection", "brief_summary": "The purpose of this study is to evaluate how well LY4005130 is tolerated and what side effects may occur in healthy participants. The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm). Blood tests will be performed to check how much LY4005130 gets into the bloodstream and how long it takes the body to eliminate it.\n\nPart A for the single-ascending doses (SAD) of the study will last about 12 weeks with 9 visits. Part B for the multiple-ascending doses (MAD) of the study will either last about 16 weeks with 13 visits or 20 weeks with 12 visits not counting the time for screening.", "keywords": []}}
{"_id": "NCT04396236", "title": "A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine", "text": "Summary: The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.\n\nInclusion criteria: inclusion criteria: \n\n Participants must have a history of migraine with or without aura as defined by International Headache Society International Classification of Headache Disorders, 3rd edition (ICHD-3) (ICHD-3 2018) diagnostic criteria 1.1 or 1.2.1 and meets the following criteria:\n\n   History of migraine attacks for more than 6 months\n   Reports at least 2 and no more than 8 moderate-to-severe migraine attacks per month in the 2 months prior to screening visit\n   Duration of a typical untreated migraine attack (excluding sleep) is greater than or equal to 3 hours\n   Participant has not, by history, experienced satisfactory response with a previous migraine therapy, in the opinion of the investigator\n Participant must be able to swallow a tablet\n For participants taking migraine preventive medication, treatment regimen is stable and has been taken for at least 3 months prior to screening\n Participants must weigh at least 15 kilograms (kg)\n\nExclusion criteria: exclusion criteria: \n\nParticipants must not be pregnant or nursing\nParticipants must not have any acute, serious, or unstable medical condition\nParticipants must not be actively suicidal or at significant risk for suicide, in the opinion of the investigator", "metadata": {"brief_title": "A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine", "phase": ["PHASE3"], "drugs_list": ["Lasmiditan", "Placebo"], "diseases_list": ["Migraine"], "enrollment": 1633, "inclusion_criteria": "inclusion criteria: \n\n Participants must have a history of migraine with or without aura as defined by International Headache Society International Classification of Headache Disorders, 3rd edition (ICHD-3) (ICHD-3 2018) diagnostic criteria 1.1 or 1.2.1 and meets the following criteria:\n\n   History of migraine attacks for more than 6 months\n   Reports at least 2 and no more than 8 moderate-to-severe migraine attacks per month in the 2 months prior to screening visit\n   Duration of a typical untreated migraine attack (excluding sleep) is greater than or equal to 3 hours\n   Participant has not, by history, experienced satisfactory response with a previous migraine therapy, in the opinion of the investigator\n Participant must be able to swallow a tablet\n For participants taking migraine preventive medication, treatment regimen is stable and has been taken for at least 3 months prior to screening\n Participants must weigh at least 15 kilograms (kg)", "exclusion_criteria": "exclusion criteria: \n\nParticipants must not be pregnant or nursing\nParticipants must not have any acute, serious, or unstable medical condition\nParticipants must not be actively suicidal or at significant risk for suicide, in the opinion of the investigator", "brief_summary": "The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.", "keywords": ["acute"]}}
{"_id": "NCT03432286", "title": "A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine", "text": "Summary: The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatment of episodic migraine. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.\n\nInclusion criteria: inclusion criteria: \n\n Have a diagnosis of migraine with or without aura as defined by the IHS ICHD-3 guidelines (1.1 or 1.2 according to ICHD-3 \\[2018\\]), with a history of migraine headaches of at least 6 months prior to screening.\n\nExclusion criteria: exclusion criteria: \n\nParticipants who are taking, or are expected to take, therapeutic antibodies during the course of the study (adalimumab, infliximab, trastuzumab, bevacizumab, etc.). Prior use of therapeutic antibodies is allowed if that use was more than 12 months prior to baseline.\nKnown hypersensitivity to monoclonal antibodies or other therapeutic proteins, or to galcanezumab or its excipients.\nCurrent use or prior exposure to galcanezumab, another CGRP antibody, or CGRP receptor antibody, including those who have previously completed or withdrawn from this study or any other study investigating a CGRP antibody.\nHistory of IHS ICHD-3 diagnosis of new daily persistent headache, cluster headache or migraine subtypes including hemiplegic (sporadic or familial) migraine and migraine with brainstem aura (previously basilar-type migraine).\nHistory of significant head or neck injury within 6 months prior to screening; or traumatic head injury at any time that is associated with significant change in the quality or frequency of their headaches, including new onset of migraine following traumatic head injury.\nParticipants with a known history of intracranial tumors or developmental malformations including Chiari malformations.", "metadata": {"brief_title": "A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine", "phase": ["PHASE3"], "drugs_list": ["Galcanezumab", "Placebo"], "diseases_list": ["Episodic Migraine"], "enrollment": 325, "inclusion_criteria": "inclusion criteria: \n\n Have a diagnosis of migraine with or without aura as defined by the IHS ICHD-3 guidelines (1.1 or 1.2 according to ICHD-3 \\[2018\\]), with a history of migraine headaches of at least 6 months prior to screening.", "exclusion_criteria": "exclusion criteria: \n\nParticipants who are taking, or are expected to take, therapeutic antibodies during the course of the study (adalimumab, infliximab, trastuzumab, bevacizumab, etc.). Prior use of therapeutic antibodies is allowed if that use was more than 12 months prior to baseline.\nKnown hypersensitivity to monoclonal antibodies or other therapeutic proteins, or to galcanezumab or its excipients.\nCurrent use or prior exposure to galcanezumab, another CGRP antibody, or CGRP receptor antibody, including those who have previously completed or withdrawn from this study or any other study investigating a CGRP antibody.\nHistory of IHS ICHD-3 diagnosis of new daily persistent headache, cluster headache or migraine subtypes including hemiplegic (sporadic or familial) migraine and migraine with brainstem aura (previously basilar-type migraine).\nHistory of significant head or neck injury within 6 months prior to screening; or traumatic head injury at any time that is associated with significant change in the quality or frequency of their headaches, including new onset of migraine following traumatic head injury.\nParticipants with a known history of intracranial tumors or developmental malformations including Chiari malformations.", "brief_summary": "The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatment of episodic migraine. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.", "keywords": ["pediatric", "children", "prevention", "prophylaxis", "headache", "pediatric migraine"]}}
{"_id": "NCT06739122", "title": "A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)", "text": "Summary: The main purpose of this study is to evaluate additional dosing options for dulaglutide in pediatric participants with Type 2 Diabetes. Participation in this study will last about 8 months.\n\nInclusion criteria: inclusion criteria: \n\n Have Type 2 diabetes treated with diet and exercise and metformin and/or basal insulin. Metformin and/or basal insulin dose must be stable for at least 8 weeks prior to screening.\n Have a body weight \u226550 kilograms (kg) and Body Mass Index (BMI) of \\>85th percentile\n\nExclusion criteria: exclusion criteria: \n\nHave Type 1 diabetes\nHave received treatment with any glucose-lowering agent(s) other than metformin or basal insulin within 8 weeks prior to screening\nAfter the Type 2 diabetes diagnosis, have a history of diabetic ketoacidosis or hyperosmolar syndrome\nHave had \u22651 episode of severe hypoglycemia and/or \u22651 episode of hypoglycemic unawareness within the last 6 months\nHave family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2)\nHave prior chronic, recurrent, or idiopathic pancreatitis, or known gallbladder disease\nHave been treated with prescription drugs or over-the-counter medications that promote weight loss within 8 weeks prior to screening", "metadata": {"brief_title": "A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)", "phase": ["PHASE3"], "drugs_list": ["Dulaglutide"], "diseases_list": ["Type 2 Diabetes"], "enrollment": 55, "inclusion_criteria": "inclusion criteria: \n\n Have Type 2 diabetes treated with diet and exercise and metformin and/or basal insulin. Metformin and/or basal insulin dose must be stable for at least 8 weeks prior to screening.\n Have a body weight \u226550 kilograms (kg) and Body Mass Index (BMI) of \\>85th percentile", "exclusion_criteria": "exclusion criteria: \n\nHave Type 1 diabetes\nHave received treatment with any glucose-lowering agent(s) other than metformin or basal insulin within 8 weeks prior to screening\nAfter the Type 2 diabetes diagnosis, have a history of diabetic ketoacidosis or hyperosmolar syndrome\nHave had \u22651 episode of severe hypoglycemia and/or \u22651 episode of hypoglycemic unawareness within the last 6 months\nHave family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2)\nHave prior chronic, recurrent, or idiopathic pancreatitis, or known gallbladder disease\nHave been treated with prescription drugs or over-the-counter medications that promote weight loss within 8 weeks prior to screening", "brief_summary": "The main purpose of this study is to evaluate additional dosing options for dulaglutide in pediatric participants with Type 2 Diabetes. Participation in this study will last about 8 months.", "keywords": []}}
{"_id": "NCT06297590", "title": "A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease", "text": "Summary: The main purpose of this study is to evaluate the safety of LY3954068 in participants with early symptomatic Alzheimer's Disease (AD). The study will also investigate how much LY3954068 gets into the bloodstream and will test the effects of LY3954068 on markers of AD.\n\nThe study will be comprised of two parts, A and B. Part B is optional, and participants from Part A may also have the opportunity to join an optional bridging period to a separate potential study where participants would receive LY3954068. Each enrolled participant in Part A will receive a single dose of LY3954068 or placebo (no active drug) given into the spinal fluid. If conducted, each participant in Part B would receive 2 doses of either LY3954068 or placebo administered into the spinal fluid.\n\nThe study will last up to approximately 45 weeks for Part A, and, if conducted, 73 weeks for Part B, including the screening period.\n\nIf the optional bridging period is conducted, participants in Part A could be enrolled in the separate potential study for up to approximately 96 weeks, including the screening period.\n\nInclusion criteria: inclusion criteria: \n\n Have a body mass index (BMI) within the range 18 (17 for Japan participants) to 40 kilograms per square meter (kg/m\u00b2), inclusive, at screening.\n Have gradual and progressive change in memory function for greater than or equal to (\u2265) 6 months as reported by the participant or informant.\n Have a mini mental state examination (MMSE) score of 18 to 30 at screening.\n Have a clinical dementia rating (CDR) global score of 0.5 to 1.0, with a memory box score \u2265 0.5 at screening.\n Meet flortaucipir F18 positron emission tomography (PET) criteria, as defined in the TAUVID\u2122 FDA label (TAUVID\u2122 prescribing information, 2024), demonstrating evidence of tau pathology.\n Males who agree to follow contraceptive requirements, or women not of childbearing potential (WNOCBP).\n Participants must have up to 2 study partners who are with contact with the participant at least 10 hours per week and one of whom can attend study appointments.\n\nExclusion criteria: exclusion criteria: \n\nHas current serious or unstable illnesses including cardiovascular, hepatic, renal, gastroenterological, respiratory, endocrinologic, neurologic (other than Alzheimer's Disease), psychiatric, immunologic, or hematologic disease and other conditions that, in the investigator's opinion, could interfere with the analyses in this study; or has a life expectancy of less than (\\<)24 months.\nHave a sensitivity to flortaucipir F18.\nHave contraindication to magnetic resonance imaging (MRI), including claustrophobia or the presence of contraindicated metal (ferromagnetic) implants/cardiac pacemaker.\nHave a current exposure to an amyloid targeted therapy (ATT). Prior exposure to ATTs greater than 1 year from the last dose may be permitted at the discretion of the investigator and in consultation with the sponsor.\nHave previous exposure to any Investigational Medicinal Product administered intrathecal (IT) or previous exposure to any anti-tau therapy.\nHave a history of clinically significant back pain, back pathology and/or back injury (for example, degenerative disease, spinal deformity or spinal surgery) that may predispose to complications or technical difficulty with lumbar puncture.", "metadata": {"brief_title": "A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease", "phase": ["PHASE1"], "drugs_list": ["LY3954068", "Placebo", "Flortaucipir F18"], "diseases_list": ["Alzheimer Disease"], "enrollment": 32, "inclusion_criteria": "inclusion criteria: \n\n Have a body mass index (BMI) within the range 18 (17 for Japan participants) to 40 kilograms per square meter (kg/m\u00b2), inclusive, at screening.\n Have gradual and progressive change in memory function for greater than or equal to (\u2265) 6 months as reported by the participant or informant.\n Have a mini mental state examination (MMSE) score of 18 to 30 at screening.\n Have a clinical dementia rating (CDR) global score of 0.5 to 1.0, with a memory box score \u2265 0.5 at screening.\n Meet flortaucipir F18 positron emission tomography (PET) criteria, as defined in the TAUVID\u2122 FDA label (TAUVID\u2122 prescribing information, 2024), demonstrating evidence of tau pathology.\n Males who agree to follow contraceptive requirements, or women not of childbearing potential (WNOCBP).\n Participants must have up to 2 study partners who are with contact with the participant at least 10 hours per week and one of whom can attend study appointments.", "exclusion_criteria": "exclusion criteria: \n\nHas current serious or unstable illnesses including cardiovascular, hepatic, renal, gastroenterological, respiratory, endocrinologic, neurologic (other than Alzheimer's Disease), psychiatric, immunologic, or hematologic disease and other conditions that, in the investigator's opinion, could interfere with the analyses in this study; or has a life expectancy of less than (\\<)24 months.\nHave a sensitivity to flortaucipir F18.\nHave contraindication to magnetic resonance imaging (MRI), including claustrophobia or the presence of contraindicated metal (ferromagnetic) implants/cardiac pacemaker.\nHave a current exposure to an amyloid targeted therapy (ATT). Prior exposure to ATTs greater than 1 year from the last dose may be permitted at the discretion of the investigator and in consultation with the sponsor.\nHave previous exposure to any Investigational Medicinal Product administered intrathecal (IT) or previous exposure to any anti-tau therapy.\nHave a history of clinically significant back pain, back pathology and/or back injury (for example, degenerative disease, spinal deformity or spinal surgery) that may predispose to complications or technical difficulty with lumbar puncture.", "brief_summary": "The main purpose of this study is to evaluate the safety of LY3954068 in participants with early symptomatic Alzheimer's Disease (AD). The study will also investigate how much LY3954068 gets into the bloodstream and will test the effects of LY3954068 on markers of AD.\n\nThe study will be comprised of two parts, A and B. Part B is optional, and participants from Part A may also have the opportunity to join an optional bridging period to a separate potential study where participants would receive LY3954068. Each enrolled participant in Part A will receive a single dose of LY3954068 or placebo (no active drug) given into the spinal fluid. If conducted, each participant in Part B would receive 2 doses of either LY3954068 or placebo administered into the spinal fluid.\n\nThe study will last up to approximately 45 weeks for Part A, and, if conducted, 73 weeks for Part B, including the screening period.\n\nIf the optional bridging period is conducted, participants in Part A could be enrolled in the separate potential study for up to approximately 96 weeks, including the screening period.", "keywords": ["Dementia", "Brain Diseases", "Central Nervous System Diseases", "Nervous System Diseases", "Tauopathies", "Tau", "Neurodegenerative Diseases", "Neurocognitive Disorders", "Mental Disorders", "Mild Cognitive Impairment"]}}
{"_id": "NCT06280703", "title": "A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)", "text": "Summary: The main purpose of this study is to look at the amount of the study drug LY3938577 that gets into the blood stream and how long it takes the body to get rid of it. At a later stage of this study (part B and C) the blood sugar lowering effect and the duration of action of LY3938577 will be evaluated compared to Insulin Degludec.\n\nThe study will also evaluate the safety and tolerability of LY3938577 and information about any side effects experienced will be collected.\n\nThe study will be conducted in three parts (A, B, and C). Healthy participants in Part A Period 1 will receive a single dose of LY3938577 or a placebo given via intravenous (IV) infusion. In Part A Period 2, participants will receive a single subcutaneous (SC) dose of either LY3938577 or placebo. Participants in Part B with Type 1 Diabetes Mellitus (T1DM) will receive single doses of either LY3938577 or Insulin Degludec given via IV infusion. Participants in Part C with Type 1 Diabetes Mellitus (T1DM) will receive two doses of either LY3938577 or Insulin Degludec administered SC.\n\nThe study will last up to approximately 11 weeks for Part A, 10 weeks for Part B, and 13 weeks for Part C including screening period.\n\nInclusion criteria: inclusion criteria: \n\nPart A -\n\n\u2022 Participants who are overtly healthy as determined by medical history and physical examination.\n\nParts B and C -\n\n Have Type 1 Diabetes Mellitus (T1DM) for at least 2 years with a fasting C-peptide level of 0.20 Nanomoles Per Liter (nmol/L) or less, or nonfasting C-peptide level of 0.30 nmol/L or less at screening.\n Have well-controlled HbA1c between 6.0% to 8.5 percent (%).\n Insulin pump users with a total daily basal dose between 15 to 45 International Unit (IU).\n\nAll Parts -\n\n Have normal blood pressure, pulse rate and safety laboratory test results that are acceptable for the study.\n Have body mass index (BMI) between 18.0 and 35.0 kilograms per meter squared (kg/m\u00b2), inclusive, at screening.\n Have venous access sufficient to allow for blood sampling.\n Male and/or female not of childbearing potential.\n\nExclusion criteria: exclusion criteria: \n\nParts B and C -\n\nHave had more than 1 emergency room visit or hospitalization due to poor glucose control (hyperglycemia or diabetic ketoacidosis) within the last 6 months prior to screening.\nHave had any episodes of severe hypoglycemia (defined as requiring assistance due to neurologically disabling hypoglycemia), hypoglycemia unawareness, or both within the last 6 months prior to screening.\nHave been treated with Glucagon-like Peptide-1 Receptor Agonists (GLP1-RA), Dipeptidyl Peptidase 4 (DPP4) inhibitor, Glucose-dependent Insulinotropic Polypeptide (GIP) agonists, Metformin, or Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors within the previous 3 months.\nHave received systemic or inhaled glucocorticoid therapy (excluding topical, intraarticular, and intraocular preparations) for more than 14 consecutive days within 4 weeks before screening.\n\nAll Parts -\n\nHave had any of the following cardiovascular conditions: acute myocardial infarction, New York Heart Association Class III or IV heart failure, or cerebrovascular accident (stroke).\nHave gastroparesis or have undergone gastric bypass (bariatric) surgery or restrictive bariatric surgery (for example, Lap-Band\u00ae) prior to screening.\nHave history of renal transplantation, currently receiving renal dialysis, have serum creatinine level of more than 2.00 milligrams per decilitre (mg/dL) or have an estimated glomerular filtration rate of less than 60.0 milliliters (mL) / minute /1.73 square meters.\nHave acute or chronic hepatitis, or obvious clinical signs or symptoms of any other liver disease except non-alcoholic fatty liver disease (that is, participants with non-alcoholic fatty liver disease are eligible for participation), and/or have elevated liver enzyme measurements, as determined by the local laboratory at screening and as indicated:\n\n  Total bilirubin (TBL) \\>2 \u00d7 the Upper Limit of Normal (ULN) in the absence of Gilbert's syndrome, or\n  Alanine aminotransferase (ALT) /serum glutamic pyruvic transaminase (SGPT) \\>2.5 \u00d7 ULN, or\n  Aspartate aminotransferase (AST) /serum glutamic oxaloacetic transaminase (SGOT) \\>2.5 \u00d7 ULN.", "metadata": {"brief_title": "A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)", "phase": ["PHASE1"], "drugs_list": ["LY3938577", "Placebo", "Insulin Degludec", "Insulin Lispro", "LY3938577", "Placebo", "insulin degludec"], "diseases_list": ["Healthy", "Type 1 Diabetes Mellitus"], "enrollment": 70, "inclusion_criteria": "inclusion criteria: \n\nPart A -\n\n\u2022 Participants who are overtly healthy as determined by medical history and physical examination.\n\nParts B and C -\n\n Have Type 1 Diabetes Mellitus (T1DM) for at least 2 years with a fasting C-peptide level of 0.20 Nanomoles Per Liter (nmol/L) or less, or nonfasting C-peptide level of 0.30 nmol/L or less at screening.\n Have well-controlled HbA1c between 6.0% to 8.5 percent (%).\n Insulin pump users with a total daily basal dose between 15 to 45 International Unit (IU).\n\nAll Parts -\n\n Have normal blood pressure, pulse rate and safety laboratory test results that are acceptable for the study.\n Have body mass index (BMI) between 18.0 and 35.0 kilograms per meter squared (kg/m\u00b2), inclusive, at screening.\n Have venous access sufficient to allow for blood sampling.\n Male and/or female not of childbearing potential.", "exclusion_criteria": "exclusion criteria: \n\nParts B and C -\n\nHave had more than 1 emergency room visit or hospitalization due to poor glucose control (hyperglycemia or diabetic ketoacidosis) within the last 6 months prior to screening.\nHave had any episodes of severe hypoglycemia (defined as requiring assistance due to neurologically disabling hypoglycemia), hypoglycemia unawareness, or both within the last 6 months prior to screening.\nHave been treated with Glucagon-like Peptide-1 Receptor Agonists (GLP1-RA), Dipeptidyl Peptidase 4 (DPP4) inhibitor, Glucose-dependent Insulinotropic Polypeptide (GIP) agonists, Metformin, or Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors within the previous 3 months.\nHave received systemic or inhaled glucocorticoid therapy (excluding topical, intraarticular, and intraocular preparations) for more than 14 consecutive days within 4 weeks before screening.\n\nAll Parts -\n\nHave had any of the following cardiovascular conditions: acute myocardial infarction, New York Heart Association Class III or IV heart failure, or cerebrovascular accident (stroke).\nHave gastroparesis or have undergone gastric bypass (bariatric) surgery or restrictive bariatric surgery (for example, Lap-Band\u00ae) prior to screening.\nHave history of renal transplantation, currently receiving renal dialysis, have serum creatinine level of more than 2.00 milligrams per decilitre (mg/dL) or have an estimated glomerular filtration rate of less than 60.0 milliliters (mL) / minute /1.73 square meters.\nHave acute or chronic hepatitis, or obvious clinical signs or symptoms of any other liver disease except non-alcoholic fatty liver disease (that is, participants with non-alcoholic fatty liver disease are eligible for participation), and/or have elevated liver enzyme measurements, as determined by the local laboratory at screening and as indicated:\n\n  Total bilirubin (TBL) \\>2 \u00d7 the Upper Limit of Normal (ULN) in the absence of Gilbert's syndrome, or\n  Alanine aminotransferase (ALT) /serum glutamic pyruvic transaminase (SGPT) \\>2.5 \u00d7 ULN, or\n  Aspartate aminotransferase (AST) /serum glutamic oxaloacetic transaminase (SGOT) \\>2.5 \u00d7 ULN.", "brief_summary": "The main purpose of this study is to look at the amount of the study drug LY3938577 that gets into the blood stream and how long it takes the body to get rid of it. At a later stage of this study (part B and C) the blood sugar lowering effect and the duration of action of LY3938577 will be evaluated compared to Insulin Degludec.\n\nThe study will also evaluate the safety and tolerability of LY3938577 and information about any side effects experienced will be collected.\n\nThe study will be conducted in three parts (A, B, and C). Healthy participants in Part A Period 1 will receive a single dose of LY3938577 or a placebo given via intravenous (IV) infusion. In Part A Period 2, participants will receive a single subcutaneous (SC) dose of either LY3938577 or placebo. Participants in Part B with Type 1 Diabetes Mellitus (T1DM) will receive single doses of either LY3938577 or Insulin Degludec given via IV infusion. Participants in Part C with Type 1 Diabetes Mellitus (T1DM) will receive two doses of either LY3938577 or Insulin Degludec administered SC.\n\nThe study will last up to approximately 11 weeks for Part A, 10 weeks for Part B, and 13 weeks for Part C including screening period.", "keywords": []}}
{"_id": "NCT06297603", "title": "Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)", "text": "Summary: The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and renal impairment, with inadequate glycemic control on basal insulin alone or a combination of basal insulin with or without metformin and/or sodium-glucose cotransporter-2 (SGLT2) inhibitor. The study will last about 14 months and may include up to 22 visits.\n\nInclusion criteria: inclusion criteria: \n\n Have Type 2 Diabetes (T2D)\n Have HbA1c \u22657.0% (53 millimoles per mole (mmol/mol)) to \u226410.5% (91 mmol/mol)\n Have moderate or severe renal impairment\n Have been on the following stable diabetes treatment during 90 days prior to screening\n\n   basal insulin (\u226520 International Units (IU)/day) with or without\n   metformin and/or SGLT2 inhibitor\n Are of stable weight for at least 90 days prior to screening\n Have a Body Mass Index (BMI) \u226523.0 kilograms per meter squared (kg/m2)\n\nExclusion criteria: exclusion criteria: \n\nHave Type 1 Diabetes (T1D)\nHave a history of ketoacidosis or hyperosmolar state or coma within the last 6 months prior to screening\nHave a history of severe hypoglycemia or hypoglycemia unawareness within the last 6 months prior to screening\nAre currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema\nHave a history of unstable or rapidly progressing renal disease\nHave a prior or planned surgical treatment for obesity\nHave New York Heart Association Functional Classification III or IV congestive heart failure\nHave had acute myocardial infarction, stroke, or were hospitalized for congestive heart failure within 90 days prior to screening\nHave a known clinically significant gastric emptying abnormality\nHave a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years\nHave a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) syndrome Type 2.\nHave any lifetime history of a suicide attempt\nHad chronic or acute pancreatitis\nHave taken prescribed or over-the-counter medication, or alternative remedies, intended to promote body weight reduction within 90 days prior to screening", "metadata": {"brief_title": "Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)", "phase": ["PHASE3"], "drugs_list": ["Retatrutide", "Placebo"], "diseases_list": ["Type 2 Diabetes"], "enrollment": 320, "inclusion_criteria": "inclusion criteria: \n\n Have Type 2 Diabetes (T2D)\n Have HbA1c \u22657.0% (53 millimoles per mole (mmol/mol)) to \u226410.5% (91 mmol/mol)\n Have moderate or severe renal impairment\n Have been on the following stable diabetes treatment during 90 days prior to screening\n\n   basal insulin (\u226520 International Units (IU)/day) with or without\n   metformin and/or SGLT2 inhibitor\n Are of stable weight for at least 90 days prior to screening\n Have a Body Mass Index (BMI) \u226523.0 kilograms per meter squared (kg/m2)", "exclusion_criteria": "exclusion criteria: \n\nHave Type 1 Diabetes (T1D)\nHave a history of ketoacidosis or hyperosmolar state or coma within the last 6 months prior to screening\nHave a history of severe hypoglycemia or hypoglycemia unawareness within the last 6 months prior to screening\nAre currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema\nHave a history of unstable or rapidly progressing renal disease\nHave a prior or planned surgical treatment for obesity\nHave New York Heart Association Functional Classification III or IV congestive heart failure\nHave had acute myocardial infarction, stroke, or were hospitalized for congestive heart failure within 90 days prior to screening\nHave a known clinically significant gastric emptying abnormality\nHave a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years\nHave a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) syndrome Type 2.\nHave any lifetime history of a suicide attempt\nHad chronic or acute pancreatitis\nHave taken prescribed or over-the-counter medication, or alternative remedies, intended to promote body weight reduction within 90 days prior to screening", "brief_summary": "The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and renal impairment, with inadequate glycemic control on basal insulin alone or a combination of basal insulin with or without metformin and/or sodium-glucose cotransporter-2 (SGLT2) inhibitor. The study will last about 14 months and may include up to 22 visits.", "keywords": ["Glucose Metabolism Disorders", "Metabolic Diseases", "Endocrine System Diseases", "Diabetes Mellitus", "Diabetes Mellitus, Type 2", "Kidney Disease", "Renal Insufficiency Chronic"]}}
{"_id": "NCT06598943", "title": "A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis", "text": "Summary: The main purpose of this study is to determine the safety and efficacy of eltrekibart and mirikizumab in adult participants with moderately to severely active ulcerative colitis (UC).\n\nInclusion criteria: inclusion criteria: \n\n Have had an established diagnosis of UC of \u22653 months in duration before baseline.\n Have moderately to severely active UC as assessed by the UC disease activity score.\n Have an inadequate response to, loss of response to, or intolerance to at least one conventional medication (including corticosteroids) or one advanced therapy (including biologics, Janus Kinase (JAK) inhibitors, or sphingosine-1-phosphate (S1P) immunomodulators).\n Are on a stable dose of certain oral UC medications (including corticosteroids).\n Must meet contraception requirements.\n\nExclusion criteria: exclusion criteria: \n\nHave received anti-interleukin (IL)-23p19 or anti-IL-12p40 antibodies in the past.\nHave experienced a thrombotic event within 24 weeks before baseline.\nHave a current diagnosis of Crohn's Disease or certain other inflammatory gastrointestinal diseases.\nHave had certain abdominal surgeries within the past 3 months or are likely to require surgery for UC during the study.\nHave a history of certain adenomas, dysplasia's, or malignancies.", "metadata": {"brief_title": "A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis", "phase": ["PHASE2"], "drugs_list": ["Eltrekibart", "Mirikizumab", "Placebo"], "diseases_list": ["Ulcerative Colitis", "Ulcerative Colitis Chronic"], "enrollment": 140, "inclusion_criteria": "inclusion criteria: \n\n Have had an established diagnosis of UC of \u22653 months in duration before baseline.\n Have moderately to severely active UC as assessed by the UC disease activity score.\n Have an inadequate response to, loss of response to, or intolerance to at least one conventional medication (including corticosteroids) or one advanced therapy (including biologics, Janus Kinase (JAK) inhibitors, or sphingosine-1-phosphate (S1P) immunomodulators).\n Are on a stable dose of certain oral UC medications (including corticosteroids).\n Must meet contraception requirements.", "exclusion_criteria": "exclusion criteria: \n\nHave received anti-interleukin (IL)-23p19 or anti-IL-12p40 antibodies in the past.\nHave experienced a thrombotic event within 24 weeks before baseline.\nHave a current diagnosis of Crohn's Disease or certain other inflammatory gastrointestinal diseases.\nHave had certain abdominal surgeries within the past 3 months or are likely to require surgery for UC during the study.\nHave a history of certain adenomas, dysplasia's, or malignancies.", "brief_summary": "The main purpose of this study is to determine the safety and efficacy of eltrekibart and mirikizumab in adult participants with moderately to severely active ulcerative colitis (UC).", "keywords": ["CXCR1/2 Ligand receptor antagonist", "IL-23 p19 antibody", "Gastrointestinal Diseases", "Inflammatory Bowel Diseases", "Digestive System Diseases", "Colonic Diseases", "Intestinal Diseases", "Colitis", "Colitis, Ulcerative", "Anti-Inflammatory Agents", "Mirikizumab", "Eltrekibart", "Adult", "Moderate to Severe"]}}
{"_id": "NCT06809400", "title": "A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease", "text": "Summary: The purpose of this study is to generate evidence of the safety, tolerability, and pharmacokinetics/pharmacodynamics of IV LY4006896 compared with placebo in healthy participants and participants with Parkinson's disease.\n\nInclusion criteria: inclusion criteria: \n\nPart A Single Ascending Dose (SAD) and B Multiple Ascending Dose (MAD)\n\n Have a body mass index within the range of 18 to 34 kilogram/square meter (kg/m\u00b2) (inclusive).\n For Japanese participants: To qualify as a participant of first-generation Japanese origin, the participant, the participant's biological parents, and all of the participant's biological grandparents must be of exclusive Japanese descent and born in Japan.\n Have venous access sufficient to allow for blood sampling or administration of study intervention for IV administration, or both.\n\nPart A (SAD) Only\n\n Are overtly healthy\n For Chinese participants: To qualify as Chinese for this study, all 4 of the participant's biological grandparents must be exclusive Chinese descent and born in China.\n\nPart B (MAD) Only\n\n Diagnosis of Parkinson's disease per United Kingdom (UK) Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria.\n If presently untreated for Parkinson's disease, clinical status is not expected to require changes in symptomatic treatment within 52 weeks from baseline.\n If presently being treated for Parkinson's disease, receiving a stable dose of symptomatic dopaminergic therapy, including monoamine oxidase-B inhibitor, levodopa/carbidopa or dopamine agonist for at least 90 days prior to baseline and not expected to change within 52 weeks.\n Have a Montreal Cognitive Assessment (MoCA) score of greater than or equal to (\u2265) 26.\n\nExclusion criteria: exclusion criteria: \n\nPart A (SAD) and B (MAD)\n\nHave significant neurological disease affecting the central nervous system (CNS) (other than Parkinson's disease in Part B cohorts) that may affect the participant's ability to complete the study.\nHave a history or presence of serious or unstable illnesses or conditions that, in the investigator's opinion, could interfere with the analyses in this study, or increase risk for study intervention administration, or result in a participant's life expectancy of less than 24 months.\nHave known allergies to LY4006896, related compounds, or any components of the formulation, or history of allergic reactions to any transferrin receptor antibodies.\nHave significant allergies to humanize monoclonal antibodies.\nHave clinically significant multiple or severe drug allergies (including, but not limited to, erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, or exfoliative dermatitis); or intolerance to topical corticosteroids, or severe posttreatment hypersensitivity reactions.\nHave history or presence of uncontrolled asthma, significant autoimmune disease, hereditary angioedema, or known history of common variable immune deficiency.\nEvidence of clinically significant anemia.\n\nPart A (SAD) Only\n\nHave an abnormal blood pressure or pulse rate, or both, as determined by the investigator, or a preexisting history of hypertension.\n\nPart B (MAD) Only\n\nHave an abnormal blood pressure or pulse rate, or both, as determined by the investigator, or have uncontrolled hypertension, defined as a systolic blood pressure \\>150 mm Hg or a diastolic blood pressure \\>95 mm Hg at Screening or Treatment Visits.", "metadata": {"brief_title": "A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease", "phase": ["PHASE1"], "drugs_list": ["LY4006896", "Placebo"], "diseases_list": ["Parkinson Disease"], "enrollment": 127, "inclusion_criteria": "inclusion criteria: \n\nPart A Single Ascending Dose (SAD) and B Multiple Ascending Dose (MAD)\n\n Have a body mass index within the range of 18 to 34 kilogram/square meter (kg/m\u00b2) (inclusive).\n For Japanese participants: To qualify as a participant of first-generation Japanese origin, the participant, the participant's biological parents, and all of the participant's biological grandparents must be of exclusive Japanese descent and born in Japan.\n Have venous access sufficient to allow for blood sampling or administration of study intervention for IV administration, or both.\n\nPart A (SAD) Only\n\n Are overtly healthy\n For Chinese participants: To qualify as Chinese for this study, all 4 of the participant's biological grandparents must be exclusive Chinese descent and born in China.\n\nPart B (MAD) Only\n\n Diagnosis of Parkinson's disease per United Kingdom (UK) Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria.\n If presently untreated for Parkinson's disease, clinical status is not expected to require changes in symptomatic treatment within 52 weeks from baseline.\n If presently being treated for Parkinson's disease, receiving a stable dose of symptomatic dopaminergic therapy, including monoamine oxidase-B inhibitor, levodopa/carbidopa or dopamine agonist for at least 90 days prior to baseline and not expected to change within 52 weeks.\n Have a Montreal Cognitive Assessment (MoCA) score of greater than or equal to (\u2265) 26.", "exclusion_criteria": "exclusion criteria: \n\nPart A (SAD) and B (MAD)\n\nHave significant neurological disease affecting the central nervous system (CNS) (other than Parkinson's disease in Part B cohorts) that may affect the participant's ability to complete the study.\nHave a history or presence of serious or unstable illnesses or conditions that, in the investigator's opinion, could interfere with the analyses in this study, or increase risk for study intervention administration, or result in a participant's life expectancy of less than 24 months.\nHave known allergies to LY4006896, related compounds, or any components of the formulation, or history of allergic reactions to any transferrin receptor antibodies.\nHave significant allergies to humanize monoclonal antibodies.\nHave clinically significant multiple or severe drug allergies (including, but not limited to, erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, or exfoliative dermatitis); or intolerance to topical corticosteroids, or severe posttreatment hypersensitivity reactions.\nHave history or presence of uncontrolled asthma, significant autoimmune disease, hereditary angioedema, or known history of common variable immune deficiency.\nEvidence of clinically significant anemia.\n\nPart A (SAD) Only\n\nHave an abnormal blood pressure or pulse rate, or both, as determined by the investigator, or a preexisting history of hypertension.\n\nPart B (MAD) Only\n\nHave an abnormal blood pressure or pulse rate, or both, as determined by the investigator, or have uncontrolled hypertension, defined as a systolic blood pressure \\>150 mm Hg or a diastolic blood pressure \\>95 mm Hg at Screening or Treatment Visits.", "brief_summary": "The purpose of this study is to generate evidence of the safety, tolerability, and pharmacokinetics/pharmacodynamics of IV LY4006896 compared with placebo in healthy participants and participants with Parkinson's disease.", "keywords": []}}
{"_id": "NCT05559359", "title": "A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis", "text": "Summary: The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to \\<18 years of age with moderate-to-severe atopic dermatitis (AD).\n\nInclusion criteria: inclusion criteria: \n\n Have a diagnosis of AD prior to screening as stated in the criteria by the American Academy of Dermatology for at least,\n\n   12 months if participants are \u22656 years of age\n   6 months if participants are 2 to \\<6 years of age\n   3 months if participants are 6 months to \\<2 years of age.\n Have an EASI score \u226516 at the screening and baseline\n Have an IGA score \u22653 (scale of 0 to 4) at the screening and baseline\n Have \u226510% BSA of AD involvement at the screening and baseline.\n\nExclusion criteria: exclusion criteria: \n\nAre currently enrolled or have participated within the last 8 weeks in a clinical study involving an investigational intervention or any other type of medical research judged not to be scientifically or medically compatible with this study.\nTreatment with the following prior to the baseline:\nAn investigational drug within 8 weeks or less than 5 half-lives, whichever is longer.\nDupilumab within 8 weeks. Note: The enrollment of participants with prior use of Dupilumab will be limited to \\<20%.\nTreatment with a topical investigational drug within 2 weeks prior to the baseline.\nHave received a Bacillus Calmette-Guerin vaccination or treatment within less than 4 weeks before randomization.", "metadata": {"brief_title": "A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis", "phase": ["PHASE3"], "drugs_list": ["Lebrikizumab", "Placebo", "Topical Corticosteroid (TCS)"], "diseases_list": ["Atopic Dermatitis", "Eczema"], "enrollment": 360, "inclusion_criteria": "inclusion criteria: \n\n Have a diagnosis of AD prior to screening as stated in the criteria by the American Academy of Dermatology for at least,\n\n   12 months if participants are \u22656 years of age\n   6 months if participants are 2 to \\<6 years of age\n   3 months if participants are 6 months to \\<2 years of age.\n Have an EASI score \u226516 at the screening and baseline\n Have an IGA score \u22653 (scale of 0 to 4) at the screening and baseline\n Have \u226510% BSA of AD involvement at the screening and baseline.", "exclusion_criteria": "exclusion criteria: \n\nAre currently enrolled or have participated within the last 8 weeks in a clinical study involving an investigational intervention or any other type of medical research judged not to be scientifically or medically compatible with this study.\nTreatment with the following prior to the baseline:\nAn investigational drug within 8 weeks or less than 5 half-lives, whichever is longer.\nDupilumab within 8 weeks. Note: The enrollment of participants with prior use of Dupilumab will be limited to \\<20%.\nTreatment with a topical investigational drug within 2 weeks prior to the baseline.\nHave received a Bacillus Calmette-Guerin vaccination or treatment within less than 4 weeks before randomization.", "brief_summary": "The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to \\<18 years of age with moderate-to-severe atopic dermatitis (AD).", "keywords": []}}
{"_id": "NCT06857942", "title": "A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)", "text": "Summary: The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe plaque PsO and obesity or overweight with at least 1 weight-related comorbidity.\n\nThe study will last up to 12 months.\n\nInclusion criteria: inclusion criteria: \n\n Have a diagnosis of moderate-to-severe plaque PsO, as defined by a dermatologist or other experienced clinician treated PsO (for example, allergologist, nurse practitioner or physician assistant)\n Have body mass index (BMI) of 30 kilograms per meter squared (kg/m\u00b2) or greater (obesity) or 27 kg/m\u00b2 to \\<30 kg/m\u00b2 (overweight) in the presence of at least 1 weight-related comorbid condition (hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular diseases).\n Must have initiated treatment with ixekizumab for approximately 3 months (\u00b1 1 month) prior to decision to add tirzepatide.\n Must be able to initiate tirzepatide (Day 0) within 30 days of treatment decision (baseline/screening).\n\nExclusion criteria: exclusion criteria: \n\nHave currently received ixekizumab for more than 4 months or less than 2 months.\nHave had any exposure to tirzepatide or other glucagon-like peptide-1 receptor agonist (GLP-1 RAs), for example, dulaglutide, liraglutide, or semaglutide.\nAre currently enrolled in any other clinical study.\n\nOther exclusions\n\nHave a known hypersensitivity to tirzepatide or to any of its component.\nHave a personal or family history of medullary thyroid cancer.\nHave multiple endocrine neoplasia type 2.\nHave type I diabetes mellitus.\nHave a history of chronic or acute pancreatitis at any time before screening (Visit 1).\nHave a history of proliferative diabetic retinopathy, diabetic maculopathy, or nonproliferative diabetic retinopathy that requires acute treatment.\nHave a history of ketoacidosis or hyperosmolar state/coma.\nHave a history of severe hypoglycemia and hypoglycemia unawareness within the 6 months before screening.\nHave a history of severe gastrointestinal complications, including gastroparesis, gastroesophageal reflux disease, dyspepsia, chronic nausea/constipation/vomiting.", "metadata": {"brief_title": "A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)", "phase": ["PHASE4"], "drugs_list": ["Tirzepatide"], "diseases_list": ["Psoriasis", "Overweight or Obesity"], "enrollment": 200, "inclusion_criteria": "inclusion criteria: \n\n Have a diagnosis of moderate-to-severe plaque PsO, as defined by a dermatologist or other experienced clinician treated PsO (for example, allergologist, nurse practitioner or physician assistant)\n Have body mass index (BMI) of 30 kilograms per meter squared (kg/m\u00b2) or greater (obesity) or 27 kg/m\u00b2 to \\<30 kg/m\u00b2 (overweight) in the presence of at least 1 weight-related comorbid condition (hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular diseases).\n Must have initiated treatment with ixekizumab for approximately 3 months (\u00b1 1 month) prior to decision to add tirzepatide.\n Must be able to initiate tirzepatide (Day 0) within 30 days of treatment decision (baseline/screening).", "exclusion_criteria": "exclusion criteria: \n\nHave currently received ixekizumab for more than 4 months or less than 2 months.\nHave had any exposure to tirzepatide or other glucagon-like peptide-1 receptor agonist (GLP-1 RAs), for example, dulaglutide, liraglutide, or semaglutide.\nAre currently enrolled in any other clinical study.\n\nOther exclusions\n\nHave a known hypersensitivity to tirzepatide or to any of its component.\nHave a personal or family history of medullary thyroid cancer.\nHave multiple endocrine neoplasia type 2.\nHave type I diabetes mellitus.\nHave a history of chronic or acute pancreatitis at any time before screening (Visit 1).\nHave a history of proliferative diabetic retinopathy, diabetic maculopathy, or nonproliferative diabetic retinopathy that requires acute treatment.\nHave a history of ketoacidosis or hyperosmolar state/coma.\nHave a history of severe hypoglycemia and hypoglycemia unawareness within the 6 months before screening.\nHave a history of severe gastrointestinal complications, including gastroparesis, gastroesophageal reflux disease, dyspepsia, chronic nausea/constipation/vomiting.", "brief_summary": "The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe plaque PsO and obesity or overweight with at least 1 weight-related comorbidity.\n\nThe study will last up to 12 months.", "keywords": []}}
{"_id": "NCT06568042", "title": "Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy", "text": "Summary: The purpose of this study is to evaluate how safe and how well a treatment works compared to placebo for people with nerve pain that begins in their feet and moves up the leg to just below the knee.\n\nParticipation may last up to 30 weeks including screening.\n\nInclusion criteria: inclusion criteria: \n\n Have a Visual Analog Scale (VAS) pain value \u226540 and \\<95 at screening.\n Presence of painful distal sensory polyneuropathy (DSP) without prominent motor or autonomic features with gradual or insidious onset with a minimum duration of 6 months and a known cause of nerve injury, such as metabolic, toxic exposure, nutritional, immunologic, infectious, hereditary, multifactorial, or no known cause identified (idiopathic), of symmetrical nature and in lower extremities (with or without involvement of the hands).\n Are willing to maintain a consistent regimen of any ongoing nonpharmacologic pain- relieving therapies and/or nutritional supplements and will not start any new nonpharmacologic pain-relieving therapies and/or nutritional supplements during study participation.\n Are willing to discontinue all medications taken for chronic pain conditions, except the allowed pain medications.\n Individuals NOT of childbearing potential may participate in the trial. Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n\nExclusion criteria: exclusion criteria: \n\nOther etiologies of pain that may not be due to DSP or confound the assessment due to painful DSP.\nHave had a procedure within the past 6 months intended to produce permanent sensory loss in the target area of interest.\nHave not achieved glycemic control on a stable diabetes treatment regimen for at least 90 days prior to screening, have a healthcare provider who manages the participants' diabetes, and have a hemoglobin A1c (HbA1c) \\>11% at screening.\nCancer within 2 years of baseline, except for:\n\n  cutaneous basal cell or squamous cell carcinoma resolved by excision, or\n  cancer treatment which led to chemotherapy that caused distal sensory polyneuropathy.\nAre, in the judgment of the investigator, actively suicidal and therefore deemed to be at significant risk for suicide.\nHave a surgery planned during the study for any reason.\nHistory of chronic alcohol, illicit drug, or narcotic use disorder within 2 years prior to screening.", "metadata": {"brief_title": "Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy", "phase": ["PHASE2"], "drugs_list": ["LY3848575", "Placebo"], "diseases_list": ["Neuropathic Pain", "Distal Sensory Polyneuropathy"], "enrollment": 450, "inclusion_criteria": "inclusion criteria: \n\n Have a Visual Analog Scale (VAS) pain value \u226540 and \\<95 at screening.\n Presence of painful distal sensory polyneuropathy (DSP) without prominent motor or autonomic features with gradual or insidious onset with a minimum duration of 6 months and a known cause of nerve injury, such as metabolic, toxic exposure, nutritional, immunologic, infectious, hereditary, multifactorial, or no known cause identified (idiopathic), of symmetrical nature and in lower extremities (with or without involvement of the hands).\n Are willing to maintain a consistent regimen of any ongoing nonpharmacologic pain- relieving therapies and/or nutritional supplements and will not start any new nonpharmacologic pain-relieving therapies and/or nutritional supplements during study participation.\n Are willing to discontinue all medications taken for chronic pain conditions, except the allowed pain medications.\n Individuals NOT of childbearing potential may participate in the trial. Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.", "exclusion_criteria": "exclusion criteria: \n\nOther etiologies of pain that may not be due to DSP or confound the assessment due to painful DSP.\nHave had a procedure within the past 6 months intended to produce permanent sensory loss in the target area of interest.\nHave not achieved glycemic control on a stable diabetes treatment regimen for at least 90 days prior to screening, have a healthcare provider who manages the participants' diabetes, and have a hemoglobin A1c (HbA1c) \\>11% at screening.\nCancer within 2 years of baseline, except for:\n\n  cutaneous basal cell or squamous cell carcinoma resolved by excision, or\n  cancer treatment which led to chemotherapy that caused distal sensory polyneuropathy.\nAre, in the judgment of the investigator, actively suicidal and therefore deemed to be at significant risk for suicide.\nHave a surgery planned during the study for any reason.\nHistory of chronic alcohol, illicit drug, or narcotic use disorder within 2 years prior to screening.", "brief_summary": "The purpose of this study is to evaluate how safe and how well a treatment works compared to placebo for people with nerve pain that begins in their feet and moves up the leg to just below the knee.\n\nParticipation may last up to 30 weeks including screening.", "keywords": ["Peripheral Neuropathy", "Diabetic Peripheral Neuropathy", "Chemotherapy Induced Peripheral Neuropathy", "HIV Induced Peripheral Neuropathy"]}}
{"_id": "NCT06566170", "title": "A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease", "text": "Summary: The main purpose of this study is to evaluate the long-term effectiveness of donanemab plus usual care versus usual care alone in participants with early symptomatic AD. The study will employ a prospective, observational cohort design with participant management resembling real-world practice to the greatest extent possible via prospective assessments and linkage to historical and prospective electronic health records. The study will last about 273 weeks and may include up to 28 visits.\n\nInclusion criteria: inclusion criteria: \n\nParticipants\n\n are under care for presumed mild cognitive impairment (MCI) or mild dementia stage of AD (Note: neither a biomarker-based diagnosis of AD nor a diagnosis in electronic health records \\[EHR\\] is required prior to screening)\n have a Telephone Interview for Cognitive Status (TICS) score of \u226521\n presence of amyloid beta (A\u03b2) pathology supported by biomarker results (e.g., P-tau, amyloid positron emission tomography (PET), and/or cerebrospinal fluid \\[CSF\\]). (Note: A historical biomarker may be used for eligibility if performed within 12 months of study entry)\n have a reliable study partner who is in frequent contact with the participant and will be available by telephone at designated times (every 6 months), and\n have EHR data available for linkage and are willing to allow access to EHR data for the duration of the study.\n\nExclusion criteria: exclusion criteria: \n\nhave prior ischemic or hemorrhagic stroke(s) with an inability to independently perform any one or more basic activities of daily living (ADLs) (i.e., walking, transferring, eating, bathing, dressing, or toileting). (Note: mixed dementias with amyloid pathology are permitted)\nhave current or recent serious or unstable illness (other than AD) that, in the investigator's opinion, could interfere with the ability of the participant or study partner to complete the study (e.g., life expectancy of less than 36 months, requirement for long-term (\\>12 months) institutional-level care, serious psychiatric illness, etc.)\nare currently enrolled or intend to enroll in a clinical trial of another investigational product, and\nhave contraindications to donanemab, magnetic resonance imaging (MRI), or amyloid PET tracers. (Donanemab group only).", "metadata": {"brief_title": "A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease", "phase": {}, "drugs_list": ["Donanemab", "Usual Care"], "diseases_list": ["Alzheimer Disease"], "enrollment": 3060, "inclusion_criteria": "inclusion criteria: \n\nParticipants\n\n are under care for presumed mild cognitive impairment (MCI) or mild dementia stage of AD (Note: neither a biomarker-based diagnosis of AD nor a diagnosis in electronic health records \\[EHR\\] is required prior to screening)\n have a Telephone Interview for Cognitive Status (TICS) score of \u226521\n presence of amyloid beta (A\u03b2) pathology supported by biomarker results (e.g., P-tau, amyloid positron emission tomography (PET), and/or cerebrospinal fluid \\[CSF\\]). (Note: A historical biomarker may be used for eligibility if performed within 12 months of study entry)\n have a reliable study partner who is in frequent contact with the participant and will be available by telephone at designated times (every 6 months), and\n have EHR data available for linkage and are willing to allow access to EHR data for the duration of the study.", "exclusion_criteria": "exclusion criteria: \n\nhave prior ischemic or hemorrhagic stroke(s) with an inability to independently perform any one or more basic activities of daily living (ADLs) (i.e., walking, transferring, eating, bathing, dressing, or toileting). (Note: mixed dementias with amyloid pathology are permitted)\nhave current or recent serious or unstable illness (other than AD) that, in the investigator's opinion, could interfere with the ability of the participant or study partner to complete the study (e.g., life expectancy of less than 36 months, requirement for long-term (\\>12 months) institutional-level care, serious psychiatric illness, etc.)\nare currently enrolled or intend to enroll in a clinical trial of another investigational product, and\nhave contraindications to donanemab, magnetic resonance imaging (MRI), or amyloid PET tracers. (Donanemab group only).", "brief_summary": "The main purpose of this study is to evaluate the long-term effectiveness of donanemab plus usual care versus usual care alone in participants with early symptomatic AD. The study will employ a prospective, observational cohort design with participant management resembling real-world practice to the greatest extent possible via prospective assessments and linkage to historical and prospective electronic health records. The study will last about 273 weeks and may include up to 28 visits.", "keywords": []}}
{"_id": "NCT06037252", "title": "A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity", "text": "Summary: The main purpose of this study is to learn more about the safety and efficacy of investigational tirzepatide doses in participants with Type 2 diabetes and obesity that are already taking metformin. The study will last for about 89 weeks.\n\nInclusion criteria: inclusion criteria: \n\n \n\nExclusion criteria: exclusion criteria: \n\nHave Type 1 Diabetes (T1D), history of ketoacidosis or hyperosmolar state/coma, or any other types of diabetes except T2D.\nHave had 1 or more episode of severe hypoglycemia and/or 1 or more episode of hypoglycemia unawareness within 6 months prior to screening.\nAre currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema.\nHave a prior or planned surgical treatment for obesity.\nUse products intended for weight loss including prescription drugs, over the counter (OTC) drugs, and herbal preparations, within 3 months prior to screening.\nHave renal impairment measured as estimated glomerular filtration rate (eGFR) \\<45 milliliter/min (mL/min)/1.73 m\u00b2.\nHave any of the following cardiovascular (CV) conditions within 2 months prior to screening.\n\n  acute myocardial infarction.\n  cerebrovascular accident (stroke).\n  unstable angina .\n  hospitalization due to congestive heart failure, or\n  coronary artery revascularization.\nHave a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) syndrome Type 2.\nHave a history of chronic or acute pancreatitis.", "metadata": {"brief_title": "A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity", "phase": ["PHASE2"], "drugs_list": ["Tirzepatide", "Placebo"], "diseases_list": ["Type 2 Diabetes", "Obesity"], "enrollment": 350, "inclusion_criteria": "inclusion criteria: \n\n ", "exclusion_criteria": "exclusion criteria: \n\nHave Type 1 Diabetes (T1D), history of ketoacidosis or hyperosmolar state/coma, or any other types of diabetes except T2D.\nHave had 1 or more episode of severe hypoglycemia and/or 1 or more episode of hypoglycemia unawareness within 6 months prior to screening.\nAre currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema.\nHave a prior or planned surgical treatment for obesity.\nUse products intended for weight loss including prescription drugs, over the counter (OTC) drugs, and herbal preparations, within 3 months prior to screening.\nHave renal impairment measured as estimated glomerular filtration rate (eGFR) \\<45 milliliter/min (mL/min)/1.73 m\u00b2.\nHave any of the following cardiovascular (CV) conditions within 2 months prior to screening.\n\n  acute myocardial infarction.\n  cerebrovascular accident (stroke).\n  unstable angina .\n  hospitalization due to congestive heart failure, or\n  coronary artery revascularization.\nHave a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) syndrome Type 2.\nHave a history of chronic or acute pancreatitis.", "brief_summary": "The main purpose of this study is to learn more about the safety and efficacy of investigational tirzepatide doses in participants with Type 2 diabetes and obesity that are already taking metformin. The study will last for about 89 weeks.", "keywords": ["Diabetes Mellitus", "Glucose Metabolism Disorders", "Metabolic Disease", "Endocrine System Diseases", "Overnutrition", "Nutrition Disorders", "Body Weight", "Tirzepatide", "Incretins"]}}
{"_id": "NCT06370715", "title": "A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India", "text": "Summary: The purpose of this study is to assess the safety of insulin lispro-aabc in adult participants with Type 2 diabetes mellitus in India.\n\nThe study will last about 33 weeks for each participant, including screening (1 week), Lead-in period (4 weeks), treatment period (26 weeks) and follow up period (2 weeks).\n\nInclusion criteria: inclusion criteria: \n\n Have Type 2 Diabetes Mellitus (T2DM) for \u22651 year prior to screening\n Treated for \u226590 days prior to screening with multiple daily injection (MDI) therapy\n\n   on basal insulin or insulin glargine 100 U/mL \\[Basaglar or Lantus\\] or insulin glargin 300 U/mL, insulin determir, insulin degludec U-100, or neutral protamine Hagedorn (NPH) insulin) in combination with at least 1 prandial injection of bolus insulin (insulin lispro 100 U/mL or 200 U/mL, insulin aspart, insulin glulisine, regular insulin, fast-acting insulin aspart), or\n   premixed analog or human insulin regimens with any basal and bolus insulin\n May have been treated with up to 3 oral antihyperglycemic medications (OAMs) including metformin, sodium-glucose cotransporter (SGLT)-2 inhibitor in accordance with local regulations. The dose of all OAMs must have been stable for \u226590 days prior to screening\n Have an HbA1c value \u22657.5% and \u226410% according to the central laboratory at screening\n Body mass index \u226445.0 kg/m\u00b2\n Have access to a telephone, or alternative means for close monitoring/communications\n Have refrigeration at home or have ready access to refrigeration for storage of insulin therapy\n Have a regular wake-sleep schedule (awake-work during the day and sleep during the night)\n\nExclusion criteria: exclusion criteria: \n\nHaving any other condition (including known drug or alcohol abuse, psychiatric disorder including eating disorder) that precludes the subject from following and completing the protocol\nHave been diagnosed, at any time, with type 1 diabetes mellitus (T1DM) or latent autoimmune diabetes in adults\nHave hypoglycemia unawareness as judged by the investigator\nHave had any episode of severe hypoglycemia (defined as requiring assistance due to neurologically disabling hypoglycemia) within the 6 months prior to screening\nHave had 1 or more episodes of diabetic ketoacidosis or hyperglycemic hyperosmolar state within the 6 months prior to screening\nHave a known diagnosis of secondary diabetes (for example, diabetes caused by hemochromatosis, acromegaly, chronic pancreatitis, or pancreatectomy)\nExcessive insulin resistance defined as having received a total daily dose of insulin \\>2.0 U/kg at the time of screening\nHave a history of or are being evaluated for bariatric surgery including Roux-en-Y gastric bypass surgery, gastric banding, and/or gastric sleeve\nHave cardiovascular disease, within the past 6 months prior to screening, defined as stroke, decompensated heart failure (New York Heart Association Class III or IV), myocardial infarction, unstable angina pectoris, or coronary arterial bypass graft\nHistory of renal transplantation\nCurrently receiving renal dialysis\nSerum creatinine \\>2.0 mg/dL (177 \u00b5mol/L) at screening\nHave obvious clinical signs or symptoms of liver disease (for example, acute or chronic hepatitis or cirrhosis), or elevated liver enzyme measurements\nHave active or untreated malignancy, have been in remission from clinically significant malignancy (other than basal cell or squamous cell skin cancer) for less than 5 years, or are at an increased risk for developing cancer or a recurrence of cancer in the opinion of the investigator\nHave had a blood transfusion or severe blood loss within 90 days prior to screening or have known hemoglobinopathy, anemia, or any other traits known to interfere with measurement of HbA1\nHave presence of clinically significant gastrointestinal disease (for example, clinically active gastroparesis associated with wide glucose fluctuations) in the investigator's opinion\nHave used thiazolidinediones, glucagon-like peptide 1 receptor agonist, or pramlintide within 90 days prior to screening", "metadata": {"brief_title": "A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India", "phase": ["PHASE4"], "drugs_list": ["Insulin Lispro-aabc", "Insulin Glargine"], "diseases_list": ["Diabetes Mellitus, Type 2"], "enrollment": 112, "inclusion_criteria": "inclusion criteria: \n\n Have Type 2 Diabetes Mellitus (T2DM) for \u22651 year prior to screening\n Treated for \u226590 days prior to screening with multiple daily injection (MDI) therapy\n\n   on basal insulin or insulin glargine 100 U/mL \\[Basaglar or Lantus\\] or insulin glargin 300 U/mL, insulin determir, insulin degludec U-100, or neutral protamine Hagedorn (NPH) insulin) in combination with at least 1 prandial injection of bolus insulin (insulin lispro 100 U/mL or 200 U/mL, insulin aspart, insulin glulisine, regular insulin, fast-acting insulin aspart), or\n   premixed analog or human insulin regimens with any basal and bolus insulin\n May have been treated with up to 3 oral antihyperglycemic medications (OAMs) including metformin, sodium-glucose cotransporter (SGLT)-2 inhibitor in accordance with local regulations. The dose of all OAMs must have been stable for \u226590 days prior to screening\n Have an HbA1c value \u22657.5% and \u226410% according to the central laboratory at screening\n Body mass index \u226445.0 kg/m\u00b2\n Have access to a telephone, or alternative means for close monitoring/communications\n Have refrigeration at home or have ready access to refrigeration for storage of insulin therapy\n Have a regular wake-sleep schedule (awake-work during the day and sleep during the night)", "exclusion_criteria": "exclusion criteria: \n\nHaving any other condition (including known drug or alcohol abuse, psychiatric disorder including eating disorder) that precludes the subject from following and completing the protocol\nHave been diagnosed, at any time, with type 1 diabetes mellitus (T1DM) or latent autoimmune diabetes in adults\nHave hypoglycemia unawareness as judged by the investigator\nHave had any episode of severe hypoglycemia (defined as requiring assistance due to neurologically disabling hypoglycemia) within the 6 months prior to screening\nHave had 1 or more episodes of diabetic ketoacidosis or hyperglycemic hyperosmolar state within the 6 months prior to screening\nHave a known diagnosis of secondary diabetes (for example, diabetes caused by hemochromatosis, acromegaly, chronic pancreatitis, or pancreatectomy)\nExcessive insulin resistance defined as having received a total daily dose of insulin \\>2.0 U/kg at the time of screening\nHave a history of or are being evaluated for bariatric surgery including Roux-en-Y gastric bypass surgery, gastric banding, and/or gastric sleeve\nHave cardiovascular disease, within the past 6 months prior to screening, defined as stroke, decompensated heart failure (New York Heart Association Class III or IV), myocardial infarction, unstable angina pectoris, or coronary arterial bypass graft\nHistory of renal transplantation\nCurrently receiving renal dialysis\nSerum creatinine \\>2.0 mg/dL (177 \u00b5mol/L) at screening\nHave obvious clinical signs or symptoms of liver disease (for example, acute or chronic hepatitis or cirrhosis), or elevated liver enzyme measurements\nHave active or untreated malignancy, have been in remission from clinically significant malignancy (other than basal cell or squamous cell skin cancer) for less than 5 years, or are at an increased risk for developing cancer or a recurrence of cancer in the opinion of the investigator\nHave had a blood transfusion or severe blood loss within 90 days prior to screening or have known hemoglobinopathy, anemia, or any other traits known to interfere with measurement of HbA1\nHave presence of clinically significant gastrointestinal disease (for example, clinically active gastroparesis associated with wide glucose fluctuations) in the investigator's opinion\nHave used thiazolidinediones, glucagon-like peptide 1 receptor agonist, or pramlintide within 90 days prior to screening", "brief_summary": "The purpose of this study is to assess the safety of insulin lispro-aabc in adult participants with Type 2 diabetes mellitus in India.\n\nThe study will last about 33 weeks for each participant, including screening (1 week), Lead-in period (4 weeks), treatment period (26 weeks) and follow up period (2 weeks).", "keywords": ["Diabetes mellitus, type 2 diabetes, Lyumjev, basaglar, Humalog"]}}
{"_id": "NCT06817356", "title": "A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder", "text": "Summary: The objective of this proof-of-concept study to evaluate mazdutide in participants with alcohol use disorder (AUD).\n\nFor any individual participant, the maximum duration of study participation is approximately 36 weeks, including screening and posttreatment follow-up.\n\nInclusion criteria: inclusion criteria: \n\n Current AUD diagnosis as defined by Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria.\n\nExclusion criteria: exclusion criteria: \n\nHave a history of significant active or unstable major depressive disorder, suicidal ideation, or other severe psychiatric disorder within the last 12 months.\nHave initiated psychotherapy, changed the intensity of psychotherapy, or other nondrug therapies (for example, acupuncture or hypnosis) within 8 weeks prior to enrollment.\nHave received any medication for AUD in the last 30 days including but not limited to, disulfiram, acamprosate, naltrexone, gabapentin, baclofen, or topiramate.\nOther protocol-specific inclusion and exclusion criteria may apply.", "metadata": {"brief_title": "A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder", "phase": ["PHASE2"], "drugs_list": ["Mazdutide", "Placebo"], "diseases_list": ["Alcohol Use Disorder"], "enrollment": 300, "inclusion_criteria": "inclusion criteria: \n\n Current AUD diagnosis as defined by Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria.", "exclusion_criteria": "exclusion criteria: \n\nHave a history of significant active or unstable major depressive disorder, suicidal ideation, or other severe psychiatric disorder within the last 12 months.\nHave initiated psychotherapy, changed the intensity of psychotherapy, or other nondrug therapies (for example, acupuncture or hypnosis) within 8 weeks prior to enrollment.\nHave received any medication for AUD in the last 30 days including but not limited to, disulfiram, acamprosate, naltrexone, gabapentin, baclofen, or topiramate.\nOther protocol-specific inclusion and exclusion criteria may apply.", "brief_summary": "The objective of this proof-of-concept study to evaluate mazdutide in participants with alcohol use disorder (AUD).\n\nFor any individual participant, the maximum duration of study participation is approximately 36 weeks, including screening and posttreatment follow-up.", "keywords": []}}
{"_id": "NCT06607185", "title": "A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors", "text": "Summary: The main purpose of the study is to assess whether the study drug, LY4066434, is safe and tolerable when administered to participants with locally advanced or metastatic solid tumors with certain KRAS mutations. LY4066434 will be given alone or in combination with other treatments. The study will have 2 parts: monotherapy dose escalation and dose optimization. The study is expected to last up to approximately 5 years.\n\nInclusion criteria: inclusion criteria: \n\n Have evidence of KRAS G12C, G12D, G12V, G12A, G12S, or G13D mutation in tumor tissue or circulating tumor DNA\n Histological or cytologically proven diagnosis of a locally advanced, unresectable, and/or metastatic solid tumor cancer\n Have measurable disease per RECIST 1.1\n Have an ECOG performance status of \u22641\n Must not be pregnant and/or planning to breastfeed during the trial or within 180 days of the last dose of trial intervention\n Must be able to swallow tablets\n Participants with asymptomatic or treated CNS disease may be eligible\n\nExclusion criteria: exclusion criteria: \n\nHave known active CNS metastases and/or carcinomatous meningitis\nHave any unresolved toxicities from prior therapy greater than NCI CTCAE Version 5.0 Grade 1 at the time of starting trial treatment, except for alopecia, peripheral neuropathy and ongoing endocrinopathies controlled on appropriate replacement therapy\nHave significant cardiovascular disease defined as unstable angina or acute coronary syndrome, history of myocardial infarction, known left ventricular ejection fraction or heart failure, uncontrolled or symptomatic arrhythmias.\nHave known active hepatitis B virus (HBV), hepatitis C virus (HCV) and untreated HIV infection\nHave other active malignancy unless in remission with life expectancy greater than 2 years.\nHave active uncontrolled systemic bacterial, viral, fungal, or parasitic infection\nHave history of non-infectious pneumonitis/interstitial lung disease that received steroids or has current clinically significant pneumonitis/interstitial lung disease", "metadata": {"brief_title": "A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors", "phase": ["PHASE1"], "drugs_list": ["LY4066434.", "Cetuximab", "Nab paclitaxel", "Gemcitabine", "Oxaliplatin", "Leucovorin", "Irinotecan", "5Fluorouracil", "Carboplatin", "Cisplatin", "Pemetrexed", "Pembrolizumab"], "diseases_list": ["Pancreatic Ductal Adenocarcinoma", "Non-small Cell Lung Cancer", "Colorectal Cancer", "Advanced Solid Tumor", "Metastatic Solid Tumor"], "enrollment": 750, "inclusion_criteria": "inclusion criteria: \n\n Have evidence of KRAS G12C, G12D, G12V, G12A, G12S, or G13D mutation in tumor tissue or circulating tumor DNA\n Histological or cytologically proven diagnosis of a locally advanced, unresectable, and/or metastatic solid tumor cancer\n Have measurable disease per RECIST 1.1\n Have an ECOG performance status of \u22641\n Must not be pregnant and/or planning to breastfeed during the trial or within 180 days of the last dose of trial intervention\n Must be able to swallow tablets\n Participants with asymptomatic or treated CNS disease may be eligible", "exclusion_criteria": "exclusion criteria: \n\nHave known active CNS metastases and/or carcinomatous meningitis\nHave any unresolved toxicities from prior therapy greater than NCI CTCAE Version 5.0 Grade 1 at the time of starting trial treatment, except for alopecia, peripheral neuropathy and ongoing endocrinopathies controlled on appropriate replacement therapy\nHave significant cardiovascular disease defined as unstable angina or acute coronary syndrome, history of myocardial infarction, known left ventricular ejection fraction or heart failure, uncontrolled or symptomatic arrhythmias.\nHave known active hepatitis B virus (HBV), hepatitis C virus (HCV) and untreated HIV infection\nHave other active malignancy unless in remission with life expectancy greater than 2 years.\nHave active uncontrolled systemic bacterial, viral, fungal, or parasitic infection\nHave history of non-infectious pneumonitis/interstitial lung disease that received steroids or has current clinically significant pneumonitis/interstitial lung disease", "brief_summary": "The main purpose of the study is to assess whether the study drug, LY4066434, is safe and tolerable when administered to participants with locally advanced or metastatic solid tumors with certain KRAS mutations. LY4066434 will be given alone or in combination with other treatments. The study will have 2 parts: monotherapy dose escalation and dose optimization. The study is expected to last up to approximately 5 years.", "keywords": ["KRAS", "KRAS mutation", "KRASG12C", "KRASG12D", "KRASG12V", "KRASG12S", "KRASG12A", "KRASG13D", "LY4066434", "Targeted therapy", "Lung cancer", "Pancreas cancer", "Colon cancer", "Rectal cancer", "Colorectal cancer", "Ovarian cancer", "Endometrial cancer", "Cholangiocarcinoma", "Esophageal cancer", "KRAS-mutant tumor"]}}
{"_id": "NCT06586515", "title": "MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors", "text": "Summary: The main purpose of this study is to assess safety \\& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.\n\nInclusion criteria: inclusion criteria: \n\n Have Histological or cytologically proven diagnosis of locally advanced, unresectable, and/or metastatic cancer and measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.\n Have evidence of KRAS G12D mutation in tumor tissue or circulating tumor DNA\n Have an ECOG performance status of \u2264 1\n Must have received \u2265 1 prior line of systemic chemotherapy for advanced or metastatic disease\n Participants with asymptomatic or treated CNS disease may be eligible.\n\nExclusion criteria: exclusion criteria: \n\nHave known active CNS metastases and/or carcinomatous meningitis.\nHave any unresolved toxicities from prior therapy greater than National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Grade 1.\nHave significant cardiovascular disease as unstable angina or acute coronary syndrome, history of myocardial infarction, known reduced left ventricular ejection fraction.\nHave active uncontrolled systemic bacterial, viral, fungal, or parasitic infection.\nHave known active hepatitis B virus (HBV) and hepatitis C virus (HCV).\nHave other active malignancy unless in remission with life expectancy greater than (\\>) 2 years.", "metadata": {"brief_title": "MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors", "phase": ["PHASE1"], "drugs_list": ["LY3962673", "Cetuximab", "Gemcitabine", "nab-paclitaxel", "Oxaliplatin", "leucovorin", "Irinotecan", "5-fluorouracil"], "diseases_list": ["Pancreatic Ductal Adenocarcinoma", "Non-small Cell Lung Cancer", "Colorectal Cancer"], "enrollment": 540, "inclusion_criteria": "inclusion criteria: \n\n Have Histological or cytologically proven diagnosis of locally advanced, unresectable, and/or metastatic cancer and measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.\n Have evidence of KRAS G12D mutation in tumor tissue or circulating tumor DNA\n Have an ECOG performance status of \u2264 1\n Must have received \u2265 1 prior line of systemic chemotherapy for advanced or metastatic disease\n Participants with asymptomatic or treated CNS disease may be eligible.", "exclusion_criteria": "exclusion criteria: \n\nHave known active CNS metastases and/or carcinomatous meningitis.\nHave any unresolved toxicities from prior therapy greater than National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Grade 1.\nHave significant cardiovascular disease as unstable angina or acute coronary syndrome, history of myocardial infarction, known reduced left ventricular ejection fraction.\nHave active uncontrolled systemic bacterial, viral, fungal, or parasitic infection.\nHave known active hepatitis B virus (HBV) and hepatitis C virus (HCV).\nHave other active malignancy unless in remission with life expectancy greater than (\\>) 2 years.", "brief_summary": "The main purpose of this study is to assess safety \\& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.", "keywords": ["KRAS G12D", "KRAS", "LY3962673", "Cetuximab", "nab-paclitaxel", "Gemcitabine", "Oxaliplatin", "Leucovorin", "Irinotecan", "5-fluorouracil"]}}
{"_id": "NCT06561685", "title": "A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors", "text": "Summary: The main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants with locally advanced or metastatic solid tumors with a BRG1 (Brahma-related gene 1, also known as SMARCA4) alteration who have previously received, do not qualify for, or are refusing standard of care treatments, or there is no standard therapy available for the disease. The study is conducted in two parts - phase Ia (dose-escalation) and phase Ib (dose-optimization, dose-expansion). The study will last up to approximately 4 years.\n\nInclusion criteria: inclusion criteria: \n\n Have one of the following locally advanced or metastatic solid tumor malignancy with SMARCA4 (BRG1) alteration:\n\n   Phase 1a dose escalation: Presence of any alteration in SMARCA4 (BRG1)\n   Phase 1b expansion: Part A: Non-small Cell Lung Cancer (NSCLC) that is locally advanced and not suitable for definitive locoregional therapy, or metastatic with presence of a known or likely loss of function alteration in SMARCA4 (BRG1) or loss of protein expression.\n   Phase 1b expansion: Part B: Any tumor type (other than NSCLC) that has the presence of a known or likely loss of function alteration in SMARCA4 (BRG1) or loss of protein expression.\n Prior Systemic Therapy Criteria:\n\n   Phase 1a dose escalation and Phase 1b (Part B): Participants who received all standard therapies for which the individual was deemed to be an appropriate candidate by the treating Investigator; or the individual is refusing the remaining most appropriate standard of care treatment; or there is no standard therapy available for the disease.\n   Phase 1b expansion (Part A): Participants must have received at least one line of therapy for advanced or metastatic disease.\n Measurability of disease\n\n   Phase 1a dose escalation (excluding backfill): measurable or non-measurable disease as defined by Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1)\n   Phase 1a backfill and Phase 1b expansion: Measurable disease required as defined by RECIST v1.1\n Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1\n\nExclusion criteria: exclusion criteria: \n\nParticipants with known loss of function alteration of SMARCA2 (BRM) or malignancy with known association with SMARCA2 (BRM) alterations\nPrior exposure to SMARCA2 (BRM) inhibitor(s) and/or degrader(s) (prior exposure may be permitted for dose escalation)\nParticipants with known or suspected history of untreated or uncontrolled central nervous system (CNS) involvement\nParticipants with history of increased risk of prolonged QT or significant arrythmia\nSignificant cardiovascular disease\nParticipants with active or recently treated (within 2 years) second primary malignancy and/or treated for an additional malignancy within 2 years prior to enrolment\nParticipants who are pregnant, breastfeeding or plan to breastfeed or expecting to conceive or father children during study or within 6 months after the last dose of study intervention", "metadata": {"brief_title": "A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors", "phase": ["PHASE1"], "drugs_list": ["LY4050784"], "diseases_list": ["Metastatic Solid Tumor", "Advanced Solid Tumor", "Non-small Cell Lung Cancer", "SMARCA4-Deficient Tumor"], "enrollment": 160, "inclusion_criteria": "inclusion criteria: \n\n Have one of the following locally advanced or metastatic solid tumor malignancy with SMARCA4 (BRG1) alteration:\n\n   Phase 1a dose escalation: Presence of any alteration in SMARCA4 (BRG1)\n   Phase 1b expansion: Part A: Non-small Cell Lung Cancer (NSCLC) that is locally advanced and not suitable for definitive locoregional therapy, or metastatic with presence of a known or likely loss of function alteration in SMARCA4 (BRG1) or loss of protein expression.\n   Phase 1b expansion: Part B: Any tumor type (other than NSCLC) that has the presence of a known or likely loss of function alteration in SMARCA4 (BRG1) or loss of protein expression.\n Prior Systemic Therapy Criteria:\n\n   Phase 1a dose escalation and Phase 1b (Part B): Participants who received all standard therapies for which the individual was deemed to be an appropriate candidate by the treating Investigator; or the individual is refusing the remaining most appropriate standard of care treatment; or there is no standard therapy available for the disease.\n   Phase 1b expansion (Part A): Participants must have received at least one line of therapy for advanced or metastatic disease.\n Measurability of disease\n\n   Phase 1a dose escalation (excluding backfill): measurable or non-measurable disease as defined by Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1)\n   Phase 1a backfill and Phase 1b expansion: Measurable disease required as defined by RECIST v1.1\n Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1", "exclusion_criteria": "exclusion criteria: \n\nParticipants with known loss of function alteration of SMARCA2 (BRM) or malignancy with known association with SMARCA2 (BRM) alterations\nPrior exposure to SMARCA2 (BRM) inhibitor(s) and/or degrader(s) (prior exposure may be permitted for dose escalation)\nParticipants with known or suspected history of untreated or uncontrolled central nervous system (CNS) involvement\nParticipants with history of increased risk of prolonged QT or significant arrythmia\nSignificant cardiovascular disease\nParticipants with active or recently treated (within 2 years) second primary malignancy and/or treated for an additional malignancy within 2 years prior to enrolment\nParticipants who are pregnant, breastfeeding or plan to breastfeed or expecting to conceive or father children during study or within 6 months after the last dose of study intervention", "brief_summary": "The main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants with locally advanced or metastatic solid tumors with a BRG1 (Brahma-related gene 1, also known as SMARCA4) alteration who have previously received, do not qualify for, or are refusing standard of care treatments, or there is no standard therapy available for the disease. The study is conducted in two parts - phase Ia (dose-escalation) and phase Ib (dose-optimization, dose-expansion). The study will last up to approximately 4 years.", "keywords": ["SMARCA2", "SMARCA4", "Lung cancer", "BRM", "BRG1", "Adenocarcinoma", "Squamous cell carcinoma", "Targeted therapy"]}}
{"_id": "NCT06143956", "title": "A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight", "text": "Summary: The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newly enrolled participants across the master and the ISAs. The ISAs may start independently of other ISAs as interventions become available for clinical testing. The results for the CWMM screening record will be reported when all the ISA's complete.\n\nInclusion criteria: inclusion criteria: \n\n Have a body mass index (BMI)\n \u226530 kilogram/square meter (kg/m\u00b2), or\n \u226527 kg/m\u00b2 and \\<30 kg/m\u00b2), or with at least 1 weight-releated comorbidity\n Have had a stable body weight for the 3 months prior to randomization (\\<5%) body weight gain and/or loss.\n\nExclusion criteria: exclusion criteria: \n\nHave a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed \\>1 year prior to screening.\nHave type 1 diabetes mellitus, latent autoimmune diabetes in adults, or history of ketoacidosis or hyperosmolar coma.\nHave poorly controlled hypertension.\nHave signs and symptoms of any liver disease other than nonalcoholic fatty liver disease.\nHave any of the following cardiovascular conditions within 3 months prior to screening:\n\n  acute myocardial infarction\n  cerebrovascular accident (stroke)\n  unstable angina, or\n  hospitalization due to congestive heart failure.\nHave a history of symptomatic gallbladder disease within the past 2 years.\nHave a lifetime history of suicide attempts.", "metadata": {"brief_title": "A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight", "phase": ["PHASE2"], "drugs_list": ["LY3305677", "LY3841136", "Tirzepatide", "Placebo", "LY3549492"], "diseases_list": ["Obesity", "Overweight"], "enrollment": 1040, "inclusion_criteria": "inclusion criteria: \n\n Have a body mass index (BMI)\n \u226530 kilogram/square meter (kg/m\u00b2), or\n \u226527 kg/m\u00b2 and \\<30 kg/m\u00b2), or with at least 1 weight-releated comorbidity\n Have had a stable body weight for the 3 months prior to randomization (\\<5%) body weight gain and/or loss.", "exclusion_criteria": "exclusion criteria: \n\nHave a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed \\>1 year prior to screening.\nHave type 1 diabetes mellitus, latent autoimmune diabetes in adults, or history of ketoacidosis or hyperosmolar coma.\nHave poorly controlled hypertension.\nHave signs and symptoms of any liver disease other than nonalcoholic fatty liver disease.\nHave any of the following cardiovascular conditions within 3 months prior to screening:\n\n  acute myocardial infarction\n  cerebrovascular accident (stroke)\n  unstable angina, or\n  hospitalization due to congestive heart failure.\nHave a history of symptomatic gallbladder disease within the past 2 years.\nHave a lifetime history of suicide attempts.", "brief_summary": "The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newly enrolled participants across the master and the ISAs. The ISAs may start independently of other ISAs as interventions become available for clinical testing. The results for the CWMM screening record will be reported when all the ISA's complete.", "keywords": []}}
{"_id": "NCT06588478", "title": "A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "text": "Summary: The main purpose of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of treatment including a covalent Bruton tyrosine kinase (BTK) inhibitor. The study is expected to last approximately 3 years.\n\nInclusion criteria: inclusion criteria: \n\n Have confirmed diagnosis of CLL/SLL as defined by these iwCLL 2018 criteria.\n Have received prior CLL/SLL treatment\n Have received at least 1, but not more than 3 lines of prior treatment for CLL/SLL\n Have received a covalent BTK inhibitor\n Have a requirement for therapy consistent with iwCLL 2018 criteria for initiation of therapy\n Capable of swallowing oral study medication.\n Have an Eastern Cooperative Oncology Group Performance Status (ECOG) score of 0 to 2.\n\nExclusion criteria: exclusion criteria: \n\nHave received prior treatment with a BTK degrader and a noncovalent BTK inhibitor\nHave a history of greater than or equal to (\\>=) Grade 3 bleeding due to treatment with a BTK inhibitor\nHave known or suspected Richter's transformation\nHave known or suspected history of central nervous system involvement by CLL/SLL\nPrevious or concurrent cancer distinct from CLL/SLL within 3 years before randomization. Exceptions may occur with documented sponsor approval. Examples include:\n\n  nonmelanoma skin cancer or lentigo maligna melanoma\n  cervical carcinoma in situ\n  localized prostate cancer undergoing active surveillance, and\n  localized (for example, lymph node negative) breast cancer with no evidence of active disease present for more than 3 years. Individual may be receiving adjuvant hormonal therapy", "metadata": {"brief_title": "A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "phase": ["PHASE2"], "drugs_list": ["Pirtobrutinib"], "diseases_list": ["Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma"], "enrollment": 249, "inclusion_criteria": "inclusion criteria: \n\n Have confirmed diagnosis of CLL/SLL as defined by these iwCLL 2018 criteria.\n Have received prior CLL/SLL treatment\n Have received at least 1, but not more than 3 lines of prior treatment for CLL/SLL\n Have received a covalent BTK inhibitor\n Have a requirement for therapy consistent with iwCLL 2018 criteria for initiation of therapy\n Capable of swallowing oral study medication.\n Have an Eastern Cooperative Oncology Group Performance Status (ECOG) score of 0 to 2.", "exclusion_criteria": "exclusion criteria: \n\nHave received prior treatment with a BTK degrader and a noncovalent BTK inhibitor\nHave a history of greater than or equal to (\\>=) Grade 3 bleeding due to treatment with a BTK inhibitor\nHave known or suspected Richter's transformation\nHave known or suspected history of central nervous system involvement by CLL/SLL\nPrevious or concurrent cancer distinct from CLL/SLL within 3 years before randomization. Exceptions may occur with documented sponsor approval. Examples include:\n\n  nonmelanoma skin cancer or lentigo maligna melanoma\n  cervical carcinoma in situ\n  localized prostate cancer undergoing active surveillance, and\n  localized (for example, lymph node negative) breast cancer with no evidence of active disease present for more than 3 years. Individual may be receiving adjuvant hormonal therapy", "brief_summary": "The main purpose of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of treatment including a covalent Bruton tyrosine kinase (BTK) inhibitor. The study is expected to last approximately 3 years.", "keywords": []}}
{"_id": "NCT06603571", "title": "A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes", "text": "Summary: The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136 for chronic weight management alone or in combination with Tirzepatide across a wide dose range in participants with Type 2 Diabetes. Participation in the study will last about 64 weeks.\n\nInclusion criteria: inclusion criteria: \n\nW8M-MC-LAA2\n\n Have a Body Mass Index (BMI) of \u226527 kilograms per square meter (kg/m\u00b2)\n Have Type 2 Diabetes\n Have a HbA1c \u22657.0 % (53 millimoles/mole (mmol/mol)) to \u226410.5% (91 mmol/mol) and treated with diet and exercise alone or with a stable dose of metformin (and not more than the locally approved dose) with or without a sodium-glucose cotransporter 2 (SGLT2) inhibitor for at least 3 months prior to screening\n\nW8M-MC-CWMM:\n\n Have had a stable body weight for the 3 months prior to randomization (\\<5% body weight gain and/or loss)\n\nExclusion criteria: exclusion criteria: \n\nW8M-MC-LAA2\n\nHave a history of severe hypoglycemia or hypoglycemia unawareness within the last 6 months prior to screening\nHave an on-going or history of bradyarrhythmia and/or sinus bradycardia\nHave an elevated resting pulse rate (mean \\>100 beats per minute (bpm)) or reduced resting pulse rate (mean \\<60 bpm) at screening\nHave any of the following cardiovascular conditions within 6 months prior to screening:\n\n  acute myocardial infarction\n  cerebrovascular accident (stroke)\n  unstable angina, or\n  hospitalization due to congestive heart failure\nHave renal impairment measured as estimated glomerular filtration rate (eGFR) \\<45 milliliters per minute (mL/min)/1.73 m2\nHave a history of acute or chronic pancreatitis\nHave fasting triglycerides \\>500 milligrams per deciliter (mg/dL) (5.7 mmol/L) at screening\nAll concomitant medications should be at a stable dose for at least 3 months prior to screening\n\nW8M-MC-CWMM\n\nHave a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed \\>1 year prior to screening.\nHave type 1 diabetes mellitus, latent autoimmune diabetes in adults, or history of ketoacidosis or hyperosmolar coma.\nHave poorly controlled hypertension.\nHave a history of symptomatic gallbladder disease within the past 2 years\nHave signs and symptoms of any liver disease other than nonalcoholic fatty liver disease.\nHave a lifetime history of suicide attempts.", "metadata": {"brief_title": "A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes", "phase": ["PHASE2"], "drugs_list": ["LY3841136", "Tirzepatide", "Placebo"], "diseases_list": ["Obesity", "Overweight"], "enrollment": 350, "inclusion_criteria": "inclusion criteria: \n\nW8M-MC-LAA2\n\n Have a Body Mass Index (BMI) of \u226527 kilograms per square meter (kg/m\u00b2)\n Have Type 2 Diabetes\n Have a HbA1c \u22657.0 % (53 millimoles/mole (mmol/mol)) to \u226410.5% (91 mmol/mol) and treated with diet and exercise alone or with a stable dose of metformin (and not more than the locally approved dose) with or without a sodium-glucose cotransporter 2 (SGLT2) inhibitor for at least 3 months prior to screening\n\nW8M-MC-CWMM:\n\n Have had a stable body weight for the 3 months prior to randomization (\\<5% body weight gain and/or loss)", "exclusion_criteria": "exclusion criteria: \n\nW8M-MC-LAA2\n\nHave a history of severe hypoglycemia or hypoglycemia unawareness within the last 6 months prior to screening\nHave an on-going or history of bradyarrhythmia and/or sinus bradycardia\nHave an elevated resting pulse rate (mean \\>100 beats per minute (bpm)) or reduced resting pulse rate (mean \\<60 bpm) at screening\nHave any of the following cardiovascular conditions within 6 months prior to screening:\n\n  acute myocardial infarction\n  cerebrovascular accident (stroke)\n  unstable angina, or\n  hospitalization due to congestive heart failure\nHave renal impairment measured as estimated glomerular filtration rate (eGFR) \\<45 milliliters per minute (mL/min)/1.73 m2\nHave a history of acute or chronic pancreatitis\nHave fasting triglycerides \\>500 milligrams per deciliter (mg/dL) (5.7 mmol/L) at screening\nAll concomitant medications should be at a stable dose for at least 3 months prior to screening\n\nW8M-MC-CWMM\n\nHave a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed \\>1 year prior to screening.\nHave type 1 diabetes mellitus, latent autoimmune diabetes in adults, or history of ketoacidosis or hyperosmolar coma.\nHave poorly controlled hypertension.\nHave a history of symptomatic gallbladder disease within the past 2 years\nHave signs and symptoms of any liver disease other than nonalcoholic fatty liver disease.\nHave a lifetime history of suicide attempts.", "brief_summary": "The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136 for chronic weight management alone or in combination with Tirzepatide across a wide dose range in participants with Type 2 Diabetes. Participation in the study will last about 64 weeks.", "keywords": ["Type 2 Diabetes"]}}
{"_id": "NCT06643728", "title": "A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight", "text": "Summary: The main purpose of this study is to evaluate the efficacy and safety of Bimagrumab and Tirzepatide, alone or in combination, in adults with obesity or overweight, with at least one obesity related comorbidity, without Type 2 Diabetes. The study will last about 70 weeks.\n\nInclusion criteria: inclusion criteria: \n\n Have a BMI of\n\n   \u226530 kilograms per square meter (kg/m2) or\n   \u226527 kg/m2 and \\<30 kg/m2, with at least one of the following weight-related comorbidities:\n\n     Hypertension\n     Dyslipidemia\n     Cardiovascular disease\n     Obstructive sleep apnea\n Have had a stable body weight for the 3 months prior to randomization (\\<5% body weight gain and/or loss)\n\nExclusion criteria: exclusion criteria: \n\nHave a prior or planned surgical treatment for obesity\nHave at least one laboratory value suggestive of diabetes during screening\nUse of metformin, or any other glucose-lowering medications\nHave Type 1 Diabetes, latent autoimmune diabetes, been diagnosed with any form of diabetes mellitus except for a prior diagnosis of gestational diabetes mellitus, or history of ketoacidosis or hyperosmolar coma\nHave poorly controlled hypertension\nHave any of the following cardiovascular conditions within 3 months prior to screening:\n\n  acute myocardial infarction\n  cerebrovascular accident (stroke)\n  unstable angina, or\n  hospitalization due to congestive heart failure\nHave ongoing or a history of frequent intermittent or chronic tachyarrhythmia syndromes\nHave ongoing or a history of bradyarrhythmias other than sinus bradycardia\nHave a history of New York Heart Association (NYHA) Functional Classification III or IV congestive heart failure\nHave a history of symptomatic gallbladder disease within the past 2 years\nHave signs and symptoms of any liver disease\nHave a disease or condition known to cause gastrointestinal malabsorption or a known clinically significant gastric emptying abnormality\nHave a history of acute or chronic pancreatitis\nHave renal impairment, measured as estimated glomerular filtration rate \\<30 mL/minute/1.73 m2\nCurrently taking or have taken medications that may cause significant weight gain or promote weight loss within 3 months prior to screening", "metadata": {"brief_title": "A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight", "phase": ["PHASE2"], "drugs_list": ["Bimagrumab", "Tirzepatide", "Bimagrumab Placebo", "Tirzepatide Placebo"], "diseases_list": ["Obesity", "Overweight"], "enrollment": 240, "inclusion_criteria": "inclusion criteria: \n\n Have a BMI of\n\n   \u226530 kilograms per square meter (kg/m2) or\n   \u226527 kg/m2 and \\<30 kg/m2, with at least one of the following weight-related comorbidities:\n\n     Hypertension\n     Dyslipidemia\n     Cardiovascular disease\n     Obstructive sleep apnea\n Have had a stable body weight for the 3 months prior to randomization (\\<5% body weight gain and/or loss)", "exclusion_criteria": "exclusion criteria: \n\nHave a prior or planned surgical treatment for obesity\nHave at least one laboratory value suggestive of diabetes during screening\nUse of metformin, or any other glucose-lowering medications\nHave Type 1 Diabetes, latent autoimmune diabetes, been diagnosed with any form of diabetes mellitus except for a prior diagnosis of gestational diabetes mellitus, or history of ketoacidosis or hyperosmolar coma\nHave poorly controlled hypertension\nHave any of the following cardiovascular conditions within 3 months prior to screening:\n\n  acute myocardial infarction\n  cerebrovascular accident (stroke)\n  unstable angina, or\n  hospitalization due to congestive heart failure\nHave ongoing or a history of frequent intermittent or chronic tachyarrhythmia syndromes\nHave ongoing or a history of bradyarrhythmias other than sinus bradycardia\nHave a history of New York Heart Association (NYHA) Functional Classification III or IV congestive heart failure\nHave a history of symptomatic gallbladder disease within the past 2 years\nHave signs and symptoms of any liver disease\nHave a disease or condition known to cause gastrointestinal malabsorption or a known clinically significant gastric emptying abnormality\nHave a history of acute or chronic pancreatitis\nHave renal impairment, measured as estimated glomerular filtration rate \\<30 mL/minute/1.73 m2\nCurrently taking or have taken medications that may cause significant weight gain or promote weight loss within 3 months prior to screening", "brief_summary": "The main purpose of this study is to evaluate the efficacy and safety of Bimagrumab and Tirzepatide, alone or in combination, in adults with obesity or overweight, with at least one obesity related comorbidity, without Type 2 Diabetes. The study will last about 70 weeks.", "keywords": ["Muscle", "Lean", "Fat"]}}
{"_id": "NCT05723198", "title": "A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata", "text": "Summary: The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hair loss) in children from 6 years to less than 18 years of age.\n\nThe study is divided into 4 periods, a 5-week Screening period, a 36-week Double-Blind Treatment Period, an approximately 2-year Long-term Extension Period, and a 4-week Post-treatment Follow-up period.\n\nInclusion criteria: inclusion criteria: \n\n Enrollment will be fully sequential by age group, with adolescents (12 to less than 18 years old) enrolling before children (6 to less than 12 years old).\n Have severe areata alopecia (AA) for at least 1 year\n Diagnosis for at least 1 year\n Current AA episode of at least 6 months' duration\n SALT score \u226550% at screening and baseline\n History of trial and failure with at least 1 available treatment (topical or other) for AA\n History of psychological counseling related to AA\n Current episode of severe AA of less than 8 years.\n\n   Note: Participants who have severe AA for \u22658 years may be enrolled if episodes of regrowth, spontaneous or under treatment, have been observed on the affected areas over the past 8 years.\n\nExclusion criteria: exclusion criteria: \n\nPrimarily \"diffuse\" type of AA (characterized by diffuse hair shedding).\nAre currently experiencing other forms of alopecia including, but not limited to trichotillomania, telogen effluvium, chemotherapy-induced hair loss, or any other concomitant conditions (for example, tinea capitis, psoriasis, lupus erythematosus, or secondary syphilis) that would interfere with evaluations of the effect of study medication on AA.\nAre largely or wholly incapacitated permitting little or no self-care, such as being bedridden\nHave uncontrolled arterial hypertension\nHave had major surgery within 8 weeks prior to screening or will require major surgery during the study\nHave a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute an unacceptable risk when taking IP or interfere with the interpretation of data.\nHave a positive test for hepatitis B virus (HBV) infection\nHave hepatitis C virus (HCV) infection (positive for anti hepatitis C antibody with confirmed presence of HCV ribonucleic acid \\[RNA\\]).\nHave evidence of human immunodeficiency virus (HIV) infection and/or positive HIV antibodies.", "metadata": {"brief_title": "A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata", "phase": ["PHASE3"], "drugs_list": ["Baricitinib", "Placebo"], "diseases_list": ["Areata Alopecia", "Alopecia", "Hypotrichosis", "Hair Diseases", "Skin Diseases", "Pathological Conditions, Anatomical"], "enrollment": 595, "inclusion_criteria": "inclusion criteria: \n\n Enrollment will be fully sequential by age group, with adolescents (12 to less than 18 years old) enrolling before children (6 to less than 12 years old).\n Have severe areata alopecia (AA) for at least 1 year\n Diagnosis for at least 1 year\n Current AA episode of at least 6 months' duration\n SALT score \u226550% at screening and baseline\n History of trial and failure with at least 1 available treatment (topical or other) for AA\n History of psychological counseling related to AA\n Current episode of severe AA of less than 8 years.\n\n   Note: Participants who have severe AA for \u22658 years may be enrolled if episodes of regrowth, spontaneous or under treatment, have been observed on the affected areas over the past 8 years.", "exclusion_criteria": "exclusion criteria: \n\nPrimarily \"diffuse\" type of AA (characterized by diffuse hair shedding).\nAre currently experiencing other forms of alopecia including, but not limited to trichotillomania, telogen effluvium, chemotherapy-induced hair loss, or any other concomitant conditions (for example, tinea capitis, psoriasis, lupus erythematosus, or secondary syphilis) that would interfere with evaluations of the effect of study medication on AA.\nAre largely or wholly incapacitated permitting little or no self-care, such as being bedridden\nHave uncontrolled arterial hypertension\nHave had major surgery within 8 weeks prior to screening or will require major surgery during the study\nHave a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute an unacceptable risk when taking IP or interfere with the interpretation of data.\nHave a positive test for hepatitis B virus (HBV) infection\nHave hepatitis C virus (HCV) infection (positive for anti hepatitis C antibody with confirmed presence of HCV ribonucleic acid \\[RNA\\]).\nHave evidence of human immunodeficiency virus (HIV) infection and/or positive HIV antibodies.", "brief_summary": "The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hair loss) in children from 6 years to less than 18 years of age.\n\nThe study is divided into 4 periods, a 5-week Screening period, a 36-week Double-Blind Treatment Period, an approximately 2-year Long-term Extension Period, and a 4-week Post-treatment Follow-up period.", "keywords": []}}
{"_id": "NCT06890598", "title": "Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer", "text": "Summary: The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective than the durvalumab and placebo combination in part B in participants with unresectable KRAS G12C-mutant non-small cell lung cancer. The study may last up to 3 years for each participant.\n\nInclusion criteria: inclusion criteria: \n\n Histological or cytological confirmation of NSCLC.\n\n   Part A\n\n    1. Clinical Stage II-IIIB (N2) treated with presurgical chemoimmunotherapy, with residual tumor present at time of surgery. Patients with a pathologic complete response are not eligible.\n    2. Pathologic Stage II-IIIB (N2) NSCLC treated with initial upfront resection.\n   Part B - Clinical Stage III, unresectable NSCLC, without progression on concurrent platinum-based chemoradiotherapy.\n Must have disease with evidence of KRAS G12C mutation.\n Must have known programmed death-ligand 1 (PD-L1) expression\n Must have an ECOG performance status of 0 or 1.\n Able to swallow oral medication.\n Must have adequate laboratory parameters.\n Contraceptive use should be consistent with local regulations for those participating in clinical studies.\n Women of childbearing potential must\n\n   Have a negative pregnancy test.\n   Not be breastfeeding during treatment\n\nExclusion criteria: exclusion criteria: \n\nHave known changes in the EGFR or ALK genes.\nHave another type of cancer that is progressing or required active treatment within the past 3 years before screening.\nHave an active autoimmune disease that required systemic treatment in the past 2 years. Endocrine replacement therapy is allowed.\nHad any immune-related side effect or allergic reaction (Grade 3 or higher) from a previous immunotherapy medicine, or any immune-related side effect greater than Grade 1 that has not resolved. This does not apply for people with hormone-related diseases who are now on stable hormone replacement therapy.", "metadata": {"brief_title": "Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer", "phase": ["PHASE3"], "drugs_list": ["Olomorasib", "Pembrolizumab", "Durvalumab", "Placebo"], "diseases_list": ["Carcinoma, Non-Small-Cell Lung"], "enrollment": 700, "inclusion_criteria": "inclusion criteria: \n\n Histological or cytological confirmation of NSCLC.\n\n   Part A\n\n    1. Clinical Stage II-IIIB (N2) treated with presurgical chemoimmunotherapy, with residual tumor present at time of surgery. Patients with a pathologic complete response are not eligible.\n    2. Pathologic Stage II-IIIB (N2) NSCLC treated with initial upfront resection.\n   Part B - Clinical Stage III, unresectable NSCLC, without progression on concurrent platinum-based chemoradiotherapy.\n Must have disease with evidence of KRAS G12C mutation.\n Must have known programmed death-ligand 1 (PD-L1) expression\n Must have an ECOG performance status of 0 or 1.\n Able to swallow oral medication.\n Must have adequate laboratory parameters.\n Contraceptive use should be consistent with local regulations for those participating in clinical studies.\n Women of childbearing potential must\n\n   Have a negative pregnancy test.\n   Not be breastfeeding during treatment", "exclusion_criteria": "exclusion criteria: \n\nHave known changes in the EGFR or ALK genes.\nHave another type of cancer that is progressing or required active treatment within the past 3 years before screening.\nHave an active autoimmune disease that required systemic treatment in the past 2 years. Endocrine replacement therapy is allowed.\nHad any immune-related side effect or allergic reaction (Grade 3 or higher) from a previous immunotherapy medicine, or any immune-related side effect greater than Grade 1 that has not resolved. This does not apply for people with hormone-related diseases who are now on stable hormone replacement therapy.", "brief_summary": "The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective than the durvalumab and placebo combination in part B in participants with unresectable KRAS G12C-mutant non-small cell lung cancer. The study may last up to 3 years for each participant.", "keywords": []}}
{"_id": "NCT06588283", "title": "Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight", "text": "Summary: The main purpose of this study is to demonstrate that when participants with moderate to severe plaque psoriasis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide concomitantly administered, participants see improvement in their psoriasis and achieve weight reduction compared to when receiving ixekizumab.\n\nParticipation in this study includes up to 12 visits and could last up to 61 weeks including screening, open label treatment period, and post-treatment follow-up period.\n\nInclusion criteria: inclusion criteria: \n\n Have a diagnosis of moderate-to-severe plaque psoriasis (PsO) for at least 6 months.\n Have both a Static Physician's Global Assessment (sPGA) score of \u22653 and a Psoriasis Area and Severity Index (PASI) \u226512.\n Have \u226510% body surface area (BSA) involvement.\n Have obesity, body mass index of \u226530 kilograms per meter squared (BMI \u226530 kg/m\u00b2) or overweight (BMI \u226527 to \\<30 kg/m\u00b2) in the presence of at least 1 of these weight-related comorbid conditions (hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, or T2DM).\n\nExclusion criteria: exclusion criteria: \n\nMedical Conditions\n\nHave Type 1 Diabetes Mellitus (T1DM).\nHave insulin-treated Type 2 Diabetes Mellitus (T2DM).\nHave a prior or planned surgical treatment for obesity.\nHave a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia (MEN) syndrome type 2.\nHave active, or a history of inflammatory bowel disease (Crohn's or ulcerative colitis).\nHave a diagnosis or history of malignant disease within the 5 years prior to randomization, with the following exceptions:\n\n  basal cell or squamous epithelial carcinomas of the skin that have been resected, with no evidence of metastatic disease for 3 years.\n  cervical carcinoma in situ, with no evidence of recurrence within the 5 years prior to randomization.\nHave serious disorder or illness other than PsO.\nHave a history of chronic or acute pancreatitis.\nHave any prior use of ixekizumab or tirzepatide.\nHave a previous failure or intolerance to an interleukin 17 inhibitor (IL-17i) or glucagon-like peptide 1 (GLP-1) receptor agonists.", "metadata": {"brief_title": "Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight", "phase": ["PHASE3"], "drugs_list": ["Ixekizumab", "Tirzepatide"], "diseases_list": ["Psoriasis", "Obesity"], "enrollment": 250, "inclusion_criteria": "inclusion criteria: \n\n Have a diagnosis of moderate-to-severe plaque psoriasis (PsO) for at least 6 months.\n Have both a Static Physician's Global Assessment (sPGA) score of \u22653 and a Psoriasis Area and Severity Index (PASI) \u226512.\n Have \u226510% body surface area (BSA) involvement.\n Have obesity, body mass index of \u226530 kilograms per meter squared (BMI \u226530 kg/m\u00b2) or overweight (BMI \u226527 to \\<30 kg/m\u00b2) in the presence of at least 1 of these weight-related comorbid conditions (hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, or T2DM).", "exclusion_criteria": "exclusion criteria: \n\nMedical Conditions\n\nHave Type 1 Diabetes Mellitus (T1DM).\nHave insulin-treated Type 2 Diabetes Mellitus (T2DM).\nHave a prior or planned surgical treatment for obesity.\nHave a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia (MEN) syndrome type 2.\nHave active, or a history of inflammatory bowel disease (Crohn's or ulcerative colitis).\nHave a diagnosis or history of malignant disease within the 5 years prior to randomization, with the following exceptions:\n\n  basal cell or squamous epithelial carcinomas of the skin that have been resected, with no evidence of metastatic disease for 3 years.\n  cervical carcinoma in situ, with no evidence of recurrence within the 5 years prior to randomization.\nHave serious disorder or illness other than PsO.\nHave a history of chronic or acute pancreatitis.\nHave any prior use of ixekizumab or tirzepatide.\nHave a previous failure or intolerance to an interleukin 17 inhibitor (IL-17i) or glucagon-like peptide 1 (GLP-1) receptor agonists.", "brief_summary": "The main purpose of this study is to demonstrate that when participants with moderate to severe plaque psoriasis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide concomitantly administered, participants see improvement in their psoriasis and achieve weight reduction compared to when receiving ixekizumab.\n\nParticipation in this study includes up to 12 visits and could last up to 61 weeks including screening, open label treatment period, and post-treatment follow-up period.", "keywords": []}}
{"_id": "NCT03519945", "title": "A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)", "text": "Summary: This study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative colitis (UC). The study will last up to 3 years. Participants who complete the 3-year study may continue to receive mirikizumab until it is (outside of this study) in their country or until they meet other discontinuation criteria.\n\nInclusion criteria: inclusion criteria: \n\n \n\nExclusion criteria: exclusion criteria: \n\n ", "metadata": {"brief_title": "A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)", "phase": ["PHASE3"], "drugs_list": ["Mirikizumab"], "diseases_list": ["Ulcerative Colitis"], "enrollment": 1063, "inclusion_criteria": "inclusion criteria: \n\n ", "exclusion_criteria": "exclusion criteria: \n\n ", "brief_summary": "This study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative colitis (UC). The study will last up to 3 years. Participants who complete the 3-year study may continue to receive mirikizumab until it is (outside of this study) in their country or until they meet other discontinuation criteria.", "keywords": ["Inflammatory Bowel Disease"]}}
{"_id": "NCT06649045", "title": "A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight", "text": "Summary: Study GZRA is a master protocol that will support 2 independent studies, GZ01 and GZ02. Participants will be assigned to the appropriate study prior to randomization. The purpose of the studies is to evaluate the efficacy and safety of orforglipron in participants who have moderate-to-severe OSA and obesity or overweight. Study GZ01 will include participants who are unable or are unwilling to use PAP therapy. Study GZ02 will include participants who are on PAP therapy for at least 3 months at time of screening and plan to continue PAP therapy during the study.\n\nInclusion criteria: inclusion criteria: \n\nMaster GZRA inclusion criteria\n\n have AHI \u226515 on PSG as part of the trial at screening (V1).\n have body mass index (BMI) \u226527 kg/m\u00b2\n\nStudy 1 GZ01 inclusion criteria\n\n Participants who are unable or unwilling to use PAP therapy.\n Participants must not have used PAP for at least 4 weeks prior to screening.\n\nStudy 2 GZ02 inclusion criteria\n\n Participants who have been on PAP therapy for at least 3 consecutive months prior to study start and plan to continue PAP therapy during the study.\n\nExclusion criteria: exclusion criteria: \n\nMaster GZRA exclusion criteria\n\nHave Type 1 diabetes (T1D) or Type 2 diabetes (T2D), history of ketoacidosis, or hyperosmolar state/coma\nHave HbA1c \u22656.5% (\u2265 48 mmol/mol), as determined by the central laboratory at Visit 1.\nHad any previous or planned upper airway surgery for sleep apnea or major ear, nose or throat surgery\nHave diagnosis of Central or Mixed Sleep Apnea with % of mixed or central apneas/hypopneas \u226550%, or diagnosis of Cheyne Stokes Respiration\nDiagnosis of Obesity Hypoventilation Syndrome or daytime hypercapnia.\nActive device treatment of OSA other than PAP therapy\nRespiratory and neuromuscular diseases that could interfere with the results of the trial in the opinion of the investigator.\nHave a self-reported change in body weight \\>5 kg within 3 months prior to screening\nHave a prior or planned surgical treatment for obesity (excluding liposuction, abdominoplasty or cryolipolysis if performed more than 1 year prior to screening)\nHave a prior or planned endoscopic and/or present device-based therapy for obesity.\nHave obesity induced by other endocrinologic disorders or diagnosed monogenetic or syndromic forms of obesity.\n\nStudy 2 GZ02 exclusion criteria\n\nHave personal or job-related responsibilities, or in the opinion of the investigator have any situation that would make it unsafe to stop PAP therapy for 7 days prior to PSG testing during the study.\nAre unwilling to temporary discontinue PAP therapy for 7 days prior to PSG testing during the study.", "metadata": {"brief_title": "A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight", "phase": ["PHASE3"], "drugs_list": ["Orforglipron", "Placebo"], "diseases_list": ["OSA", "Overweight or Obesity"], "enrollment": 600, "inclusion_criteria": "inclusion criteria: \n\nMaster GZRA inclusion criteria\n\n have AHI \u226515 on PSG as part of the trial at screening (V1).\n have body mass index (BMI) \u226527 kg/m\u00b2\n\nStudy 1 GZ01 inclusion criteria\n\n Participants who are unable or unwilling to use PAP therapy.\n Participants must not have used PAP for at least 4 weeks prior to screening.\n\nStudy 2 GZ02 inclusion criteria\n\n Participants who have been on PAP therapy for at least 3 consecutive months prior to study start and plan to continue PAP therapy during the study.", "exclusion_criteria": "exclusion criteria: \n\nMaster GZRA exclusion criteria\n\nHave Type 1 diabetes (T1D) or Type 2 diabetes (T2D), history of ketoacidosis, or hyperosmolar state/coma\nHave HbA1c \u22656.5% (\u2265 48 mmol/mol), as determined by the central laboratory at Visit 1.\nHad any previous or planned upper airway surgery for sleep apnea or major ear, nose or throat surgery\nHave diagnosis of Central or Mixed Sleep Apnea with % of mixed or central apneas/hypopneas \u226550%, or diagnosis of Cheyne Stokes Respiration\nDiagnosis of Obesity Hypoventilation Syndrome or daytime hypercapnia.\nActive device treatment of OSA other than PAP therapy\nRespiratory and neuromuscular diseases that could interfere with the results of the trial in the opinion of the investigator.\nHave a self-reported change in body weight \\>5 kg within 3 months prior to screening\nHave a prior or planned surgical treatment for obesity (excluding liposuction, abdominoplasty or cryolipolysis if performed more than 1 year prior to screening)\nHave a prior or planned endoscopic and/or present device-based therapy for obesity.\nHave obesity induced by other endocrinologic disorders or diagnosed monogenetic or syndromic forms of obesity.\n\nStudy 2 GZ02 exclusion criteria\n\nHave personal or job-related responsibilities, or in the opinion of the investigator have any situation that would make it unsafe to stop PAP therapy for 7 days prior to PSG testing during the study.\nAre unwilling to temporary discontinue PAP therapy for 7 days prior to PSG testing during the study.", "brief_summary": "Study GZRA is a master protocol that will support 2 independent studies, GZ01 and GZ02. Participants will be assigned to the appropriate study prior to randomization. The purpose of the studies is to evaluate the efficacy and safety of orforglipron in participants who have moderate-to-severe OSA and obesity or overweight. Study GZ01 will include participants who are unable or are unwilling to use PAP therapy. Study GZ02 will include participants who are on PAP therapy for at least 3 months at time of screening and plan to continue PAP therapy during the study.", "keywords": []}}
{"_id": "NCT06890611", "title": "A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants", "text": "Summary: The main purpose of this study is to evaluate the body concentration of different forms of bimagrumab, administered alone or with tirzepatide. Participation in the study will last about 4.5 months, including screening and follow-up.\n\nInclusion criteria: inclusion criteria: \n\n Are considered healthy as determined by medical evaluation including medical history and physical examination\n Have a body mass index (BMI) within the range of 22.0 to 30.0 kilograms per square meter (kg/m2), inclusive\n\nExclusion criteria: exclusion criteria: \n\nHave current or a history of pancreatitis or hepatitis\nHave a self-reported increase or decrease in body weight, greater than 5 kilograms (kg), within 3 months prior to screening\nHave uncontrolled high blood pressure\nHave taken medications or alternative remedies to promote weight loss within 3 months prior to screening", "metadata": {"brief_title": "A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants", "phase": ["PHASE1"], "drugs_list": ["Bimagrumab", "Tirzepatide", "Bimagrumab + Tirzepatide Coformulation"], "diseases_list": ["Healthy"], "enrollment": 100, "inclusion_criteria": "inclusion criteria: \n\n Are considered healthy as determined by medical evaluation including medical history and physical examination\n Have a body mass index (BMI) within the range of 22.0 to 30.0 kilograms per square meter (kg/m2), inclusive", "exclusion_criteria": "exclusion criteria: \n\nHave current or a history of pancreatitis or hepatitis\nHave a self-reported increase or decrease in body weight, greater than 5 kilograms (kg), within 3 months prior to screening\nHave uncontrolled high blood pressure\nHave taken medications or alternative remedies to promote weight loss within 3 months prior to screening", "brief_summary": "The main purpose of this study is to evaluate the body concentration of different forms of bimagrumab, administered alone or with tirzepatide. Participation in the study will last about 4.5 months, including screening and follow-up.", "keywords": []}}
{"_id": "NCT06719128", "title": "A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants", "text": "Summary: The main purpose of this study is to assess how olomorasib gets into the blood stream and how long it takes the body to remove it when administered to participants with mild, moderate and severe impaired liver function compared to participants with normal liver function. The safety and tolerability of olomorasib will also be evaluated. The study may last up to 6 weeks for each participant including the screening period.\n\nInclusion criteria: inclusion criteria: \n\n Males and females of non-childbearing potential.\n Men or women with a body mass index of 18.0 to 40.0 kilograms per meter squared (kg/m\u00b2).\n Able to comply with all study procedures, including the 5- to 6-night stays at the CRU and the follow-up phone call.\n Healthy participants: In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead ECG, vital sign measurements, or clinical laboratory evaluations at screening and/or admission as assessed by the investigator (or designee).\n Participants with hepatic impairment: Diagnosis of cirrhosis due to parenchymal liver disease, which is confirmed and documented by at least one of the following: medical history, physical examination, hepatic ultrasound, computed axial tomography scan, magnetic resonance imaging, and/or liver biopsy.\n\nExclusion criteria: exclusion criteria: \n\nFemales who are lactating or of childbearing potential.\nHistory or presence of any of the following, deemed clinically significant by the Investigator (or designee), and/or Sponsor:\n\n  1. Metabolic disease\n  2. Gastrointestinal disease\n  3. Hematological disease\n  4. Neurological disease\n  5. History or presence of clinically significant cardiovascular disease.\nAbnormal laboratory values determined to be clinically significant by the Investigator (or designee).\nClinically significant abnormality, as determined by the Investigator (or designee), from physical examination.\nParticipation in any other investigational study drug trial involving administration of any investigational drug in the past 30 days or 5 half-lives, whichever was longer, prior to the first dose administration (Day 1).\nUse or intention to use any prescription or over-the-counter medications within 14 days prior to the first dose administration (Day 1) and through end of trial, unless deemed acceptable by the investigator (or designee) and medical monitor.\nHistory or presence, upon clinical evaluation, of any illness that, in the opinion of the Investigator, would interfere with the ability to provide informed consent or comply with study instructions, or that might confound the interpretation of the study results, or put the participant at undue risk.", "metadata": {"brief_title": "A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants", "phase": ["PHASE1"], "drugs_list": ["Olomorasib"], "diseases_list": ["Hepatic Insufficiency", "Healthy"], "enrollment": 48, "inclusion_criteria": "inclusion criteria: \n\n Males and females of non-childbearing potential.\n Men or women with a body mass index of 18.0 to 40.0 kilograms per meter squared (kg/m\u00b2).\n Able to comply with all study procedures, including the 5- to 6-night stays at the CRU and the follow-up phone call.\n Healthy participants: In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead ECG, vital sign measurements, or clinical laboratory evaluations at screening and/or admission as assessed by the investigator (or designee).\n Participants with hepatic impairment: Diagnosis of cirrhosis due to parenchymal liver disease, which is confirmed and documented by at least one of the following: medical history, physical examination, hepatic ultrasound, computed axial tomography scan, magnetic resonance imaging, and/or liver biopsy.", "exclusion_criteria": "exclusion criteria: \n\nFemales who are lactating or of childbearing potential.\nHistory or presence of any of the following, deemed clinically significant by the Investigator (or designee), and/or Sponsor:\n\n  1. Metabolic disease\n  2. Gastrointestinal disease\n  3. Hematological disease\n  4. Neurological disease\n  5. History or presence of clinically significant cardiovascular disease.\nAbnormal laboratory values determined to be clinically significant by the Investigator (or designee).\nClinically significant abnormality, as determined by the Investigator (or designee), from physical examination.\nParticipation in any other investigational study drug trial involving administration of any investigational drug in the past 30 days or 5 half-lives, whichever was longer, prior to the first dose administration (Day 1).\nUse or intention to use any prescription or over-the-counter medications within 14 days prior to the first dose administration (Day 1) and through end of trial, unless deemed acceptable by the investigator (or designee) and medical monitor.\nHistory or presence, upon clinical evaluation, of any illness that, in the opinion of the Investigator, would interfere with the ability to provide informed consent or comply with study instructions, or that might confound the interpretation of the study results, or put the participant at undue risk.", "brief_summary": "The main purpose of this study is to assess how olomorasib gets into the blood stream and how long it takes the body to remove it when administered to participants with mild, moderate and severe impaired liver function compared to participants with normal liver function. The safety and tolerability of olomorasib will also be evaluated. The study may last up to 6 weeks for each participant including the screening period.", "keywords": ["Olomorasib", "Hepatic Impairment"]}}
{"_id": "NCT06439277", "title": "A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)", "text": "Summary: The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition and physical activity in adolescents with obesity and multiple weight related comorbidities. The study will last approximately 76 weeks and may include up to 23 visits.\n\nInclusion criteria: inclusion criteria: \n\n Have body mass index (BMI) equal to or above the 95th percentile for age and sex (on age and gender-specific growth chart for diagnosis of obesity) with at least 2 of the following predefined weight-related comorbidities: hypertension, prediabetes and hypertriglyceridemia.\n Have history of at least 1 self-reported unsuccessful dietary effort to lose weight.\n Are capable of giving signed informed consent by a legal representative or assent by a study participant (when applicable).\n\nExclusion criteria: exclusion criteria: \n\nHave undergone or plan to undergo a weight reduction procedure during the study, such as, but not limited to\n\n  gastric bypass\n  sleeve gastrectomy\n  restrictive bariatric surgery, such as Lap-Band gastric banding, or\n  any other procedure intended to result in weight reduction.\nHave a self-reported, or by parent or legal guardian where applicable, decrease in body weight greater than 5 kg (11 lbs) within 90 days before screening irrespective of medical records\nHave type 1 diabetes or history of ketoacidosis, or hyperosmolar state\nHave type 2 diabetes or have a HbA1c \\> 6.4% at screening\nHave a history of chronic or acute pancreatitis\nHave a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2", "metadata": {"brief_title": "A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)", "phase": ["PHASE3"], "drugs_list": ["Tirzepatide", "Placebo"], "diseases_list": ["Obesity", "Weight Gain"], "enrollment": 300, "inclusion_criteria": "inclusion criteria: \n\n Have body mass index (BMI) equal to or above the 95th percentile for age and sex (on age and gender-specific growth chart for diagnosis of obesity) with at least 2 of the following predefined weight-related comorbidities: hypertension, prediabetes and hypertriglyceridemia.\n Have history of at least 1 self-reported unsuccessful dietary effort to lose weight.\n Are capable of giving signed informed consent by a legal representative or assent by a study participant (when applicable).", "exclusion_criteria": "exclusion criteria: \n\nHave undergone or plan to undergo a weight reduction procedure during the study, such as, but not limited to\n\n  gastric bypass\n  sleeve gastrectomy\n  restrictive bariatric surgery, such as Lap-Band gastric banding, or\n  any other procedure intended to result in weight reduction.\nHave a self-reported, or by parent or legal guardian where applicable, decrease in body weight greater than 5 kg (11 lbs) within 90 days before screening irrespective of medical records\nHave type 1 diabetes or history of ketoacidosis, or hyperosmolar state\nHave type 2 diabetes or have a HbA1c \\> 6.4% at screening\nHave a history of chronic or acute pancreatitis\nHave a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2", "brief_summary": "The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition and physical activity in adolescents with obesity and multiple weight related comorbidities. The study will last approximately 76 weeks and may include up to 23 visits.", "keywords": []}}
{"_id": "NCT05509777", "title": "A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease", "text": "Summary: Study participants will be screened during the platform study and randomly assigned to receive mirikizumab or another intervention. The purpose of the mirikizumab study is to evaluate efficacy, safety, tolerability, and how well mirikizumab absorbs into the body of pediatric participants with Crohn's disease.\n\nStudy periods for the intervention-specific appendix (ISA) will be as follows:\n\n* A 12-week induction period\n* A maintenance period from Week 12 to Week 52, and\n* A safety follow-up period up to 16 weeks.\n\nThe study will last about 74 weeks and may include up to 19 visits.\n\nInclusion criteria: inclusion criteria: \n\n Participants must have a diagnosis of CD or fistulizing CD, with active colitis, ileitis, or ileocolitis, confirmed at any time in the past by clinical, endoscopic, and histologic criteria.\n Participants have moderately to severely active CD (as defined by a baseline PCDAI score \u226530).\n Participants must have endoscopy with evidence of active CD defined as SES-CD score \u22656 (or \u22654 for participants with isolated ileal disease) within 1 month of receiving study intervention at Week 0.\n Participants must have a documented history of inadequate response, loss of response or intolerance to at least one medication used to treat CD, which may include immunomodulators, oral or IV corticosteroids, a biologic therapy or a JAK inhibitor.\n\nExclusion criteria: exclusion criteria: \n\nParticipants must not have complications of CD such as symptomatic strictures or stenosis, short gut syndrome, or any other manifestations that might be anticipated to require surgery.\nParticipants must not have an abscess.\nParticipants must not have any kind of bowel resection within 26 weeks or any other intra-abdominal surgery within 12 weeks of baseline.", "metadata": {"brief_title": "A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease", "phase": ["PHASE3"], "drugs_list": ["Mirikizumab"], "diseases_list": ["Crohn's Disease"], "enrollment": 90, "inclusion_criteria": "inclusion criteria: \n\n Participants must have a diagnosis of CD or fistulizing CD, with active colitis, ileitis, or ileocolitis, confirmed at any time in the past by clinical, endoscopic, and histologic criteria.\n Participants have moderately to severely active CD (as defined by a baseline PCDAI score \u226530).\n Participants must have endoscopy with evidence of active CD defined as SES-CD score \u22656 (or \u22654 for participants with isolated ileal disease) within 1 month of receiving study intervention at Week 0.\n Participants must have a documented history of inadequate response, loss of response or intolerance to at least one medication used to treat CD, which may include immunomodulators, oral or IV corticosteroids, a biologic therapy or a JAK inhibitor.", "exclusion_criteria": "exclusion criteria: \n\nParticipants must not have complications of CD such as symptomatic strictures or stenosis, short gut syndrome, or any other manifestations that might be anticipated to require surgery.\nParticipants must not have an abscess.\nParticipants must not have any kind of bowel resection within 26 weeks or any other intra-abdominal surgery within 12 weeks of baseline.", "brief_summary": "Study participants will be screened during the platform study and randomly assigned to receive mirikizumab or another intervention. The purpose of the mirikizumab study is to evaluate efficacy, safety, tolerability, and how well mirikizumab absorbs into the body of pediatric participants with Crohn's disease.\n\nStudy periods for the intervention-specific appendix (ISA) will be as follows:\n\n* A 12-week induction period\n* A maintenance period from Week 12 to Week 52, and\n* A safety follow-up period up to 16 weeks.\n\nThe study will last about 74 weeks and may include up to 19 visits.", "keywords": ["Inflammatory Bowel Disease"]}}
{"_id": "NCT04086745", "title": "A Study of Baricitinib in Participants With Rheumatoid Arthritis", "text": "Summary: This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis (RA).\n\nInclusion criteria: inclusion criteria: \n\n Participants must have at least one of the following characteristics:\n\n   Documented evidence of a VTE prior to this study\n   At least 60 years of age\n   A body mass index (BMI) greater than or equal to 30 kilograms per meter squared (kg/m\u00b2), or\n   Age 50 to less than 60 years and BMI 25 to less than 30 kg/m\u00b2\n Participants must have an inadequate response or intolerance to at least 1 disease-modifying antirheumatic drugs (DMARD) (synthetic or biologic)\n\nExclusion criteria: exclusion criteria: \n\nParticipant must not have prior use of a Janus kinase (JAK) inhibitor or have received more than 1 prior TNF inhibitor that was:\n\n  discontinued for IR (lack or loss of efficacy) for RA, or\n  discontinued for intolerance (AE) when used for any indication\nParticipants must not be pregnant or breastfeeding\nParticipants must not have had more than one VTE\nParticipants must not have cancer\nParticipants must not have active herpes zoster, serious infection, active tuberculosis, or any other serious illness\nParticipants must not have had a live vaccine within four weeks of study start\nParticipants must not have participated in any other clinical trial within four weeks of study start\nParticipants must not have a history of IV drug use, other illicit drug abuse, or chronic alcohol abuse in the past year", "metadata": {"brief_title": "A Study of Baricitinib in Participants With Rheumatoid Arthritis", "phase": ["PHASE4"], "drugs_list": ["Baricitinib", "TNF Inhibitor"], "diseases_list": ["Rheumatoid Arthritis"], "enrollment": 1300, "inclusion_criteria": "inclusion criteria: \n\n Participants must have at least one of the following characteristics:\n\n   Documented evidence of a VTE prior to this study\n   At least 60 years of age\n   A body mass index (BMI) greater than or equal to 30 kilograms per meter squared (kg/m\u00b2), or\n   Age 50 to less than 60 years and BMI 25 to less than 30 kg/m\u00b2\n Participants must have an inadequate response or intolerance to at least 1 disease-modifying antirheumatic drugs (DMARD) (synthetic or biologic)", "exclusion_criteria": "exclusion criteria: \n\nParticipant must not have prior use of a Janus kinase (JAK) inhibitor or have received more than 1 prior TNF inhibitor that was:\n\n  discontinued for IR (lack or loss of efficacy) for RA, or\n  discontinued for intolerance (AE) when used for any indication\nParticipants must not be pregnant or breastfeeding\nParticipants must not have had more than one VTE\nParticipants must not have cancer\nParticipants must not have active herpes zoster, serious infection, active tuberculosis, or any other serious illness\nParticipants must not have had a live vaccine within four weeks of study start\nParticipants must not have participated in any other clinical trial within four weeks of study start\nParticipants must not have a history of IV drug use, other illicit drug abuse, or chronic alcohol abuse in the past year", "brief_summary": "This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis (RA).", "keywords": []}}
{"_id": "NCT05936151", "title": "A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes", "text": "Summary: The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D). The study will last around 31 weeks.\n\nInclusion criteria: inclusion criteria: \n\n Have a body mass index (BMI) \u226527 kilogram/square meter (kg/m\u00b2)\n Have either\n\n   no T2D with an HbA1c \\< 6.5% or\n   have T2D with an HbA1c \u2264 9.5% and treated with diet and exercise only or with stable doses of up to 3 oral antihyperglycemic medications, with or without basal insulin for at least 90 days before screening.\n Have been diagnosed with chronic kidney disease (CKD).\n\nExclusion criteria: exclusion criteria: \n\nHave a self-reported change in body weight \\>5 kilogram (kg) (11 pounds) within 90 days before screening.\nHave used in 90 days before the screening any of the following antihyperglycemic class: Dipeptidyl Peptidase IV (DPP4) inhibitors, amylin analogs, glucagon-like peptide-RA (GLP-RA), gastric inhibitory polypeptide (GIP)/GIP-1 RA, and short acting or rapid acting insulins or U500 Insulin\nHave a prior or planned surgical treatment for obesity\nHave Type 1 Diabetes (T1D)\nHave acute or chronic hepatitis\nHave a history of malignant disease within 5 years before screening.", "metadata": {"brief_title": "A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes", "phase": ["PHASE2"], "drugs_list": ["Retatrutide", "Placebo"], "diseases_list": ["Overweight or Obesity", "CKD", "Type 2 Diabetes"], "enrollment": 120, "inclusion_criteria": "inclusion criteria: \n\n Have a body mass index (BMI) \u226527 kilogram/square meter (kg/m\u00b2)\n Have either\n\n   no T2D with an HbA1c \\< 6.5% or\n   have T2D with an HbA1c \u2264 9.5% and treated with diet and exercise only or with stable doses of up to 3 oral antihyperglycemic medications, with or without basal insulin for at least 90 days before screening.\n Have been diagnosed with chronic kidney disease (CKD).", "exclusion_criteria": "exclusion criteria: \n\nHave a self-reported change in body weight \\>5 kilogram (kg) (11 pounds) within 90 days before screening.\nHave used in 90 days before the screening any of the following antihyperglycemic class: Dipeptidyl Peptidase IV (DPP4) inhibitors, amylin analogs, glucagon-like peptide-RA (GLP-RA), gastric inhibitory polypeptide (GIP)/GIP-1 RA, and short acting or rapid acting insulins or U500 Insulin\nHave a prior or planned surgical treatment for obesity\nHave Type 1 Diabetes (T1D)\nHave acute or chronic hepatitis\nHave a history of malignant disease within 5 years before screening.", "brief_summary": "The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D). The study will last around 31 weeks.", "keywords": []}}
{"_id": "NCT05514054", "title": "A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer", "text": "Summary: The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have already taken endocrine therapy for two to five years and must have a higher-than-average risk for their cancer to return. Study participation could last up to 10 years.\n\nInclusion criteria: inclusion criteria: \n\n Have a diagnosis of ER+, HER2- early-stage, resected, invasive breast cancer without evidence of distant metastasis.\n Participants must have received at least 24 months but not more than 60 months of any adjuvant ET, from time of adjuvant ET initiation.\n Participants may have received (neo) adjuvant chemotherapy and/or targeted therapy with a CDK4/6- or PARP- inhibitor.\n Must have an increased risk of disease recurrence based on clinical-pathological risk features.\n Have a Performance Status of 0 or 1 on the Eastern Cooperative Oncology Group scale.\n Have adequate organ function.\n\nExclusion criteria: exclusion criteria: \n\nHave any evidence of metastatic disease (including contralateral ALN) or inflammatory breast cancer at primary breast cancer diagnosis.\nParticipants with more than a 6-month consecutive gap in therapy during the course of prior adjuvant ET.\nParticipants who have completed or discontinued prior adjuvant ET \\>6 months prior to screening.\nParticipants with a history of previous breast cancer are excluded, with the exception of ipsilateral DCIS treated by locoregional therapy alone \u22655 years ago.\nPregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 180 days after the last dose of study intervention.\nParticipant has previously received ET of any duration for breast cancer prevention (tamoxifen or AIs) or raloxifene.\nParticipants with a history of any other cancer.\nHave serious preexisting medical conditions that, in the judgment of the investigator, would preclude participation in this study.", "metadata": {"brief_title": "A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer", "phase": ["PHASE3"], "drugs_list": ["Imlunestrant", "Tamoxifen", "Anastrozole", "Letrozole", "Exemestane"], "diseases_list": ["Breast Neoplasms"], "enrollment": 8000, "inclusion_criteria": "inclusion criteria: \n\n Have a diagnosis of ER+, HER2- early-stage, resected, invasive breast cancer without evidence of distant metastasis.\n Participants must have received at least 24 months but not more than 60 months of any adjuvant ET, from time of adjuvant ET initiation.\n Participants may have received (neo) adjuvant chemotherapy and/or targeted therapy with a CDK4/6- or PARP- inhibitor.\n Must have an increased risk of disease recurrence based on clinical-pathological risk features.\n Have a Performance Status of 0 or 1 on the Eastern Cooperative Oncology Group scale.\n Have adequate organ function.", "exclusion_criteria": "exclusion criteria: \n\nHave any evidence of metastatic disease (including contralateral ALN) or inflammatory breast cancer at primary breast cancer diagnosis.\nParticipants with more than a 6-month consecutive gap in therapy during the course of prior adjuvant ET.\nParticipants who have completed or discontinued prior adjuvant ET \\>6 months prior to screening.\nParticipants with a history of previous breast cancer are excluded, with the exception of ipsilateral DCIS treated by locoregional therapy alone \u22655 years ago.\nPregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 180 days after the last dose of study intervention.\nParticipant has previously received ET of any duration for breast cancer prevention (tamoxifen or AIs) or raloxifene.\nParticipants with a history of any other cancer.\nHave serious preexisting medical conditions that, in the judgment of the investigator, would preclude participation in this study.", "brief_summary": "The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have already taken endocrine therapy for two to five years and must have a higher-than-average risk for their cancer to return. Study participation could last up to 10 years.", "keywords": []}}
{"_id": "NCT06653153", "title": "A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)", "text": "Summary: The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo.\n\nParticipation could last up to 255 weeks including screening, a double-blind treatment period, and a double-blind observation period. In addition, eligible participants who receive placebo during the double-blind treatment period may choose to extend their study participation to receive open-label remternetug in an extension period.\n\nInclusion criteria: inclusion criteria: \n\n Have a phosphorylated tau (P-tau) result consistent with the presence of amyloid pathology.\n Have a reliable study partner and backup study partner familiar with overall function and behavior, such as day-to-day activities and cognitive abilities.\n Have adequate literacy, vision, and hearing for neuropsychological testing at screening.\n Have a Mini Mental Status Exam (MMSE) score consistent with no to minimal cognitive impairment.\n Have a Functional Activities Questionnaire (FAQ) score consistent with no to minimal functional impairment.\n If currently receiving medications as symptomatic treatment for AD, dose has been stable for at least 30 days before screening.\n\nExclusion criteria: exclusion criteria: \n\nHave dementia or significant other neurological disease that can affect cognition.\nHave current serious or unstable illnesses that in the investigator's opinion, could interfere with the analyses of the study.\nHave a history of cancer that, in the investigator's opinion, has a high risk of recurrence.\nHave a history of clinically significant multiple or severe drug allergies, or hypersensitivity reactions.\nHave a clinically important laboratory test result or other abnormality as determined by investigator, prior to randomization, that could be detrimental to the participant or could compromise the study.\nHave any contraindications for magnetic resonance imaging (MRI).\nHave a centrally read MRI that does not meets study entry criteria.\n\nPrior or Current Therapies\n\nHave ever had prior treatment with a passive anti-amyloid immunotherapy.\nHave received active immunization against A\u03b2 in any other study.", "metadata": {"brief_title": "A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)", "phase": ["PHASE3"], "drugs_list": ["Remternetug", "Placebo"], "diseases_list": ["Alzheimer's Disease"], "enrollment": 1200, "inclusion_criteria": "inclusion criteria: \n\n Have a phosphorylated tau (P-tau) result consistent with the presence of amyloid pathology.\n Have a reliable study partner and backup study partner familiar with overall function and behavior, such as day-to-day activities and cognitive abilities.\n Have adequate literacy, vision, and hearing for neuropsychological testing at screening.\n Have a Mini Mental Status Exam (MMSE) score consistent with no to minimal cognitive impairment.\n Have a Functional Activities Questionnaire (FAQ) score consistent with no to minimal functional impairment.\n If currently receiving medications as symptomatic treatment for AD, dose has been stable for at least 30 days before screening.", "exclusion_criteria": "exclusion criteria: \n\nHave dementia or significant other neurological disease that can affect cognition.\nHave current serious or unstable illnesses that in the investigator's opinion, could interfere with the analyses of the study.\nHave a history of cancer that, in the investigator's opinion, has a high risk of recurrence.\nHave a history of clinically significant multiple or severe drug allergies, or hypersensitivity reactions.\nHave a clinically important laboratory test result or other abnormality as determined by investigator, prior to randomization, that could be detrimental to the participant or could compromise the study.\nHave any contraindications for magnetic resonance imaging (MRI).\nHave a centrally read MRI that does not meets study entry criteria.\n\nPrior or Current Therapies\n\nHave ever had prior treatment with a passive anti-amyloid immunotherapy.\nHave received active immunization against A\u03b2 in any other study.", "brief_summary": "The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo.\n\nParticipation could last up to 255 weeks including screening, a double-blind treatment period, and a double-blind observation period. In addition, eligible participants who receive placebo during the double-blind treatment period may choose to extend their study participation to receive open-label remternetug in an extension period.", "keywords": []}}
